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ABSTRACT
The beta adducin gene has a very complex architecture, with tissue-specific use of pro­
moters and polyadenylation sites (PAS). Its expression is restricted to neuronal and he­
matopoietic tissues. In mice, usage of a distal brain-specific PAS (PAS4) generates an 8.3 
kb long mRNA with an unusually long 3’UTR of about 5.7 kb. Instead, the use of proximal 
erythroid-specific PASs results in short 3.1 -3.7 kb mRNA isoforms. The presence and use 
of the different alternative PASs in the beta adducin gene are very well conserved among 
species suggesting an important and specific role for each of the generated 3’UTRs.
To study the regulatory mechanisms involved in beta adducin polyadenylation, minige­
ne constructs containing the mouse beta adducin polyadenylation signals were used. 
The constructs were transfected into HeLa cells and their expression and PAS selection 
determined by Northern blot analysis. The exclusive usage of the PAS4 in HeLa cells 
has been observed. All the elements defining the core polyadenylation signal were cha­
racterized: the hexanucleotide motif (Hm), the upstream and downstream sequence 
elements (USE and DSE, respectively) elements, and the cleavage site.
Interestingly, I have detected the presence of two novel non-canonical cis-acting ele­
ments regulating 3’end processing at the PAS4. Both elements act on long-distance 
and to the best of our knowledge, long-distance upstream polyadenylation regulatory 
elements have not previously been described for the non-viral eukaryotic transcripts. 
The first of these elements was essential to enable polyadenylation at the PAS4. It was 
located in a region spanning 355 nucleotides and includes the stop codon of beta addu­
cin. The second non-canonical upstream polyadenylation regulatory element seems to 
inhibit processing at the PAS4. It was located in the region close to the second proximal 
PAS, about 4.5 kb upstream of the PAS4.
These results highlight the complexity of the regulatory mechanisms directing beta ad­
ducin pre-mRNA 3 ’end processing.
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Introduction
1.1 Pre-mRNA processing
Eukaryotic protein-coding gene expression is a very complex and tightly regulated 
process. One of the reasons for the complexity of the eukaryotic protein-coding gene 
expression lies in the regulation of the processing of the primary transcripts (pre- 
mRNAs). Pre-mRNA processing includes 5’end capping, editing, splicing and 3’end 
processing events. Once processed in the nucleus, mature mRNAs are exported to 
the cytoplasm and translated.
1.1.1 5’end capping
When the nascent transcript reaches a length of 25-30 nucleotides, the 7-methyl-guany- 
late cap structure is added to its 5’ end. The 5’cap structure is subsequently recognized 
by the cap binding protein complex (CBC). This complex protects the nascent transcript 
from 5’-3’ exonuclease degradation. It is also important for pre-mRNA splicing, 3’end 
processing and nuclear export of the mature mRNA and its translation (Lewis and Izaur- 
ralde, 1997; Sonenberg, 1988).
11
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1.1.2 Editing
RNA editing is a rare form of RNA processing in which the nucleotide sequence of the 
primary transcript is altered from that encoded by the genome (Keegan et al., 2001). 
Cytosine (C) to Uracil (U) and Adenosine (A) to Inosine (I) editing have been described 
for mammals. Site-specific C to U editing in the apolipoprotein B pre-mRNA introduces 
a stop codon resulting in the synthesis of a truncated protein, apoB48. A to I editing has 
been found to alter the amino-acid composition of the ionotropic glutamate receptor 
subunit GluR-B leading to a decrease in Ca2+ permeability. Transcripts that undergo A 
to I editing are mostly expressed in the brain. Aberrant editing has been associated with 
certain cancers and a range of abnormal behaviors including epilepsy and depression 
(Brusa et al., 1995; Gurevich et al., 2002; Maas et al., 2001).
1.1.3 Splicing
Before being transported to the cytoplasm where the mature transcripts can be tran­
slated, intronic sequences are removed from the pre-mRNAs and exons are joined to­
gether in a process called “splicing”. Splicing, which essentially is a two-step transe- 
sterification reaction is carried out by a multicomponent complex, the spliceosome. 
The spliceosome is a dynamic ribonucleoprotein complex composed of five snRNAs 
(U1, U2, U4, U5 and U6) and numerous associated proteins (Jurica and Moore, 2003). 
Components of the spliceosome interact with defined sequences at the exon/intron 
boundaries, the so called splice sites (5’ and 3’ splice site, respective to the intron), 
the polypyrimidine tract and the branch point sequence. Upstream from the typical AG 
dinucleotide at the 3’ splice site a polypyrimidine tract (PPT) is present. The branch 
point sequence (BPS) is located upstream from the PPT. In higher eukaryotes it does 
not have a clear consensus sequence, exept for the presence of an Adenosine which 
serves as the branch point in the splicing reaction. Splice sites are defined by GU and 
AG dinucleotides positioned at the 5’ and 3’ ends of the introns, respectively. However, 
other sequences flanking these dinucleotides are necessary, which help to define
12
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the strength of the splice sites. The 5’ splice site has the consensus CAG:GURAGU 
(where : denotes the exon-intron borders) and deviation from this consensus affects 
the strength of the splice site. In the same way, the presence of a polypyrimidine 
tract interrupted by purines weakens the 3’ splice site. Exons that contain weak core 
splice sites need additional auxiliary elements to procure efficient splicing, named exonic 
splicing enhancers (ESE) and/or intronic splicing enhancers (ISE). Moreover, ESEs may also 
be necessary for the correct exon recognition of exons separated by large introns . Many 
ESE sequences are characterized by the enrichment in purines, which provide binding si­
tes for proteins of the SR protein family (Busch and Hertel, 2012). Each member of the SR 
protein family contains a characteristic arginine/serine rich domain (RS domain) and one or 
two RNA Recognition Motifs (RRM). There are twelve SR protein members detected in 
humans, named Serine/Arginine-rich Splicing Factors 1 to 12 (SRSF1-12) (Manley and 
Krainer, 2010). The most studied ones are SRSF1 and 2 (formerly known as ASF/SF2 
and SC35, respectively). The ESE sequences recognized by these factors have dege­
nerated purine-rich structure, but are nevertheless specific for each of them. In addition 
to the SR protein family, there is a group of SR-related proteins that can interact with 
ESEs. The SR-related proteins are also characterized by the presence of a RS domain, 
whereas the presence of the RRM is optional. Some of the members of this family 
are splicing factors which associate with the major spliceosomal components, such as 
UlsnRNP (U170K factor), or with the polypyrimidine tract (U2AF35 and 65). Others act 
as splicing coactivators, for example the SRm160/300 complex, which lacks the RRM 
and acts in promoting purine-rich ESE function in splicing through its interaction with other 
factors that are directly bound to the ESE (Blencowe, 2000). Moreover, along the exons and 
introns different silencer elements can be found: exonic and intronic splicing silencers (ESS 
and ISS, respectively). These elements are recognized by a group of heterogeneous nuclear 
ribonucleoproteins (hnRNPs) which, apart from their role in splicing, have a wide range of 
cellular functions (Han et al., 2010). hnRNPs bind to the silencer sequences through their 
RNA binding domain, which is mostly represented by one to four RRMs. RNA binding motifs
13
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are deviated and specific for each member of the hnRNP family. A well studied member of 
the hnRNP family, hnRNP I, widely known as PTB (Polypyrimidine Tract Binding protein), 
acts in the repression of exon or intron definition through the binding to CU-rich silencer 
sequences. hnRNPs F/H operate as splicing repressors recognizing G-rich sequences whi­
le hnRNP L binds CA repeats. Together, SR proteins and hnRNPs, through their binding to 
enhancer and silencer elements, allow fine tuning in the regulation of the pre-mRNA splicing 
and determine alternative splicing patterns. Moreover, SR proteins and hnRNPs are the main 
regulators of the alternative splicing events.
1.1.4 3’end processing
The final pre-mRNA processing reaction required for the maturation of pre-mRNAs is 
3 ’end processing. 3’ end processing is a two step reaction in which the pre-mRNA is 
first cleaved and subsequently polyadenylated. The only mRNAs that are not polya- 
denylated are the transcripts of the replication-dependent histone genes. These tran­
scripts are matured at their 3’ends by a cleavage event only, directed by the U7snRNP 
(Dominski and Marzluff, 2007). As for the splicing reaction, specific cis-acting elements 
that are recognized by specific trans-acting factors are necessary for correct and effi­
cient 3’end processing. The core elements that are involved in the correct definition of 
the place where the cleavage and polyadenylation will occur represent the polyadeny­
lation signal. Mammalian polyadenylation signals are characterized by the presence of 
the hexanucleotide motif (AAUAAA or similar sequence located 20-30 bases upstre­
am of the cleavage site), subsequently named "Hm", the U-rich and/or U/GU-rich ele­
ments located immediately upstream and downstream of the cleavage site, respectively 
(upstream sequence element or USE and downstream sequence element or DSE) and 
the cleavage site itself, named also poly(A) site (PAS) as it is the site of the polyA tail 
addition (Figure 1) (Proudfoot, 2011).
The 3’end processing machinery that recognizes and interacts with these elements of 
the mammalian polyadenylation signals is composed of several multisubunit protein
14
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AAUAAA
Figure 1
Schem atic representation of the sequence com position of the m am m alian polyadenylation signal.
USE - upstream sequence element; DSE -  downstream sequence element; double arrowheads indicate the distance 
in nucleotides (nt) between the indicated elements; the scissors indicate the position of the cleavage site; adapted 
from Proudfoot 2011.
factors: Cleavage and Polyadenylation Specificity Factor (CPSF), Cleavage stimulatory 
Factor (CstF), Cleavage Factor I and II (CFI and CFII); as well as of the single polypepti­
des: PolyA Polymerase (PAP), PolyA Binding Proteins (PABPs), symplekin and the large 
subunit of the RNA Polymerase II (RNAP II). A recent study showed that the human 
3’end processing complex is composed of at least -85 proteins (Shi et al., 2009). In 
addition to the main cleavage and polyadenylation factors, more than 50 of the protein 
factors identified link 3’end processing of pre-mRNAs with other cellular processes.
1.1.4.1 The 3’end processing complex assembly
The assembly of the mammalian 3’end processing complex is shown in Figure 2 and is 
described below. The main characteristic of the 3’end processing complex assembly is 
the recruitment of CPSF and CstF onto sequences present upstream and downstream 
of the cleavage site, the Hm and the DSE, respectively.
Components of CPSF are CPSF-160, CPSF-100, CPSF-73, CPSF-30, hFipl and 
WDR33. The AAUAAA hexanucleotide motif is recognized and bound by the CPSF-160 
subunit (Keller et al., 1991; Murthy and Manley, 1995). CPSF-73 and CPSF-100 subu­
nits, together with symplekin, form the core cleavage complex (Sullivan et al., 2009). 
This complex is assembled at the cleavage site. CPSF-30 and hFipl are bound to the 
U-rich sequences found immediately upstream of the cleavage site (Barabino et al., 
1997; Kaufmann et al., 2004). WDR33, a recently identified component of CPSF, is in 
close connection with CPSF-73 (Shi et al., 2009).
15
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CstF is composed of three subunits, CstF-50, 64 and 77, each of them likely to form 
homodimers (Moreno-Morcillo et al., 2011). CstF-50 binds to the RNAP II carboxi- 
terminal domain (RNAP II CTD). CstF-64 is responsible for the recognition and binding to 
the U/GU-rich DSE (MacDonald et al., 1994). CstF-77 is important for the interaction with 
the CPSF-160 subunit, and it is also mediating the binding of the other subunits of CstF. 
CFI is a heterotetrameric protein composed of the CFI-25 homodimer linked to CFI-59 
or CFI-68 homodimers. Through the CFI-25 subunit, CFI recognizes UGUA elements pre­
sent in the 3’UTR (Brown and Gilmartin, 2003; Yang et al., 2010).
CFI I is believed to associate transiently with the 3’end processing complex, as one of 
its subunits, Clp1, is completely absent and the other one, Pcf11, is present only at 
low levels in the recently analyzed human 3’end processing complex (Shi et al., 2009). 
However, its role is of high importance in the stimulation of cleavage, as a purified 
human 3’end processing complex was inactive in cleavage until the addition of CFII 
and CFI (Shi et al., 2009).
PAP is anchored to the 3’end processing complex by CPSF-160 and hFipl (Kaufmann et 
al., 2004). CPSF-73 is the endonuclease that cleaves the pre-mRNA (Mandel 2006, Nature), 
after which PAP catalyzes the contemplated addition of adenosines. At this point the CstF, 
CFI and CFII dissociate from the polyadenylation complex. Afterwards, nuclear PABP is 
recruited on the growing polyA tail, which enables PAP to proceed rapidly until the addition 
of -250 adenosine residues (Figure 2B). The serine/threonine phospatase PPI has been 
recently described to be an additional factor important for the polyadenylation step (Shi et 
al., 2009). The remaining fragment downstream of the cleavage site is rapidly degraded by 
the nuclear 5’-3’ exonuclease (Xrn2) (Figure 2B). Xrn2 stimulates transcription termination, 
by a so far unknown mechanism.
1.1.4.2 The hexanucleotide motif (Hm)
Observing the high variability in sequence composition of the polydenylation signal 
elements, it is quite fascinating how the 3’end processing factors recognize the
16
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M am m alian 3 ’end processing com plex assembly.
For detailed explanation see text.
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polyadenylation signals. The only element that has a well-defined consensus sequence 
is the highly conserved hexanucleotide motif, AAUAAA. Thus, it is not surprising that the 
AAUAAA was the first polyadenylation signal element to be described (Proudfoot and 
Brownlee, 1976). In vitro studies in which point mutations in the AAUAAA were introduced 
demonstrated the specificity and importance of this element for efficient cleavage and 
polyadenylation of pre-mRNAs (Sheets et al., 1990). All the introduced point mutations 
led to the almost complete abolishment of polyadenylation, apart from the mutation 
of the second A to U (the AUUAAA hexanucleotide), which showed the -80%  of the 
wild type hexanucleotide activity (Sheets et al., 1990)(Figure 3). This study mirrors the 
situation of thalassemias where different mutations in the AAUAAA sequence of the 
alpha or beta globin gene affect globin mRNA levels, resulting in abnormal hemoglobin 
production (Chen et al., 2006). Availability of the whole genome sequences, cDNAs 
and expressed sequence tags (ESTs) data allowed the bioinformatic analyses of the 
most representative hexanuleotide motifs upstream of the cleavage site in a genome 
wide context. These analyses confirmed the importance of the AAUAAA sequence, 
showing the presence of this Hm in -60%  of human and mouse genes (Beaudoing et 
al., 2000; Tian et al., 2005) (Figure 3). The counterpart of the AAUAAA sequence, the 
AUUAAA sequence is present in -15%  of the analyzed genes. Nowadays, both the 
AAUAAA and the AUUAAA hexamers are considered as canonical ones. All the other 
detected hexanucleotide motifs, the non-canonical ones, are present in about 20-30% 
of the analyzed genes and most of them contain a single base difference in respect to 
the AAUAAA (Figure 3). For about 8% of the analyzed genes no clear hexamer can be 
assigned (Tian et al., 2005).
1.1.4.3 The cleavage (polyA) site
Initial analysis of the pre-mRNA cleavage process showed that the cleavage site is mo­
stly represented by a CA dinucleotide (Sheets et al., 1990). Further studies demonstra­
ted that the order of the preferred nucleotide at the cleavage site is A>U>C»G (Chen
18
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Figure 3
Correlation between the frequency and 
polyadenylation efficiency of different 
hexanucleotide motif variants.
Data regarding frequency are taken from 
Tian et al 2005.; Hs - Homo sapiens; Mm - 
Mus musculus; polyadenylation efficiency 
data are taken from Sheets et al 1991.
et al., 1995). Both of these studies demonstrated that the mutation of the nucleotide at 
the cleavage site position does not interfere with the cleavage efficiency, but shift the cle­
avage site to a close nucleotide. Thus, pre-mRNA cleavage is a rather imprecise process 
and does not necessarily occur at a specific nucleotide. This observation was confirmed 
by other studies, which demonstrated the presence of multiple cleavage sites for a single 
polyadenylation signal (Pauws et al., 2001; Tian et al., 2005). It has been estimated that 
51.25% of human and 46.97% of mouse polyadenylation signals have more than one 
cleavage site (Tian et al., 2005). Although these results show high heterogeneity in the 
selection of the cleavage site, the site of cleavage is always placed at the certain distance 
in between the AAUAAA motif and the DSE (Chen et al., 1995) (Figure 1).
1.4.4.4 The downstream sequence element (DSE)
The DSE is usually represented by a number of U-rich or/and G/U-rich elements placed 
immediately downstream of the cleavage site (Zarudnaya et al., 2003) (Figure 1), but
hexamer
variant
frequency(%) 
Hs Mm
polyA
efficiency(%)
AAUAAA 53.18 59.16 100
AUUAAA 16.78 16.11 77 ±4.7
UAUAAA 4.37 3.79 17 ± 3.0
AGUAAA 3.72 3.28 29 ±8.1
AAGAAA 2.99 2.15 6 ±1.0
AAUAUA 2.13 1.71 10 ± 2.3
AAUACA 2.03 1.65 11 ± 2.3
CAUAAA 1.92 1.80 18 ± 6.4
GAUAAA 1.75 1.16 11 ±1.0
AAUGAA 1.56 0.90 4.3 ± 0.6
UUUAAA 1.20 1.08 /
ACUAAA 0.93 0.64 11 ± 6.0
AAUAGA 0.60 0.36 3.3 ±1.5
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there is no defined consensus sequence for the DSE. Unlike the AAUAAA motif, in 
which point mutations have a severe impact on the efficiency of 3 ’end processing, 
mutations of the DSE had a less pronounced influence on the 3’end processing of the 
tested pre-mRNAs, perhaps due to its divergence in sequence composition (Zarudnaya 
et al., 2003; Zhao et al., 1999). Studies of the DSEs were mostly conducted in the con­
text of strong polyadenylation signals that are represented by the canonical AAUAAA 
Hm. Some of the well characterized DSE of viral and cellular polyadenylation signals are 
represented in Figure 4 (Zarudnaya et al., 2003).
The importance of the DSE for the recognition of the polyadenylation signal in the 
absence of the canonical Hm was highlighted in the study of the human intronless 
melanocortin 4 receptor gene (MC4R) 3 ’end processing (Nunes et al., 2010). The 
MC4R pre-mRNA cleavage efficiency depends mostly on the presence of a strong 
DSE, whereas the hexanucleotide motif appears to be less important. In fact, in the 
MC4R gene the natural hexamer can be mutated and an A-rich upstream element is 
sufficient, together with the strong MC4R DSE, to direct efficient 3’end processing. 
This observation was extended to the whole genome. A genome-wide bioinformatic 
analysis showed that non-canonical polyA signals characterized by the presence of 
A-rich upstream sequences are usually associated with stronger DSE, characterized 
by downstream sequences richer in U- and G/U than DSEs of genes having canonical 
Hm (Nunes et al., 2010). These experiments highlight the role of the DSE in the polyA 
site definition in the absence of the canonical Hm.
In addition, another sequence positioned just downstream of the core DSE, called 
the G-rich auxiliary DSEs, has been described to enhance 3’end processing of va­
rious pre-mRNAs (Zarudnaya et al., 2003). Interestingly, the G-rich element placed far 
downstream of the cleavage site (440 nucleotides downstream) has been reported to 
be important for the efficient 3’end processing of the melanocortin receptor 1 gene 
(MC1R) (Dalziel et al., 2007). Members of the hnRNP H protein family are bound to 
the G-rich auxiliary DSEs and stimulate 3’end processing probably by enhancing the
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AAUAAAACCCACGGGUGUUGGGUCGUUUGUU 
Mouse IgM heavy chain (secretory site)
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ACUGGUUUUGAUUAUACAAUGCUCAUGCCUGCUGAGACAGUUGUGUUUUGCUUGCUCUGCACACACCCUG
Figure 4
Sequence composition of downstream sequence elements found in viral and mammalian polyadenylation 
signals.
U- and GU-rich tracts are underlined; double line indicates G-rich tract; +1 indicates the first nucleotide after the 
cleavage site; adapted from Zarudnaya et al 2003.
efficiency of the CstF64 assembly on the core DSE (Arhin et al., 2002; Bagga et al., 
1998; Dalziel et al., 2007).
1.1.4.5 The upstream sequence element (USE)
Additional elements enhancing 3’end processing can be found immediately upstream 
of the hexanucleotide motif: the upstream sequence elements (USEs) (Figure 1). Similar 
to the DSEs, the USEs have no defined consensus sequence motif and are generally 
represented by a variable number of U-rich elements. Bioinformatic analysis of the hu­
man and mouse genes showed a general AU enrichment in the 100 bases upstream of 
the cleavage site (Tian et al., 2005). Some of the well described USEs are represented in 
Figure 5 and are discussed below. The first studies of the USE were conducted on viral 
polyadenylation signals. The USE of the SV40 late polyadenylation signal is represented 
by the three AUUUGURA sequence motifs (Schek et al., 1992). This element is recogni­
zed by the U1 snRNP-A protein, which interacts with CPSF-160 stabilizing its binding
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SV40 late
AUGCAGUGAAAAAAAUGCUUUAUUUGUGAAAUUUGUGAUGCUAUUGCUUUAUUUGUAACCAUUAUAAGCUGC AAUAAA
C2 complement
GACUUGACUCAUGCUUGUUUCACUUUCACAUGGAAUUUCCCAGUUAUGAAAU AAUAAA
lamin B2
AUUCGGUUUUUAAGAAGAUGCAUGCCUAACGUGUUCUUUUUUUUUUCCAAUGAUUUGUAAUAUACAUUUUAUGACUGG
AAACUUUUUUGUACAACACUCC AAUAAA
papolG
GUUGUUUGUAAAUGAAGUCGUAUGUAUUUUCAGAGUAUUUUUGUAUGUACUGUAAGAUACCAUCUUUUdAAAGAGAAA
Figure 5
Sequence composition of upstream sequence elements found in viral and mammalian polyadenylation 
signals.
U- and GU-rich tracts are underlined; open box indicates hexanucleotide motif.
to the AAUAAA, and thus enhancing polyadenylation efficiency (Lutz and Alwine, 1994; 
Lutz et al., 1996). The first non-viral example of the USE was described for the human 
C2 complement gene (Moreira et al., 1995), which is bound by PTB enhancing the cle­
avage efficiency (Moreira et al., 1998). As for the SV40, the USE of the human lamin B2 
polyadenylation signal enhances cleavage and polyadenylation by increasing the stabi­
lity of the CPSF-AAUAAA complex, although by a different mechanism (Brackenridge 
and Proudfoot, 2000). The stabilization of the CPSF-AAUAAA complex can be achieved 
also through the direct binding of the CPSF components, CPSF-30 and hFipl, to the 
U-rich USEs (Barabino et al., 1997; Kaufmann et al., 2004). The importance of the USEs 
is highlighted in the recognition of the polyadenylation signals having the non-canonical 
hexanucleotide motif (Venkataraman et al., 2005). These USEs are characterized by the 
presence of the UGUAN consensus sequence and are recognized by the CFI. This in­
teraction stimulates polyadenylation in the absence of the canonical AAUAAA, through 
the recruitment of the hFipl and PAP to the RNA substrate.
The above mentioned studies introduced only a few concepts of the highly complex 
world of pre-mRNA 3’end processing. The strength of the polyadenylation signal de­
pends on different combinatorial codes of its multiple sequence elements, which are 
recognized by a specific set of 3’end processing factors.
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1.1.5 Crosstalk between the cotranscriptional pre-mRNA 
processing events
Pre-mRNA processing events take place mostly cotranscriptionaly (Proudfoot et al., 
2002). They are in close connection with the RNAP.II through its CTD, which serves as 
a landing pad for different processing factors. Moreover, the pre-mRNA processing 
events are also interconnected and influence one another.
1.1.5.1 3 ’end processing and transcription
Transcription and 3’end processing factors are interconnected from the initiation until the 
termination of the transcription. TFIID and TFPBII associate with CPSF and CstF, respecti­
vely, and bring them to the preinitiation complex (Dantonel et al., 1997; Wang et al., 2010). 
When transcription initiates, CPSF and CstF are recruited onto elongating RNAP II CTD 
and carried all the way until RNAP II transcribes polyadenylation signal. Then, CPSF and 
CstF are recruited from the RNAP II CTD onto the pre-mRNA polyadenylation signal. This 
recruitment is followed by the incorporation of the other 3’end processing factors comple­
ting complex assembly and leading to cleavage and polyadenylation of the nascent tran­
script. As previously mentioned, the CTD of RNAPII is an active component of the 3’end 
processing complex. 3’end processing has an important role in the termination of RNAP II 
mediated transcription (Buratowski, 2005; Proudfoot, 2004). As mentioned above, the re­
maining downstream cleaved RNA product is rapidly degraded by the 5’-3’ exonuclease 
Xrn2 (Figure 2B). By the proposed torpedo model of trancription termination, it is believed 
that once Xrn2 reaches RNAP II, it causes dissociation of RNAP II from the DNA template, 
promoting termination of transcription (Buratowski, 2005). Moreover, additional elements, 
placed downstream of the polyadenylation site, have been described to influence tran­
scription termination. Such elements are cotranscriptional cleavage sites (CoTC) and/or 
RNAP II transcriptional pause sites, usually represented by G-rich sequence (Dye and 
Proudfoot, 2001; Gromak et al., 2006). Additionally, all the assembled cleavage and polya­
denylation factors remain on the pre-mRNA after the cleavage event. Polyadenylation and,
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in the case of intron-containing pre-mRNAs, splicing events are necessary to release 
the transcript from the RNAP II polymerase (Rigo and Martinson, 2009).
A recent study demonstrated that 3 ’end processing facilitates recycling of RNAP II and 
other transcription factors to the promoter region after the first round of transcription, 
thus stimulating transcription initiation (Mapendano et al., 2010). This finding is in agre­
ement with studies showing physical connections between promoter and polyadenyla­
tion site regions, termed gene loops (Perkins et al., 2008; O'Sullivan et al., 2004). Thus, 
the presence of gene loops could facilitate recycling of transcription factors from the 
3’end of genes to the promoter.
1.1.5.2 3’end processing and 5’end capping
The pre-mRNA 5’end capping and 3’end processing interaction is established through di­
rect connection of the nuclear cap binding complex (CBC) and 3’end processing complex 
(Flaherty et al., 1997). This interaction maintains the loop structure of the pre-mRNA and 
mature mRNA necessary for its stability and nuclear export. Moreover, the interaction of 
the CBC and 3’end processing complex is important for the efficient cleavage reaction.
1.1.5.3 3’end processing and splicing
The crosstalk between pre-mRNA 3’end processing and splicing reactions is empha­
sized in terminal exon definition and last intron removal (Martison 2011) (Figure 6). The 
terminal exon is a very particular case since it has only the 3’splice site, whereas the 
5’splice site is lacking. Terminal exon definition depends on the interaction between 
splicing factors recognizing its 3’splice site and 3’end processing factors bound to the 
polyadenylation signal core elements. Early in vitro studies showed that the presen­
ce of an upstream intron in the pre-mRNA leads to enhancement of 3’end processing 
(Niwa et al., 1990). Additionally, the polyadenylation signal can also influence splicing of 
proximal introns (Niwa et al., 1991). In vitro studies showed that PAP is able to interact 
with the splicing factor U2AF65 enhancing its binding to the polypyrimidine tract of the
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Figure 6
Crosstalk between 3’end processing and splicing factors.
For detailed explanation see text; double arrowheads indicate interactions between 3 ’end processing and spli­
cing factors; plus and minus indicate positive and negative actions of factors shown, respectively; adapted from  
Pandya-Jones2011.
terminal exon 3’splice site and thus acts in the stimulation of the last intron splicing 
(Vagner et al., 2000). In turn, another study demonstrated that binding of U2AF65 to the 
polypyrimidine tract of the beta globin last intron stimulates in vivo and in vitro 3’end 
processing (Millevoi et al., 2002). Comparably, different mutations of the polypyrimi­
dine tract and AG dinucleotide at the 3’splice site of the beta globin last intron led to 
inefficient 3’end processing (Antoniou et al., 1998; Dye and Proudfoot, 1999). An ad­
ditional in vitro study using as a model the adenovirus L3 polyadenylation site showed 
that U2AF65 exerts its 3’end processing stimulatory activity through direct interaction 
with the 59 kDa subunit of CFI (Millevoi et al., 2006). This interaction relies on the con­
tact between the RS-domains present in both proteins. Similar RS-domain interactions 
have also been observed for the CFI-68 subunit and the SR proteins SRSF3, SRSF7 
and SRSF10 (former SRp20, 9G8 and hTra2Beta, respectively) (Dettwiler et al., 2004). 
Another RS-domain containing protein, the SR-related protein SRm-160, is involved in 
the enhancement of the 3'end cleavage efficiency in vitro and in vivo (McCracken et al.,
2002). This enhancement is probably due to the association of SRm-160 with CPSF. In 
another study, CPSF is found in close connection with the splicing factor U2snRNP and 
this interaction is necessary for efficient splicing and cleavage reactions in a coupled
25
Chapter 1
system (Kyburz et al., 2006). Depletion of the CPSF-100 subunit from an in vitro spli­
cing and cleavage coupled assay decreased not only the cleavage but also the splicing 
efficiency. Similarly, depletion of only U2 snRNA in the same assay led to a significant 
decrease in the cleavage efficiency and the complete abolishment of splicing.
The above described examples show stimulatory interactions between splicing and 
3’end processing factors. However, the interactions between splicing and 3’end pro­
cessing factors can be directed to the inhibition of the splicing and/or 3’end processing 
reactions. One of the examples of inhibition is the direct competition observed betwe­
en splicing and 3’end processing reactions in the case of defining alternative terminal 
exons. This example of competition will be discussed below in the section Alternative 
processing. Several examples are known where splicing factors directly affect the cle­
avage and polyadenylation efficiencies. Early studies showed that U1A, a protein part 
of the UlsnRNP complex, interacts with PAP to inhibit polyadenylation of its own tran­
script (Gunderson et al., 1997). Moreover, polyadenylation at the bovine papillomavirus 
(BPV) late polyadenylation signal is inhibited by the binding of UlsnRNP to an element 
containing consensus 5’splice site sequence located upstream of the PAS. Mutation of 
this 5’splice site rescued the UlsnRNP-dependent inhibition. The UlsnRNP exhibited 
its inhibitory role on BPV polyadenylation through the interaction between its compo­
nent, U1 70K, and PAP (Gunderson et al., 1998). A recent study demonstrated the role 
of UlsnRNP in preventing premature cleavage and polyadenylation by a mechanism 
similar to that observed for the BPV late polyadenylation signal (Kaida et al., 2010). 
Depletion of UlsnRNP from HeLa cells or mutation of the 5’splice site results in the ac­
tivation of cryptic polyadenylation signals located downstream of the 5’splice site. These 
cryptic polyadenylation signal elements can be commonly found across intronic regions. 
Usage of such polyadenylation signals could disrupt normal processing (splicing and con­
stitutive polyadenylation signal usage), leading to the formation of aberrant transcripts. 
Therefore, inhibition of 3’end processing at the cryptic intronic polyadenylation signals by 
UlsnRNP is of high importance for the normal maturation of the pre-mRNA.
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1.2 Alternative polyadenylation
As mentioned at the beginning of the Introduction section, the complexity of eukaryotic 
protein-coding gene expression lies mostly in the regulation of the pre-mRNA proces­
sing events. In particular, alternative processing of pre-mRNAs represents an important 
step in the regulation of gene expression. Alternative processing includes transcription 
initiation at alternative promoters, alternative splicing and alternative polyadenylation. 
For many years, the importance of alternative promoter and polyadenylation site usage 
compared to alternative splicing was underestimated. The reason for this lies in the 
huge potential of alternative splicing for the production of many different protein iso­
forms from a single gene (Black, 2003). The extreme example is the Drosophila Dscam 
gene, where alternative splicing of a single pre-mRNA transcript can potentially gene­
rate -38 000 different protein isoforms. In addition, recent analysis of 15 diverse human 
tissues and cell line transcriptomes indicate that 92-94% of human genes undergo al­
ternative splicing (Wang et al., 2008). However, during the last years increasing atten­
tion has been given to alternative polyadenylation. It is estimated that over half of the 
human and mouse genes undergo alternative cleavage and polyadenylation (Shepard et 
al., 2011; Tian et al., 2005). Several reviews have recently been published stressing the
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growing importance of alternative polyadenylation in the regulation of gene expression 
(Di Giammartino et al., 2011; Lutz and Moreira, 2011; Proudfoot, 2011).
In general, there are two types of alternative polyadenylation (Figure 7). In the first type, 
alternative polyadenylation signals are present in different upstream introns or exons 
ending the message in alternative 3’terminal exons which normally results in different 
protein isoforms. This type represents a combination of alternative splicing and alter­
native polyadenylation. In the second type, multiple alternative polyadenylation signals 
are present in the 3’most terminal exon (tandem polyadenylation sites), leading to the 
formation of mRNA isoforms that differ in the lengths of their 3’UTRs. Changes in the 
3’UTR length can influence mRNA stability, localization and translatability.
1.2.1 Regulatory mechanisms involved in alternative 3’terminal 
exon selection
The molecular mechanisms involved in the regulation of alternative polyadenylation 
and, thus, the recognition of specific polyadenylation sites are to date poorly under­
stood. There are a few individual cases in which the regulatory mechanisms involved in 
alternative polyadenylation have been addressed in detail, such as in the well-studied 
immunoglobulin M (IgM) heavy chain and calcitonin/CGRP transcripts (Figure 8). Both 
belong to the first type of alternative polyadenylation, where alternative polyadenylation 
sites usage results in the presence of different terminal exons in the final transcripts. In 
immature B cells, IgM heavy chain pre-mRNAs are mostly polyadenylated at the distal 
site leading to the production of a membrane bound form of the IgM heavy chain. Du­
ring differentiation to plasma cells, the secreted form of IgM (ps) is produced and the 
promoter-proximal cleavage-polyadenylation site is used. The membrane-associated 
IgM (pm) encoding mRNA is polyadenylated at the downstream "pm" PAS which is only 
used when the ps site is removed by alternative splicing. It has been demonstrated that 
the switch from the membrane bound to the secreted form is directed by the relative
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amounts of CstF-64 and hnRNP F (Takagaki et al., 1996; Veraldi et al., 2001). CstF-64 
binding affinity for the DSE of the proximal secretory-specific ps PAS is lower than for 
the DSE present in the distal membrane-specific polyadenylation site of the IgM heavy 
chain pre-mRNA. In addition, the binding site for hnRNP F is placed in the DSE of the 
proximal secretory-specific polyadenylation site, thus competing for access to this site 
with CstF-64. In B cells, high levels of hnRNP F and low levels of CstF-64 are detected, 
leading to the inefficient usage of the proximal secretory-specific site, its splicing and 
favour of the usage of the distal membrane-specific site. In plasma cells we observe 
the opposite situation: the levels of the hnRNP F are lower, whereas the levels of CstF- 
64 are higher, favouring the usage of the proximal secretory-specific poladenylation 
site and the expression of the secreted IgM heavy chain form. Additionaly, it has been 
shown that expression of the transcription elongation factor ELL2 is induced in plasma 
cells and that ELL2 can stimulate usage of the proximal secretory-specific poladenyla­
tion site (Martincic et al., 2009).
Another example of alternative polyadenylation through the selection of alternative 
3’terminal exons is the calcitonin/CGRP pre-mRNA, where the proximal PAS is present in 
exon 4 and the distal PAS in exon 6, which is the 3’most terminal exon (Amara et al., 1984) 
(Figure 8). In neuronal tissues, the exon 4 is skipped from the calcitonin pre-mRNA and 
the distal polyadenylation site is used, leading to the production of the calcitonin gene- 
related peptide (CGRP). In thyroid C cells, the exon 4 is included and, thus, the proximal 
polyadenylation site is used leading to the production of the hormone calcitonin. Exon 4 
inclusion and the usage of the proximal polyadenylation site of the calcitonin pre-mRNA 
are stimulated by the presence of a 127 nt long enhancer element. The enhancer element 
is located in the intronic region, 150 nt downstream of exon 4. The splicing factors PTB, 
SRSF3 (former name SRp20) and UlsnRNP bind the enhancer element and positively 
regulate the inclusion of exon 4 and the usage of the proximal polydenylation site of the 
calcitonin/CGRP pre-mRNA (Lou et al., 1999; Lou et al., 1998).
Both, the IgM heavy chain and calcitonin/CGRP pre-mRNAs contain alternative exonic
30
Introduction
polyadenylation signals. Examples of intronic alternative polyadenylation signals are 
found to be common in the gene expression regulation of the receptor tyrosine kinase 
(RTK) (Vorlova et al., 2011). Usage of the intronic alternative polyadenylation signals in 
the RTK pre-mRNAs leads to the generation of soluble truncated RTK isoforms, which 
lack the C-terminal trans-membrane domain. The soluble RTK isoforms preserve the 
binding properties for the ligand and are important for the dominant-negative regulation 
of the signaling pathway, and are termed soluble decoy RTK isoforms (sdRTK). The 
activation of the intronic alternative polyadenylation signals of RTK pre-mRNAs can be 
achieved through the inhibition of UlsnRNP binding to the upstream 5’splice site (Vor­
lova et al., 2011). This result is consistent with the above-mentioned role of UlsnRNP in 
the inhibition of the premature cleavage and polyadenylation in the introns (Kaida et al., 
2010) and highlights the importance of UlsnRNP in the regulation of intronic alternative 
polyadenylation. Vorlova and collaborators demonstrated that activation of the sdRTK 
isoforms by blocking U1 snRNP is important not only from the mechanistic point of view 
but also could be a potent therapeutic strategy for a number of diseases which involve 
aberrant RTK signaling.
1.2.2 Regulatory mechanisms involved in tandem alternative 
polyadenylation site selection
Although the number of individual examples of tandem alternative polyadenylation is con­
stantly increasing, the molecular mechanisms that regulate these events remain largely un­
characterized. As described below, there are a few isolated studies proposing that different 
trans-acting factors can regulate the usage of tandem alternative polyadenylation sites.
In addition to the above described alternative polyadenylation regulation in the IgM heavy 
chain pre-mRNA, CstF-64 levels can also regulate the usage of other alternative polyadeny­
lation sites present in the 3’UTR of genes. Overexpression of CstF-64 in LPS-stimulated 
macrophages leads to a shift in the usage of the distal to the proximal polyadenylation sites 
in a number of genes (Shell et al., 2005).
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In similar fashion, knock-down of CFI-25 in HeLa cells influences the switching in the 
usage of tandem alternative polyadenylation sites present in the 3’UTR of TIMP-2, syn- 
decan2, ERCC6 and DHFR transcripts (Kubo et al., 2006). For all the analyzed genes the 
distal site(s) were preferentially used in HeLa cells, and CFI-25 depletion caused a shift 
from the usage of the distal to the proximal polyadenylation sites in these genes.
Very recently, the nuclear factor PABP1 (PABPN1), another component of the 3’end 
processing machinery, was shown to be important for polyadenylation site selection. 
Using a deep-sequencing-based approach tailored to the analysis of 3’end formation, 
the effects of PABPN1 knock-downs on polyadenylation site selection were analyzed. 
The knock-downs were performed in human cancer (U20S - osteosarcoma) and non­
transformed (RPE-1 - retinal pigment epithelial) cells. The authors identified 572 and 
357 transcripts in U20S and RPE-1 cells, respectively, showing a shift in polyadeny­
lation site usage in the absence of PABPN1 (Jenal et al., 2012). More than 90% of the 
detected transcripts in U20S cells and 82% in RPE-1 cells showed a shift towards 
proximal polyadenylation sites, a trend similar to that observed in CFI-25 depleted cells 
(Kubo et al., 2006). Furthermore, the authors proposed that PABPN1 directly inhibits 
3’end processing at proximal polyadenylation signals. Short expansions of GCG triplet 
repeats in the PABPN1 gene (trePABPNI) are the cause of oculopharyngeal muscular 
dystrophy (OPMD). 3’Seq analysis of skeletal muscle from a mouse model of OPMD, 
expressing the trePABPNI allele, demonstrated the same shift in polyadenylation site 
selection as was detected in cell lines artificially depleted of PABPN1.
NOVA2, a neuronal-specific splicing factor known to influence alternative splicing, was 
shown to be also implicated in the regulation of alternative polyadenylation. Affymetrix 
exon arrays of mRNAs derived from NOVA2 wild-type or knockout mouse brains led to 
the identification of 297 transcripts that showed differences in their 3’UTR length (Licata- 
losi et al., 2008). NOVA2 binding sites were found to be enriched around polyadenylation 
sites. The effect of NOVA2 on polyadenylation site usage was shown to be positional 
dependent. Stimulation of polyadenylation site usage was observed when the binding
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sites of NOVA2 were positioned upstream of the polyadenylation sites. In contrast, an 
inhibitory role was observed when NOVA2 binding sites were present downstream of the 
polyadenylation sites. For example, in the case of the Cugbp2 and Slc8a1 genes it was 
shown that NOVA2 binding sites are enriched downstream of the proximal polyadenyla­
tion sites of their transcripts. NOVA2 knockout resulted in a shift from the distal towards 
proximal polyadenylation site usage in both genes.
The AU-rich element (ARE) binding protein HuR is expressed ubiquitously and is critical 
in the regulation of mRNA stability. Recently, it has been demonstrated that HuR auto- 
regulates its expression by influencing alternative polyadenylation site usage in its own 
transcript (Dai et al., 2012). Elevated levels of HuR in the nucleus stimulate its binding 
to the GU-rich DSE of the proximal polyadenylation site in the HuR pre-mRNA. Thus, 
HuR is able to compete with the binding of CstF-64 to the proximal polyadenylation site 
favouring usage of the distal site. Thus, high levels of HuR result in the formation of the 
long HuR mRNA isoform. In contrast to the short, this long isoform contains destabilizing 
AU-rich elements in its 3’UTR, increasing mRNA decay rates and so result in a reduction 
of HuR protein production. Moreover, it has also been found that three neuron-specific 
Hu family members influence alternative polyadenylation of the HuR pre-mRNA in the 
same manner as HuR, leading to the production of the long HuR mRNA isoform and the 
decrease HuR levels in neurons (Mansfield and Keene, 2012). Interestingly, the ELAV 
protein, a Drosophila homolog of the mammalian Hu family, was shown to regulate al­
ternative 3’terminal exon selection of the ewg pre-mRNA in neurons (Soller and White,
2003). The usage of the ewg pre-mRNA intronic polyadenylation site is inhibited by ELAV 
binding to the AU-rich elements downstream of that site, leading to intron splicing and 
polyadenylation at the 3’most terminal exon. However, contrary to the HuR protein, ELAV 
does not affect dCstF-64 binding to the DSE of the intronic polyadenylation site present 
in the ewg pre-mRNA (Soller and White, 2003).
Interestingly, another example of polyadenylation in Drosophila revealed that RNAP II 
elongation kinetics can influence site usage of tandem alternative polyadenylation sites
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(Pinto et al., 2011). The polyadenylation pattern in Drosophila was analyzed in strains 
containing a mutant version of the RNAPII which shows 50% decrease in the transcrip­
tion elongation rates. A shift from distal to proximal polyadenylation site usage has been 
observed in mutant flies for six out of the eight analyzed genes.
1.2.2.1 3 ’Untranslated region (3’UTR)
As already mentioned, the usage of different tandem polyadenylation sites leads to the 
formation of mRNAs with the same coding capacity but different 3’UTR length. A va­
riety of cis-regulatory elements can be found along the 3’UTR which can influence the 
mRNA stability, cytoplasmic localization and translational efficiency (Figure 9). Usage 
of the tandem alternative polyadenylation sites frequently depends on the tissue type, 
the developmental stage, state of the cell growth and differentiation, and also different 
pathological conditions, like cancer. For example, during proliferation, dedifferentiation 
or cell transformation, the usage of proximal polyadenylation sites is stimulated leading 
to the formation of mRNAs with shorter 3 ’UTRs (Ji and Tian, 2009; Mayr and Bartel, 
2009; Sandberg et al., 2008). Shorter 3’UTRs contain less regulatory elements, which 
are associated with increased protein production (Mayr and Bartel, 2009; Sandberg et 
al., 2008). On the contrary, during differentiation or development, the usage of distal 
polyadenylation sites is favored leading to the formation of mRNA isoforms containing 
longer 3’UTRs (Ji et al., 2009). Longer 3 ’UTRs contain more regulatory elements that are 
able to cause destabilization of mRNAs and reduction in their translational efficiency, 
leading to a decrease in protein production (Mayr and Bartel, 2009; Sandberg et al., 
2008). Regulatory elements located along the 3’UTR are recognized by different RNA- 
binding proteins and/or microRNAs. For example, the previously mentioned members 
of the mammalian Hu family are AU-rich element (ARE) binding proteins which stimu­
late mRNA stability. Moreover, there are other ARE binding proteins that can provoke 
mRNA destabilization and degradation, such as tristetraproline (TTP) (von Roretz et al.,
2011). AU-rich elements are usually represented by one or several AUUUA pentamers
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Schematic representation of the cis-acting regulatory elements present in the 3’UTR.
Red box indicates microRNAs (miRNAs) target sites; green box indicates cis-acting elements that are recognized 
by the trans-acting factors other then CPEB and ARE-binding proteins; blue box indicates AU-rich element (ARE); 
violet box indicates cytoplasmic polyadenylation element (CPE) and adenylation control element (ACE); AAUAAA 
indicates the position of polyadenylation signal; arrowheads indicate various pathways by which cis-acting regula­
tory elements present in the 3 ’UTR influence gene expression; adapted from Lutz and Moreira 2011.
or UUAUUUA(U/A)(U/A) nonamers. Another element that can be present in the 3’UTR is 
the cytoplasmic polydenylation element (CPE). The consensus sequence of CPE is the 
UUUUAU motif, which is bound by the cytoplasmic polyadenylation element binding 
protein (CPEB) (Mendez and Richter, 2001). Association of CPEB with the CPE leads to 
translational repression of the mRNAs. Phosphorylation of the CPEB results in its disso­
ciation from the CPE, triggering cytoplasmic polyadenylation and translational activa­
tion of the mRNA. The impact of the CPEB translational repression depends on the po­
sition and number of CPEs in respect to the hexanucleotide motif and pumilio-binding 
element (PBE) (Pique et al., 2008). The PBE is another important element implicated in 
translational repression. The UGUANAUA sequence is the PBE consensus motif and 
represents one of the 50 most conserved octamers present in the mammalian 3’UTRs 
(Xie et al., 2005). Members of the PUF protein family (Pumilio protein in Drosophila 
melanogaster and fem-3 binding factor protein in Caenorhabditis elegans) recognize 
the PBEs and stimulate translational repression. There are two members of mammalian 
PUF proteins, called PUM1 and PUM2. The PUM2 is expressed in hippocampal neu­
rons localizing to dendrites and its depletion leads to altered dendritic outgrowth and 
synaptic function (Vessey et al., 2010). The CPEB was also shown to regulate translation 
of mRNAs localized in dendrites of mammalian neurons, such as CAMKIIa mRNA. In 
addition to its role in translational repression, CPEB was shown to affect the dendritic 
targeting of the CAMKIIa mRNA (Huang et al., 2003). Other proteins are also found to sti-
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mulate targeting of mRNAs to dendrites, such as ZBP1 and Staufen. These proteins bind 
localization elements placed along the 3’UTR of the target mRNAs.
As mentioned above, some of the 3’UTR sequence motifs are targets for microRNAs 
(miRNAs). miRNAs are -22 nucleotides long noncoding RNAs. 6-8 nucleotides of the 
5’end of the miRNAs represent the seed region which binds imperfectly complementary 
elements in the 3’UTR of their target mRNA (Bartel, 2004). Binding of the miRNAs to their 
target sequences results in mRNA degradation and repression of translation. Translatio­
nal repression by miRNAs is a potent and widespread mechanism of gene expression 
regulation. According to the latest realase of the constantly growing miRNA database, 
miRBase (Release 19, August 2012, http://www.mirbase.org), there are 1600 precursors 
and 2042 mature human miRNAs. It has been estimated that miRNAs regulate the expres­
sion of more than half of the mammalian genes (Friedman et al., 2008). Therefore, miRNAs 
are, directly or indirectly, implicated in all cellular pathways, including RNA processing. 
For example, splicing outcome can be influenced by the biogenesis of intronic miRNAs 
(Janas et al., 2011; Shomron and Levy, 2009), or by direct miRNA targeting of splicing fac­
tors, such as PTB (Makeyev et al., 2007). The neuronal specific microRNA mir-124 directly 
targets PTB, a repressor of neuronal specific splicing, causing the increase in the inclusion 
of neuron-specific alternative exons and enhancing neuronal diferentiation (Makeyev et 
al., 2007). The miRNAs exert their role in the cytoplasm. However, certain miRNAs can be 
localized in the nucleus (Hwang et al., 2007; Liao et al., 2010; Jeffries et al., 2011), where 
they can mediate transcriptional gene silencing (TGS) (Malumbres, 2012). For example, 
mir-320 was shown to mediate TGS at the POLR3D promoter (Kim et al., 2008). It was 
also shown that nuclear miRNAs can target antisense non-coding RNAs, as in the case of 
nuclear mir-671, which directly downregulates circular antisense transcript of the CDR1 
gene (Hansen et al., 2011). The antisense CDR1 non-coding RNA positively regulates 
CDR1 mRNA levels and its downregulation leads to a decrease in the CDR1 mRNA levels. 
As miRNAs target 3'UTRs, it would be interesting to study the possible role of the nuclear 
miRNAs in the regulation of 3'end processing.
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1.3 Beta adducin
Beta adducin is a member of the adducin protein family. In mammals adducin pro­
tein family comprises of alpha, beta and gamma adducins which are encoded by the 
ADD1, ADD2 and ADD3 genes, respectively. Adducin is a membrane skeleton protein 
and functions as a dimer-tetramer composed of alpha/beta or alpha/gamma hetero­
dimers. It is localized at the spectrin-actin junctions where it has a role in capping the 
fast-growing ends of actin filaments, bundling actin filaments and recruiting spectrin to 
actin (Matsuoka et al., 2000).
The expression of beta adducin is restricted to brain and hematopoietic tissues, where­
as alpha and gamma subunits are expressed ubiquitously (Gilligan et al., 1999). Several 
alpha and beta adducin polymorphisms have been found to be associated with hyper­
tension in humans and Milan hypersensitive rats (Cusi et al., 1997; Tripodi et al., 1991). 
In addition, beta-adducin-deficient mice suffer from mild anemia with compensated 
hemolysis, which corresponds to the human spherocytic hereditary elliptocytosis syn­
drome (Muro et al., 2000). Moreover, absence of beta adducin in the knockout (KO) mice 
causes motor coordination, behavioral and learning deficits which are associated with 
impairment of long-term potentiation (LTP) and complete abolishment of long-term de­
pression (LTD) (Porro et al., 2010). Beta adducin is involved in the stabilization of synap­
tic structures in mice housed in an enriched environment, containing different types of 
stimuli such as toys and running wheels, which lead to enhanced plasticity (Bednarek
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and Caroni, 2011). Upon environmental enrichment, increased levels of phosphorylated 
beta adducin in mice hippocampus influence the disassembly of synapses, whereas non- 
phosphorylated beta adducin increases the assembly of new synapses (Bednarek and 
Caroni, 2011). Therefore, upon enhanced plasticity the absence of beta adducin in KO 
mice leads to increased synapse turnover and impairment of long-term memory and lear­
ning (Bednarek and Caroni, 2011).
1.3.1 Mouse beta adducin gene structure and expression
The mouse beta adducin gene is located on chromosome 6, spans about 100 Kbp and 
comprises 16 exons (Figure 10). Tissue-specific expression of the mouse beta addu­
cin gene is predetermined by the use of alternative tissue-specific promoters and first 
exons (Costessi et al., 2006). The gene promoter and the first exon that are specific for 
neuronal tissues (brain promoter and first exon) are located roughly 50 Kbp upstream of 
the ones specific for erythropoietic tissues (spleen promoter and first exon). Tissue spe­
cificity of the brain promoter is only observed in mice and rats, whereas in human its ac­
tivity is also observed in spleen and bone marrow, as revealed by the RT-PCR analyses 
of the first exon expression in different human, mouse and rat tissues (Costessi et al.,
2012). Activation of the spleen promoter is detected only in erythropoietic tissues for all 
three species. The translation start site is located in the second common exon, thus the 
presence of the tissue-specific first exons is not involved in the structure of the final pro­
tein product. In addition to the tissue specificity of the promoter usage, tissue specific 
mRNA isoforms are created by the usage of three tandem alternative polyadenylation 
sites placed in the 3’most terminal exon of the mouse beta adducin pre-mRNA (Costes­
si et al., 2006). In mice, the use of the proximal polyadenylation sites (PAS1 and PAS2-3) 
in erythroid tissues generates 3’UTRs in length of -800 and -1300 bases, respectively, 
while the use of the distal polyadenylation site (PAS4) in brain generates an unusually
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Structure of the mouse beta adducin gene.
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Figure 11
Tissue specific expression of the short and long beta adducin mRNA isoforms.
Left panel -  Northern blot analysis of RNAs from mouse, rat and human brain and spleen, and human bone marrow  
(BM); Right panel -  Western blot analysis of mouse brain and ghost protein extracts. Taken from Costessi et al. 2006.
long 3’UTR of about 5.7 kilobases. The presence and use of the different tandem alter­
native polyadenylation sites of the beta adducin is very well conserved among different 
species suggesting an important and tissue specific roles for each of the generated 
3’UTRs possibly by affecting mRNA stability, translatability and subcellular localization. 
To summarize, in mouse erythroid tissues, beta adducin gene expression is determined 
by the usage of the spleen specific promoter and the proximal polyadenylation sites 
leading to the formation of a -3.1 -3.7 Kb long mRNA isoform (Figure 11, left panel, (Co­
stessi et al., 2006)). In contrast, in mouse brain, an -8.3 Kb long beta adducin mRNA 
isoform is formed, due to the usage of the brain specific promoter and the distal
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polyadenylation site. Both mRNA isoforms lead to the production of a protein that is 
similar in size in mouse erythroid tissues (97 kDa) and brain (110 kDa) (Figure 11, right 
panel, (Costessi et al., 2006)). The molecular mechanism involved in the regulation of 
the beta adducin tissue specific alternative promoter and polyadenylation site usage 
to date are not characterized.
To complicate matters, beta adducin pre-mRNA is also subjected to alternative splicing 
and alternative 3'terminal exon selection. Alternative splicing of several internal exons of 
the beta adducin pre-mRNAs leads to the formation of different mRNA variants. However, 
these transcript variants represent a low fraction of the total beta adducin mRNA pool and 
the corresponding proteins have not been detected. In addition, intron 13 retention and 
usage of the polyadenylation site placed in this intron leads to the formation of shorter 
mRNA transcripts (beta-add63 mRNAs). Although low levels of the beta-add63 mRNAs 
can be detected by Northern blots using RNAs isolated from mouse spleen and brain 
(Costessi et al., 2006), a corresponding protein has not yet been detected.
1.3.1.1 Mouse beta adducin tandem alternative polyadenylation signals 
(structure and conservation)
As previously mentioned, there are three polyadenylation signals placed in the mouse 
beta adducin 3’UTR. The conservation between humans, mice and rats and the predicted 
cis-acting elements of each signal are described in Costessi et al., 2006. Mice and rats 
contain two proximal polyadenylation signals, whereas three sites are present in humans. 
All species contain only one distal polyadenylation signal.
The region of the first proximal polyadenylation signal shows modest sequence conser­
vation between humans, mice and rats (Figure 12). The cleavage and polyadenylation 
site (PAS1) is represented by a Guanosine at the base position 1076, relative to the first 
base of the mouse beta adducin last exon. A canonical AUUAAA hexanucleotide motif is 
found 18 nucleotides upstream of the cleavage site. The observed hexanucleotide motif is 
poorly conserved, as in the humans the noncanonical ACUAAA motif is present. Also the
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Figure 12
Sequence structure and conservation of the region containing mouse beta adducin first proximal 
polyadenylation signal.
Upper panel -  schematic representation of the mouse beta adducin last exon; numbers indicate nucleotide positions; 
a dark grey box indicates the coding region; a light gray box indicates the 3 ’UTR; a white box indicates 3 ’genomic 
flanking region; S T O P -s to p  codon; PAS1 -  the first polyadenylation site; PAS23 -  the second polyadenylation site; 
PAS4 -  the fourth polyadenylation site; the alignment of the genomic sequences of humans, rats and mice in the first 
proximal polyadenylation region is enlarged below; MultiPipMaker global sequence alignment program was used; 
USE -  upstream sequence element; Hm -  hexanucleotide motif; DSE -  downstream sequence element.
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putative U/GU- rich upstream and downstream sequence elements are poorly conserved. 
The second proximal polyadenylation signal contains multiple cleavage sites that are 
located in the region from the base 1549 to the base 1624, relative to the first base 
of the mouse last exon (Figure 13). Cleavage at either of these sites is considered as 
the usage of the second proximal polyadenylation site (PAS2-3). None of the descri­
bed hexanucleotide motifs (Tian et al 2005) are present in the PAS2-3 region. The ali­
gnment of the second proximal polyadenylation signal has shown poor conservation 
among the analyzed species.
Contrary to the proximal polydenylation signals, the distal polyadenylation signal 
is well conserved between humans, mice and rats (Figure 14). Moreover, compa­
rison of the beta adducin last exon genomic sequences in 30 vertebrate species 
showed two major islands of conservation (Figure 15). The first island represents 
the coding region of the last exon, which was expected as the coding regions are 
highly conserved. The second island of conservation is located in the genomic re­
gion containing the distal polyadenylation signal. A high degree of conservation has 
been found in all the analyzed polyadenylation elements: the hexanucleotide motif, 
the cleavage site and the U/GU rich upstream and downstream sequence elements 
(Figure 14). The cleavage and polyadenylation site of the distal polyadenylation 
signal (PAS4) is represented by the CA dinucleotide, the most common dinucleo­
tide found for vertebrate cleavage sites (Sheets et al., 1990). The CA dinucleotide 
is positioned at the base 5931, relative to the starting base of the mouse beta ad­
ducin last exon. The putative hexanucleotide motif is located 20 bases upstream 
of the cleavage site and is represented by the AGUAAA variant, which is found as 
the polyadenylation hexamer in -4%  of the human and mouse genes (Tian et al., 
2005). The absence of the canonical and more efficient AAUAAA hexanucleotide 
motif is probably compensated by the presence of the highly conserved U/GU rich 
upstream and downstream elements. Additionally, about 200 bases upstream of 
the cleavage site, in the highly conserved and AU-rich region, one putative ARE
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Figure 13
Sequence structure and conservation of the region containing mouse beta adducin second proximal 
polyadenylation signal.
Upper panel -  schematic representation of the mouse beta adducin last exon; indications are as described in Figure 
12; the alignment of the genomic sequences of humans, rats and mice in the second proximal polyadenylation region 
is enlarged below; MultiPipMaker global sequence alignment program was used.
and two putative CPE motifs are found.
Overall, the distal polyadenylation signal of the mouse beta adducin and its flanking 
regions show a higher level of conservation, suggesting that this signal could be more 
efficiently used than the proximal ones. In general, distal signals are stronger than the 
proximal ones in an array of tandem polyadenylation signals (Beaudoing et al., 2000; 
Legendre and Gantheret, 2003). Diverse sequence composition and conservation 
rate of the mouse beta adducin polyadenylation signals could acount for the alter­
native polyadenylation regulation.
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Figure 14
Sequence structure and conservation of the region containing mouse beta adducin distal polyadenylation signal.
Upper panel -  schematic representation of the mouse beta adducin last exon; indications are as described in Fi­
gure 12; the alignment of the genomic sequences of humans, rats and mice in the distal polyadenylation region is 
enlarged below; MultiPipMaker global sequence alignment program was used; CPE -  cytoplasmic polyadenylation 
element; ARE -  AU-rich element.
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Figure 15
Conservation along the mouse beta adducin last exon betw een 30 vertebrate species
The data were obtained from the UCSC genome browser; lower panel -  schematic representation of the mouse 
beta adducin last exon, indications are described in Figure 12
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Aims of the thesis
As already mentioned, the beta adducin pre-mRNA undergoes tissue specific alternative 
polyadenylation. Two proximal spleen-specific and one distal brain-specific polyadenylation 
sites are placed along the 3’UTR of the mouse beta adducin gene. In the mouse brain, the 
usage of the distal polyadenylation site leads to the formation of an mRNA isoform with 
an unusually long 3’UTR (-5.7 Kb), which can contain different cis-regulatory elements 
regulating stability, localization and translability of the beta adducin mRNA.
In order to understand the molecular mechanisms regulating alternative polyadenylation 
of the mouse beta adducin pre-mRNA, the main aim of the thesis is the identification 
of cis-acting elements, and possible trans-acting factors, that regulate the usage 
of the distal polyadenylation site (PAS4) in the pre-mRNA. In addition, we aim to 
clarify whether the long 3’UTR harbors regulatory sequences that influence mRNA 
stability and translational efficiency.
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Results
2.1 Identification of the canonical cis-acting elements 
regulating usage of the distal PAS4 of the beta-adducin 
pre-mRNA
The beta-adducin pre-mRNA can be cleaved and polyadenylated at different PASs in 
a tissue-specific manner. However, it is certainly unclear if alternative polyadenylation 
plays a physiological role in the regulation of this gene. We therefore, aim to establish 
to what extent alternative polyadenylation affects beta-adducin gene expression. Un­
derstanding the regulatory mechanisms involved in this alternative pre-mRNA proces­
sing is the first step to address this question. To do so, it is important to identify the 
cis-acting sequences and characterize the trans-acting factors that direct alternative 
polyadenylation in the beta-adducin pre-mRNA. An effective strategy to study this issue 
is based in the generation of chimeric reporter minigenes in which the genomic regions 
of interest are cloned downstream of an alpha globin based reporter construct (See 
Materials and Methods Section). We therefore cloned the three PASs present in the 
mouse beta adducin 3 ’UTR and their respective flanking sequences downstream of the 
alpha globin gene, effectively substituting the alpha globin PAS. The final construct and 
the selected beta adducin sequences included are represented in Figure 16. The first 
region, called A1, contained the PAS1 spanning from base 17 to 1416, respective to 
the first base of the beta adducin last exon. The region called A23 included the PAS2-3
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Figure 16
Schematic representation of the generation of the mouse beta adducin chimeric minigene construct.
A: schem atic representation of the mouse beta adducin last exon as shown in Figure 12.; different regions 
(A1, A23 and A4) containing polyadenylation sites mouse beta adducin polyadenylation sites (PAS1, PAS23 
and PAS4) are represented as orange, yellow and blue boxes, respectively; arrowheads indicate the size of 
each region; B: schem atic representation of the mouse beta adducin chimeric minigene construct containing 
all three polyadenylation sites, A1-A23-A4; green box indicates SV40 promoter region; violet boxes indicate 
exons of the alpha globin gene; STOP indicates the position of the beta adducin stop codon, which is also the 
expected stop codon of the globin-adducin chimera.
and extended from base 1416 to 1994. The last region, called A4, contained the PAS4 
and spanned from base 5405 to 6567. The final construct, called A1-A23-A4, contai­
ned all three regions (A1, A23 and A4) (Figure 16B). The chimeric gene was under the 
transcriptional control of the SV40 promoter. Due to its high transfection efficiency rate, 
the HeLa cell line was the first one in which expression of the A1-A23-A4 construct was 
analyzed. As it can be seen in Figure 17B, only one signal was obtained in the Northern 
blot analysis. The size of the detected band suggested that the PAS used was the PAS4 
(the expected size was 2.93Kb without the polyA tail). To confirm this hypothesis, a 
3’RACE PCR experiment was performed, followed by sequencing of the amplified PCR 
products (Figure 17A and 17C). This experiment demonstrated that pre-mRNA proces­
sing in HeLa cells of the transcript originating from the A1-A23-A4 construct reprodu­
ced the use of the PAS4, as it normally occurs for the endogenous beta-adducin gene in 
neuronal tissues (Costessi et al., 2006). In mouse and rat brain, the majority of the beta 
adducin transcripts is processed at the PAS4, whereas a small fraction of transcripts 
ends at proximal PASs (PAS1 and PAS2-3) (Costessi et al., 2006; Tripodi et al., 1991). 
The less efficient 3‘end procesing of the PAS1 and PAS2-3 in the brain could be due to 
their supression by some factors and/or a lack of specific factors that are present jn the 
erythroid tissues, where these PASs are efficiently used. Consequently, the supressing
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Identification of the core elem ents of the m ouse beta adducin distal polyadenylation signal.
A: schematic representation of the mouse beta adducin chimeric minigene construct, A1-A23-A4; indications are as 
described in Figure 16; region containing distal polyadenylation signal is enlarged below; arrowheads indicate the 
primer pairs (I and II) used for the 3 ’RACE analysis, panel C; B: Northern blot analysis of 15 pg total RNA prepared 
from mouse brain (mBR) and 1,5 pg total RNA prepared from HeLa cells previously transfected with the A1-A23-A4, 
A1-A23-A4[AHm], A1-A23-A4[AUSE] and A1-A23-A4[ADSE] constructs; the positions of the 28S and 18S rRNAs 
are indicated with black arrows; the sizes of the mRNAs are indicated on the left; there is no control for the tran­
sfection efficiency. C: 3 ’RACE analysis of the RNAs used for the Northern blot showed in panel B; the first (I) and the 
second (II) 3’RACE PCR reactions are indicated on the left; MWM -  molecular weight marker.
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factors could direct the polyadenylation machinery to the distal PAS4. However, the 
mechanisms regulating 3'end processing of the beta adducin transcripts are not known. 
Considering the fact that polydenylation of the beta-adducin pre-mRNA occurs in a 
tissue-specific manner, expression of the A1-A23-A4 construct has been tested in dif­
ferent cell lines of neuronal (SK-N-BE, SH-SY5Y and PC12 cells) or erythroid (MEL and 
K562 cells) origin. Unfortunately, no reporter signal was detected in these cells, proba­
bly due to low transfection efficiency, low activity of the SV40 promoter, or a combina­
tion of both. Transfection of these cell types was repeated using different cationic lipid 
transfection reagents and five to ten times higher amounts of total RNA were loaded in 
the Northern blot experiments. To circumvent the possibility of low promoter activity, the 
SV40 promoter was replaced with the mouse beta adducin spleen specific one and its 
activity tested in MEL cells. However, no signal was detected after the introduction of the 
above-mentioned changes (data not shown). At this point, with the main aim of characte­
rizing the cis-acting regulatory elements and trans-acting factors involved in the use of 
the distal PAS4, we decided to do this analysis in HeLa cells. First, we looked for the 
core cis-acting elements regulating cleavage and polyadenylation. Putative polydenyla­
tion core elements, hexanucleotide motif (Hm), upstream and downstream sequence ele­
ments (USE and DSE), were identified after visual inspection of the sequence and in silico 
comparison with the reported consensus sequences of these elements (Figure 17A, open 
boxes). To test their functionality, each of these putative elements was deleted in the ori­
ginal A1-A23-A4 minigene resulting in the three mutant constructs: A1-A23-A4[AHm], 
A1 -A23-A4[AUSE] and A1-A23-A4[ADSE]. Deletion of the USE caused a decrease in 
the mRNA levels, probably due to a reduction in polyadenylation efficiency (Figure 17B). 
Absence of either the Hm or the DSE resulted in shorter mRNAs (Figure 17B). 3’RACE 
(Figurel 7C) and subsequent sequencing analysis of the PCR products showed that the­
se differences in the size of the mRNA were due to the activation of two cryptic PASs, 
located about 200 bases upstream of the natural PAS4 (Figure 17A, indicated as “cryp­
tic PAS4 (a) and (b)”). Therefore, these experiments confirmed the role and importance
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of the core elements for the definition and correct 3’end processing of the beta-adducin 
pre-mRNA at the PAS4.
I should mention that the described study of the cis-acting elements had started 
prior to my arrival at the lab. I have contributed to this work studying the effect of 
the deletion of putative DSE from the PAS4. To this end, I have performed Northern 
blot, 3 ’RACE and sequencing analysis. I have also performed the transfection ex­
periments of the A1-A23-A4 construct in MEL, K562 and SK-N-BE cells to evaluate 
alternative PAS use.
After the determination of the cis-acting elements of the PAS4, this research line was 
directed towards the identification of trans-acting factors recognizing these cis-acting 
elements and participating in the 3’end processing of the beta-adducin pre-mRNA at 
the PAS4. These studies, and those related to the characterization of the core cis-acting 
elements mentioned above, were conducted by a postdoctoral fellow in the lab, Dr. Lui­
sa Costessi, and are not part of this thesis. Instead, my research project focused on the 
characterization of the non-canonical cis-acting elements regulating polyadenylation of 
the beta-adducin pre-mRNA and the obtained results are described below.
2.1.1 Influence of the position of the PAS4 for its usage
To understand whether the absence of activity of the PAS1 and PAS23, and the use of 
the PAS4 site were influenced by their relative position, the additional A4 region was 
inserted upstream of the two proximal PASs (Figure 18A, A4-A1-A23-A4 construct). Af­
ter transfecting this construct into HeLa cells, no signal was obtained by Northern blot 
analysis (Figure 18B, Lane 2). This result shows that neither the artificially “proximal” 
PAS4, nor the artificially “distal” PAS1 and PAS2-3 or the original distal PAS4 were used 
in this particular construct. Therefore, these results suggested that both the position 
and order of the different PASs present in the 3’UTR of the beta-adducin pre-mRNA 
may influence their usage.
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Figure 18
Influence of the position of the PAS4 for its usage.
A: schem atic representation of the mouse beta adducin chimeric minigene constructs, A1-A23-A4 (1) and A4- 
A1-A23-A4 (2); STOP indicates the position of the beta adducin stop codon, which is also the expected stop 
codon of the globin-adducin chim era in the construct 1; expSTOP indicates the expected stop codon of the  
globin-adducin chimera in the construct 2. B: Northern blot analysis of 1 ,5  pg total RNA prepared from HeLa 
cells previously transfected w ith the constructs shown in panel A; the positions of the 28S and 1 8S rRNAs are 
indicated on the right; the expected sizes shown in panel C are indicated on the left; there is no control for the 
transfection efficiency. C: the expected sizes of the mRNAs of the constructs shown in Panel A, up to the pre­
dicted PAS4, (i.e., the asterisk indicates w ithout the pA tail).
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Figure 19
Effect of the addition of beta adducin introns on PAS4 usage.
A: schematic representation of the mouse beta adduci n chimeric minigene constructs, A1-A23-A 4 (1) EX-A1-A23-A4  
(2) and A4-A1-A 23-A4 (3) and EX-A4-A1-A23-A4 (4); the alpha globin fragment used as a probe for the Northern blots 
is indicated; STOP indicates the position of the beta adducin stop codon, which is also the expected stop codon 
of the giobin-adducin chimera in the construct 1 and 2; expSTOP indicates the expected stop codon of the 
globin-adducin chimera in the constructs 3 and 4. B: Northern blot analysis of 10 pg total RNA prepared from HeLa 
cells previously transfected with the constructs shown in panel A; the positions of the 28S and 18S rRNAs are indicated 
on the right; the expected sizes shown in panel C are indicated on the left; there is no control for the transfection 
efficiency. C: the expected sizes of the mRNAs of the constructs shown in Panel A, up to the predicted PAS4 (i.e., the aste­
risk indicates without the pA tail).
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In order to generate more physiologically relevant minigenes, I replaced the alpha glo- 
bin terminal exon with a fragment that included sequences from the mouse beta ad­
ducin Exon 14, 15 and the first 16 bases of exon 16 and the respective introns into the 
A1-A23-A4 and A4-A1-A23-A4 constructs (Figure 19A). The expression pattern deter­
mined by Northern blot was similar to that of minigenes not-containing the extra exons 
and introns (Figure 19B), indicating that the introduced sequences had no influence on 
pre-mRNA processing and PAS choice in the reporter transripts.
Flowever, the absence of expression from both A4-A1-A23-A4 constructs was very 
surprising. It appeared that the position of the PAS4 was important and that it was not 
processed when placed upstream of the proximal sites. But, what also remained unex­
plained was why the distal PAS4 in the A4-A1-A23-A4 was not functional.
Once the pre-mRNA is cleaved at the PAS, termination of the transcription should oc­
cur somewhere in the region downstream of the cleavage site. Thus, we reasoned that 
the region downstream of the PAS4 could contain elements causing RNA Polymerase 
II to terminate or pause transcription. By inserting the PAS4 sequence in the upstream 
region in the A4-A1-A23-A4 construct, premature termination or pausing could occur in 
these constructs. To test this hypothesis, I removed the 552 bp long region downstream 
of the "proximal" PAS4 DSE from both the A4-A1-A23-A4 and EX-A4-A1-A23-A4 con­
structs (Figure 20A, A4[5405-6015]-A1-A23-A4 and EX-A4[5405-6015]-A1 -A23-A4 
constructs). No signal was observed by Northern blot analysis of RNAs prepared from 
FleLa cells transfected with these constructs (Figure 20B), suggesting that this region 
was not responsible for the absence of any detectable transcript from the A4-A1-A23- 
A4 and EX-A4-A1-A23-A4 constructs.
Overall, we could conclude that:
• The position of the PAS4 was important
• The addition of the mouse beta-adducin exons 14 and 15, and their corresponding introns 
to improve the genomic context had no influence on the efficiency of the pre-mRNA pro­
cessing and PAS choice.
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Figure 20
Influence of the position of the PAS4 for its usage: deletion of the downstream region of the proximal PAS4.
A: schematic representation of the mouse beta adducin chimeric minigene constructs, A4[5405-6015]-A1-A23-A4 
(1) and EX-A4[5405-6015]-A1-A23-A4 (2); expSTOP indicates the expected stop codon of the globin-adducin  
chimera. B: Northern blot analysis of 5 pg total RNA prepared from HeLa cells previously transfected with the con­
structs shown in panel A; the positions of the 28S and 18S rRNAs are indicated on the right; the expected sizes shown 
in panel C are indicated on the left; C - control RNA; there is no control for the transfection efficiency. C: the 
expected sizes of the mRNAs of the constructs shown in Panel A, up to the predicted PAS4 (i.e., the asterisk indicates 
without the pA tail).
• The deletion of the sequences placed downstream of the proximal PAS4 (in the A4[5405- 
6015]-A1-A23-A4 and EX-A4[5405-6015]-A1-A23-A4 constructs) did not activate the use 
of the distal PAS4.
The precise reasons why the A4-A1-A23-A4 and EX-A4-A1-A23-A4 constructs showed no 
expression in the Northern blot still remains unclear.
It should be taken into account that the above-mentioned experiments were performed 
in the absence of transfection efficiency controls and thus conclusions drawn are only 
qualitative. The preliminary initial experiment with the A4-A1-A23-A4 construct was per­
formed by Dr. Luisa Costessi (Figure 18), prior to my arrival to the lab but this research line 
was temporarily postponed until my arrival to the lab. I have prepared the rest of the above 
mentioned constructs and performed experiments represented in Figures 19 and 20.
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2.2 Identification of non-canonical cis-acting elements 
regulating usage of the distal PAS4 in the beta-adducin 
pre-mRNA
Above, I have described the studies that revealed the canonical cis-acting elements ne­
cessary for the correct definition and 3’end processing of the beta-adducin pre-mRNA 
at the PAS4 (Figure 17). These studies were conducted in a context where all three 
known PASs of beta-adducin were present. Considering the results we obtained with 
the A4-A1-A23-A4 construct in the previous section, we wondered whether the pre­
sence of a proximal PASs could have an impact on the usage of the distal PAS4. To test 
this possibility, the regions containing the proximal PASs, A1 and A23, were removed 
from the original minigene A1-A23-A4 construct generating the A4 construct (Figure 
21 A). Surprisingly, no signal was detected after transiently transfecting the A4 construct 
into HeLa cells (Figure 21B, Lane 2). Adding back only the A23 region (Figure 21 A, 
construct A23-A4) was not enough to completely restore the mRNA levels detected for 
the A1-A23-A4 construct (Figure 21B and D, Lane 3 compared to Lane 1). Interestingly, 
adding back only the A1 region (Figure21A, construct A1-A4) restored the activity of 
the PAS4 (Figure 21B, Lane 4). In addition, the presence of the A1 region immediately 
upstream of PAS4 increased mRNA levels by two fold when compared to the product 
obtained with the A1-A23-A4 construct (Figure 21B and D, Lane 4 compared to Lane 
1). On the contrary, a construct containing the A1 region in the antisense orientation 
showed no activity (Figure 21 A, construct INA1-A4, Figure 21B, Lane 5), ruling out that 
the increase in mRNA levels produced by the A1-A4 construct could be related to the 
positioning of the PAS4 relative to the terminal exon. Consequently, the A1 region con­
tains cis-acting regulatory elements important to make transcripts viable.
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Figure 21
The presence of the A1 region is necessary to get ch im eric m inigene construct expression.
A:Schematic representation of the chimeric minigene constructs: A1-A 23-A 4 (1), A4 (2), A23-A4 (3), A1-A 4 (4) and 
INA1-A4 (5); the alpha globin fragment used as a probe for the Northern blots is indicated; the green box indicates 
the SV40 promoter; the orange, yellow and blue boxes indicate A1, A23 and A4 region, respectively; the different beta 
adducin polyadenylation sites (PAS) and stop codon are indicated. B: Northern blot analysis of total RNA prepared 
from HeLa cells previously transfected with the constructs shown in panel A; the p-EGFP-C2 plasmid was used for 
the normalization of the transfection efficiency; the positions of the 28S and 18S rRNAs are indicated on the right; the 
expected sizes shown in panel C are indicated on the left; C: the expected sizes of the mRNAs of the constructs 
shown in Panel A, up to the predicted PAS4 (i.e., the asterisk indicates without the pA tail). D: the relative mRNA levels 
were calculated as the ratio between the analyzed mRNAs and GFP mRNA represented in Panel B; quantification of the 
Northern blot signals has been performed using the Cyclone Phosphorimager and the OptiQuant software (Packard); the 
mean + /- S.D. of three independent experiments is shown.
59
Chapter 2
One of the possible reasons for the absence of signal observed with the A4 and INA1- 
A4 constructs could be the degradation of the transcribed mRNA. mRNA degradation 
can be triggered as a part of mRNA surveillance pathway activated during translation 
(Garneau et al.f 2007). If the mRNAs produced from the A4 and INA1-A4 constructs 
were degraded during translation, then blocking translation of mRNAs should lead to an 
increase in the levels of A4- and INA1-A4-derived mRNAs, should this become visible 
by the Northern blot. To prevent translation dependent mRNA degradation, after tran­
sfection of the A4 and INA1-A4 constructs, HeLa cells were treated with cycloheximi- 
de, an inhibitor of protein synthesis in eukaryotes. I have prepared total RNA from the 
cycloheximide-treated cells and analyzed it by Northern blot. As can be seen in Figure 
22A, despite the inhibition of translation, no mRNAs were detected in RNA isolations 
from cells transfected with either A4 or INA1-A4 construct. As a control for the effi­
ciency of the cycloheximide treatment, I have performed semiquantitative RT-PCR of a 
TDP-43 mRNA variant generated by alternative splicing, named V2, known to undergo 
nonsense mediated decay (NMD) (Figure 22C and D) (Ayala et al., 2011). Therefore, I 
can conclude that the absence of expression of the A4 and INA1-A4 constructs was not 
due to mRNA degradation by mRNA surveillance pathways activated during translation. 
In the nucleus, inefficiently polyadenylated mRNAs are targeted, retained near or at the site of 
their transcription and degraded by the nuclear RNA exosome complex (Hilleren et al., 2001; 
Schmid and Jensen, 2008). Therefore, another possible cause for the absence of expression 
from the A4 and INA1-A4 constructs could be inefficient 3’end processing of the pre-mRNA
at the PAS4 which could lead to its degradation. Additionally, the observed differences in 
Figure 22 »
Determination of RNA degradation by cycloheximide treatment.
A: Northern blot analysis of total RNA prepared from HeLa cells previously transfected with the A4, A1-A4 and 
INA1-A4 constructs; 24h after the transfection 50 pg/ml cycloheximide (CHX) was added to the cells, and after 3  
hours cells were collected and RNA was prepared; the p-EFGP-C2 plasmid was used to normalize the transfec­
tion efficiency; the positions of the 28S and 18S rRNAs are indicated on the right; the expected mRNA sizes are 
indicated on the left; B: The relative mRNA levels were calculated as described for Figure 21; the mean + / -  S.D. 
of three independent experiments is shown. C: RT-PCR analysis of TD P-43 V2 and GAPDH transcripts from the 
same RNAs used for the Northern blot shown in Panel A; RT indicates reverse transcriptase, MW  indicates mole­
cular weight marker; D: Quantification of the TD P-43 V2 normalized to the GAPDH signal obtained in Panel C; the 
quantification has been performed using Quantity One software (BioRad).
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the expression levels of the constructs shown in Figure 21 could be the consequence of 
differences in the efficiency of 3’end processing at the PAS4. To test this hypothesis, I have 
performed RNase protection assays (RPA) with the same RNA isolations previously used for 
the Northern blot experiments shown in Figure 21. For the RPA, a 324 nt long input probe 
(IP) was used, that has 289 nt complementary to the pre-mRNA transcript (205nt upstream 
and 84nt downstream of the PAS4. Figure 23B). As a positive control, a total RNA from adult 
mouse brain (mBR) was also assayed. In addition to the expected band (205nt), two addi­
tional mBR protected products were observed (Figure 23C, asterisks). However, these pro­
ducts are likely unspecific as in the Northern blot and 3'RACE analyses only the expected 
product was detected (Figure 17B and C) and there is no EST-support for the presence of 
additional beta adducin PASs downstream of the PAS4. The cleaved protected product 
(pA) was clearly detected for the A1-A23-A4, A23-A4 and A1-A4 constructs (Figure 23C, 
Lanes mBR, 1,3 and 4), but not for A4 and INA1-A4 (Figure 23C, Lanes 2 and 5), as alrea­
dy observed with the Northern blot analysis (Figure 21B). In addition, uncleaved protected 
products (RT-readthrough) were detected in all tested constructs at roughly the same levels, 
suggesting that all constructs were transcriptionally active. Cleavage efficiency was calcu­
lated as the ratio between the signal obtained for the pA product and that of the RT band, 
as described in Dalziel et al 2007. The A1-A4 construct showed a twofold increase in the 
cleavage efficiency in comparison with the A1-A23-A4 one (Figure 23D, Lane 4 compared 
with Lane 1). The A23-A4 construct showed more than two-fold decrease in cleavage effi­
ciency compared to the A1-A23-A4 construct (Figure 23D, Lane 3 compared with Lane 1).
Figure 23 »
Cleavage efficiency of the pre-mRNA is enhanced by the presence of the A1 region.
A: Schematic representation of the chimeric minigene constructs: A1-A23-A4 (1), A4 (2), A23-A4 (3), A1-A4 (4) and 
INA1-A4 (5). B: Schematic representation of the A4 region containing PAS4 and the probe used in the RNase protection 
experiment shown below. The expected protected fragments, with their expected sizes are shown. Nucleotide positions 
are numbered respective to the first base of the last mouse beta adducin exon. C: RNase protection analysis of total RNA 
prepared from mouse brain (mBR) and HeLa cells previously transfected with the constructs shown in panel A (1-5); IP, 
input probe; RT, uncleaved protected product; pA, cleaved protected product; MWM, molecular weight marker; the asterisk 
indicates unidentified products in the mBR sample. D:The cleavage efficiency was calculated as the ratio between cleaved 
and uncleaved protected products represented in Panel C (1-5). The quantification of the protected signals has been per­
formed using the Cyclone Phosphorimager and the OptiQuant software (Packard); the mean + /-  S.D. of three independent 
experiments is shown; data were analyzed using one-way ANOVA and Tukey's multiple comparison test, *** p<0.0001.
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Interestingly, there is a similarity between the observed differences in the cleavage effi­
ciency and the amount of mRNAs detected by the Northern blot analysis (compare Fi­
gure 23D with Figure 21D). These results support the hypothesis that the differences in 
mRNA expression levels from the described constructs may be caused by a reduction 
in 3 ’end processing efficiency.
The readthrough products in all tested RNA isolations, are roughly at similar levels, 
suggesting that all constructs are transcriptionally active. RT-qPCR amplification of the 
pre-mRNA, with primers annealing to sequences in the first intron and the second exon 
of the alpha globin gene, respectively, showed similar levels of pre-mRNA for constructs 
A4, A23-A4, A1-A4 and INA1-A4 which were roughly half of A1-A23-A4 pre-mRNA 
levels (Figure 24).
Summarizing the above-mentioned results, I could conclude that:
• the A1 and A23 regions contain cis-acting elements which are required for cleavage 
and polyadenylation of the beta-adducin pre-mRNA at the PAS4. Deletion of the A1 
and A23 regions from the A1-A23-A4 construct results in the absence of expression 
(A4 construct).
• pre-mRNA processing activity at the PAS4 is rescued by the addition of the A1 region 
upstream of the A4 segment (A1-A4 construct), as this construct is more active than the 
A1-A23-A4 construct. The A1 region appears to contain positive cis-acting element(s) 
enhancing 3’end processing at the PAS4.
• the rescue in the activity of the PAS4 caused by the presence of A1 region in the A1- 
A4 construct was not related to the distance between the 3’ splice site and the PAS4, 
as the same A1 region in the inverted orientation led to the complete absence of the 
activity of PAS4.
• the A23 region contains negative cis-element(s) suppressing 3’end processing at the 
PAS4, since its inclusion into the A1-A4 construct (the A1-A23-A4 construct) led to a 
significant decrease of A1-A23-A4 mRNA levels, possibly by decreasing the cleavage 
efficiency at the PAS4.
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Figure 24
Determination of pre-mRNA levels by RT-qPCR.
A: Schematic representation of the chimeric minigene constructs: A1-A23-A4 (1), A4 (2), A23-A4 (3), A1-A4 (4) and 
INA1-A4 (5); green arrows indicate primer pair used for the RT-qPCR showed in panel B. B: Quantification of the 
pre-mRNA levels by RT-qPCR from the total RNA prepared from HeLa cells previously transfected with the constructs 
shown in panel A; the p-EFGP-C2 plasmid was used to normalize the transfection efficiency: the relative pre-mRNA  
levels are represented, measured as the ratio between the analyzed RNAs and the GFP control; the mean + / -  S.D. of 
two independent experiments is shown; experiments were performed in duplicates.
Taken together, these results demonstrated the presence of novel non-canonical 3 ’end 
processing-regulatory elements in the A1 and A23 regions of the beta-adducin pre- 
mRNA that were capable of enhancing or suppressing, 3’end processing at the distal 
PAS4. The next series of studies were directed to the fine mapping of the enhancer and 
silencer elements present in the A1 and A23 regions.
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2.2.1 Mapping of the silencer elements of the A23 region
Deletion of the A23 region in the A1-A23-A4 construct resulting in the A1-A4 plasmid 
led to an important increase in the levels of expressed mRNA (Figure 21B and D, com­
pare Lane 4 to 1; and Figure 23C, compare Lane 1 to Lane 4). Since all other possible 
mechanisms were ruled out (see above Figures 22 and 31), these results strongly sug­
gest that the effects could be related to the presence of a negative cis-acting element 
within the A23 region, which suppresses cleavage efficiency at the PAS4. In order to 
map more in detail this potential negative cis-acting element, a “deletion” strategy simi­
lar to that one used for the A1 region was adopted. Deleted segments of the A23 region 
were introduced at the place of the full size A23 present in the A1-A23-A4 construct 
(Figure 25A, constructs A1-A23[1416-1781]-A4 and A1-A23[1416-1581]-A4). The ex­
pression profiles of the new constructs were determined by Northern blot analysis of 
total RNA prepared from transiently transfected HeLa cells. Transfection efficiency was 
normalized by cotransfection with a control plasmid expressing Renilla luciferase. Re­
moval of the negative cis-acting element should be seen as an increase in the mRNA 
levels in the Northern blot, similar to that one observed after deletion of the whole A23 
region (Figures 21B and 23C, compare Lane 1 to Lane 4). I observed such an increase 
for the A1-A23[1416-1581]-A4 construct (Figure 25B and D, compare Lanes 1 and 3). 
The observed increase was even bigger in comparison to the increase observed when 
whole A23 is absent (Figure 21B and D, Lane 1 and 4). This result suggests the location 
of the silencer element within the 200 bp region that spans from 1581 to 1781 bp relati­
ve to the first base of the last exon of the mouse beta-adducin gene.
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Figure 25
Mapping of the silencer element.
A:Schematic representation of the chimeric minigene constructs: A1-A23-A4 (1), A1 -A23[1416-1781 ]-A4 (2) 
and A1-A23[1416-1581]-A4 (3). B: Northern blot analysis of total RNA prepared from HeLa cells previously 
transfected with the constructs shown in panel A; the alpha globin probe was used to detect the mRNAs of inte­
rest; phRG-TK (Renilla) plasmid was used for the normalization of the transfection efficiency; the positions of the 
28S and 18S rRNAs are indicated on the right; the expected sizes shown in panel C are indicated on the left; C: 
the expected sizes of the mRNAs of the constructs shown in Panel A, up to the predicted PAS4 (i.e., the asterisk  
indicates without the pA tail). D: RT-qPCR analysis of the relative mRNA levels calculated as the ratio between  
analyzed mRNAs and Renilla control mRNA; the mean + / -  S.D. of three independent experiments is shown; expe­
riments were performed in duplicates.
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2.2.2 Mapping of the enhancer elements present in the A1 region
The A1 region spans 1400 bp comprising coding and noncoding sequences of the last 
mouse beta-adducin exon (Figure 16A). To have a deeper insight in the elements enhan­
cing 3’end processing at the PAS4, the A1 region was divided in three partially overlap­
ping sub-regions, A1 [17-305], A1 [284-887] and A1 [868-1416]. Each of these sub-re­
gions replaced the full A1 region of the A1-A4 construct, thus creating A1 [17-305]-A4, 
A1 [284-887]-A4 and A1 [868-1416]-A4 constructs (Figure 26A). All constructs contai­
ned the intact A4 region. The expression pattern of the new constructs was determined 
after transfection of HeLa cells followed by Northern blot analysis. Only the A1 [17-305]- 
A4 construct (containing the most proximal sub-region) produced a signal visible by 
Northern blot analysis, but the intensity of this signal was very faint (Figure 26B, Lane 
2). Complete absence of the signal was observed for the other two constructs (Figure 
26B, Lanes 3 and 4). These results suggest that the enhancer elements may be disrup­
ted in those constructs. To identify the enhancer elements that were needed to recover 
the full function of the PAS4,1 joined the A1 [17-305] to the A1 [284-887] sub-region, as 
well as the A1 [284-887] to the A1 [868-1416]. Next, I replaced the A1 region upstream 
of the A4 region by the A1 [17-887] and A1 [284-1416] segments to create A1 [17-887]- 
A4 and A1 [284-1416]-A4 constructs (Figure 26A). The presence of the A1 [17-887] 
segment completely restored the signal obtained with the full A1 region, whereas the 
A1 [284-1416]-A4 construct, which contained sequences downstream to the stop co­
don, produced no signal (Figure 26B, Lanes 5 and 6, respectively). Consequently, the 
A1 [868-1416] segment containing the PAS1 had no influence on the processing at the 
PAS4. This result suggested that regions upstream and downstream of the stop codon 
contain elements that interact to enhance the activity of the PAS4. Next, I started with a 
more detailed analysis of the bipartite enhancer element present in the A1 region.
In order to map the enhancer element located upstream of the stop codon, I have 
adopted an approach based on serial deletions starting from the 5’end of the A1 region,
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Figure 26
Mapping of the enhancer elem ent present in the A1 region.
A:Schematic representation of the chimeric minigene constructs: A1-A4 (1), A1[17-305]-A4 (2), A1 [284-887]-A4 (3), 
A1 [868-1416]-A4 (4), A1 [17-887]-A4 (5) and A1 [284-1416]-A4 (6). B: Northern blot analysis of total RNA prepared 
from HeLa cells previously transfected with the constructs shown in panel A; the alpha globin fragment used as a probe 
for the Northern blots is indicated in figure 21; the p-EGFP-C2 plasmid was used for the normalization of the transfection 
efficiency; the positions of the 28S and 18S rRNAs are indicated on the right; the expected sizes shown in panel C are 
indicated on the left; C: the expected sizes of the mRNAs of the constructs shown in Panel A, up to the predicted PAS4 
(i.e., the asterisk indicates without the pA tail). D: the relative mRNA levels were calculated as described for Figure 21; the 
mean +/- S.D. of three independent experiments is shown.
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thus partially eliminating the coding portion of the A1 (Figure 27A). All deletions were 
done without altering the reading frame of the coding sequence. I have replaced the 
A1 region from the A1-A4 construct by these new deleted segments (Figure 27A). I 
expected that by deleting the specific bases of the enhancer element, the levels of 
the minigene-derived transcript should be affected. The difference in mRNA levels 
should be observed as an important reduction or complete absence of the signal in 
the Northern blot. All constructs tested generated the expected bands, except for the 
A1[284-1416]-A4 construct (Figure 27B, Lane 4) where no band was observed. The 
only difference between the A1 [260-1416]-A4 construct, which still maintained full 
pre-mRNA processing activity, and the A1[284-1416]-A4 construct, which was inacti­
ve, consisted in the presence of 24 nt in the A1 [260-1416]-A4 construct (Figure 27B, 
Lane 3). Therefore, the presence of these 24 nt were essential to confer pre-mRNA 
processing activity and were thus considered to be an upstream enhancer element.
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M apping of the enhancer elem ent present in the A1 region: upstream  of the stop codon.
A:Schematic representation of the chimeric minigene constructs: A1-A4 (1), A1 [215-1416]-A4 (2), A1 [260-1416]-A4 (3) 
and A1 [284-1416]-A4 (4). B: Northern blot analysis of total RNA prepared from HeLa cells previously transfected 
with the constructs shown in panel A; the alpha globin fragment used as a probe for the Northern blots is indicated 
in figure 21; the p-EGFP-C2 plasmid was used for the normalization of the transfection efficiency; the positions of 
the 28S and 18S rRNAs are indicated on the right; the expected sizes shown in panel C are indicated on the left; 
C: the expected sizes of the mRNAs of the constructs shown in Panel A, up to the predicted PAS4 (i.e., the asterisk 
indicates without the pA tail). D: the relative mRNA levels were calculated as described for Figure 21; the mean + /- 
S.D. of three independent experiments is shown.
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To complement the above described approach, I have created serial deletions starting 
from the 3’end of the A1 region. The fragments containing these deletions substitu­
ted the whole A1 region present in the A1-A4 construct (Figure 28A). All constructs 
contained the full A4 region. As done previously, the effect of the deletions on mRNA 
expression was monitored by Northern blot. As expected, the reduction in the size of 
the detected mRNAs correlated, in each construct, with the length of the deletion (Fi­
gure 28B). Similarly to the approach adopted above, a significant drop of mRNA levels 
was observed when the deletion reached a region immediately downstream of the stop 
codon. All constructs generated a strong band in the Northern blot, except for the faint 
signal observed for the A1[17-305]-A4 construct (Figure 28B, Lane 10). The difference 
between the constructs A1[17-305]-A4 and A1 [17-328]-A4 was the presence of just 
23bp in the latter. Therefore, these 23 nt in the A1 [17-328]-A4 construct were necessary 
to enable pre-mRNA 3’end processing activity at the PAS4 and were considered as the 
downstream enhancer element.
Figure 2 8 »
Mapping of the enhancer element present in the A1 region: downstream of the stop codon.
A:Schematic representation of the chimeric minigene constructs: A1-A4 (1), A 1[17-887]-A 4  (2), A1[17-531 ]-A 4  (3), 
A1 [17-471 ]-A 4  (4), A 1 [17-420]-A 4  (5), A 1 [17-380]-A 4  (6), A 1 [17-371]-A 4  (7), A 1[17-351]-A 4  (8), A 1[17-328]-A 4  
(9) and A1 [17-305J-A4 (10). B: Northern blot analysis of total RNA prepared from HeLa cells previously transfected with 
the constructs shown in panel A; the alpha globin fragment used as a probe for the Northern blots is indicated in Figure 
21; the p-EGFP-C2 plasmid was used for the normalization of the transfection efficiency; the positions of the 28S and 
18S rRNAs are indicated on the right. C: the expected sizes of the mRNAs of the constructs shown in Panel A, up to the 
predicted PAS4 (i.e., the asterisk indicates without the pA tail). D: the relative mRNA levels were calculated as described 
for Figure 21; the mean + /-  S.D. of three independent experiments is shown; data were analyzed using one-way ANOVA 
and Tukey's multiple comparison test, * **  p<0 .001 , ** p<0.01, * p<0.05, ns - not significant for the p<0.05 as a threshold.
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Chapter 2
Taking both analyses together, it was possible to denote a composite enhancer ele­
ment composed of at least of 69 bases, centered around the stop codon of the beta- 
adducin gene (Figure 29A). To test the functionality of the putative 69 bases-long 
enhancer element, I have made another set of constructs, by introducing deletions 
of either the upstream or downstream element, both together or the deletion of all 69 
bases-long enhancer element into the A1-A4 construct (Figure 29B). All of the dele­
tion constructs showed the same level of expression, which was also similar to that of 
the A1-A4 construct (Figure 29C and E). These results suggested that the 69 bases- 
long enhancer may represent an important but not essential element, depending on 
the context, to confer processing activity at the PAS4. Thus, other cis-acting elements 
located nearby could compensate for the absence of the 69 bases-long enhancer 
element, indicating redundancy of the system. However, the possibility remains that 
the 69 bases-long enhancer element may be enough to enhance the processing at 
the PAS4. To check for this possibility, I placed the 69 bases-long enhancer element 
upstream of the A4 region generating the A1[260-328]-A4 construct (Figure 30A). 
A very faint signal was observed in the Northern blot analysis, after transfecting the 
construct into HeLa cells (Figure 30B, Lane 3). This results suggested that the 69 
bases-long enhancer was not enough to activate processing of the A1[260-328]-A4 
transcript, and that additional elements are needed to provide full pre-mRNA proces­
sing activity full activity to the enhancer element. Therefore, in order to identify these 
additional elements, I placed a 166 bp segment upstream of the A4 region, which con­
tained about 50 bp of additional sequences at each side of the 69 bp element (Figure 
30A, construct A1[215-380]-A4). The 166 bases-long segment was able to enhance 
the processing at the PAS4 and to rescue the signal in the Northern blot (Figure 30B, 
Lane 4). However, the detected signal did not reach the levels of the signal obtained 
from the A1-A4 construct (Figure 30C, Lane 4 compared with 1), suggesting that other 
cis-acting sequences may still be necessary. Another possible explanation could be 
associated to differences in stability of the mRNAs. Therefore, I have compared
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Deletion of the putative enhancer elem ents.
A: Sequence composition of the 69 nt long enhancer element; capital letters indicate the stop codon (TGA); UP and 
DOWN indicate the upstream and downstream elements, marked by orange-coloured letters; numbers correspond to 
the nucleotide position respective to the first base of the last mouse beta adducin exon. B: Schematic representation 
of the chimeric minigene constructs: A1-A4 (1), A1 [A260-283]-A4 (2), A1 [A306-328]-A4 (3), A1 [A260-283&A306-328]-A4 
(4) and A1 [A260-328]-A4 (5); the white boxes indicate the deleted regions. C: Northern blot analysis of total RNA prepared 
from HeLa cells previously transfected with the constructs shown in Panel B; the alpha globin fragment used as a 
probe for the Northern blots is indicated in figure 21; p-EGFP-C2 plasmid was used for the normalization of the 
transfection efficiency; the positions of the 28S and 18S rRNAs are indicated on the right. D: the expected sizes 
of the mRNAs of the constructs shown in Panel B, up to the predicted PAS4 (i.e., the asterisk indicates without the 
pA tail). E: The relative mRNA levels were calculated as the ratio between analyzed mRNAs and GFP control mRNA 
shown in Panel C; quantification of the Northern blot signals has been performed as described above; the mean + /- 
S.D. of three independent experiments is shown.
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166nt long enhancer elem ent is enough to activate  the PAS4.
A: Schematic representation of the chimeric minigene constructs: A1-A4 (1), A4 (2), A1 [260 -328 ]-A 4  (3), 
A1 [215 -3 8 0 ]-A 4  (4); B: Northern blot analysis of total RNA prepared from HeLa cells previously transfected with 
the constructs shown in Panel A; the alpha globin fragment used as a probe for the Northern blots is indicated in 
figure 21; p-EGFP-C2 plasmid was used for the normalization of the transfection efficiency; the positions of the 28S 
and 18S rRNAs are indicated on the right; the expected sizes shown in panel C are indicated on the left; C: the 
expected sizes of the mRNAs of the constructs shown in panel A up to the predicted PAS4, without pA tail (indicated 
by an asterisk). D: The relative mRNA levels calculated as the ratio between analyzed mRNAs and GFP mRNA control 
represented in panel B; quantification of the Northern blot signals has been performed as described above; the mean 
+ /- S.D. of four independent experiments is shown.
mRNA stabilities for the A1[215-380]-A4, A1-A4 and A1-A23-A4 constructs.
In order to block the new synthesis of mRNAs and to monitor the decay of the already-syn­
thesized ones, transfected HeLa cells were treated with actinomycin D and total RNA was 
collected at different time points. Cells were co-transfected with a plasmid coding for GFP to 
normalize for transfection efficiency and the amount of mRNA at the time zero was chosen 
as reference. As expected, the detected signal decreased with the Actinomycin D treatment, 
but the rate of decay was similar for all three mRNAs (Figure 31A and B) suggesting that there
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Figure 31
Determ ination of mRNA stab ility  by actinom ycin D treatm ent.
A: Northern blot analysis of total RNA prepared from HeLa cells previously transfected with the A1-A23-A4, A 1-A 4 and 
A1 [215-380]-A 4  constructs; 24h after the transfection 50 pg/ml actinomycin D (Act. D) was added to the cells; RNAs 
were collected at different time points after the Act. D treatment; the alpha globin probe was used to detect the mRNAs 
of interest; p-EGFP-C2 plasmid was used to normalize the transfection efficiency; the lower panel shows the relative 
mRNA levels calculated as the ratio between analyzed mRNAs and GFP control mRNA; quantification of the Northern 
blot signals has been performed using OptiQuant; mean + /- S.D. of the two independent experiments is shown; B: 
Comparison of the mRNA stability between A1-A23-A4, A1-A4 and A1 [215-380 ]-A 4  mRNAs. C: Northern blot analysis 
of the same RNAs shown in panel A, using probes to detect endogenous c-myc and GAPDH mRNA levels.
were no significant differences in the stability of the analyzed mRNAs. As a control for the effi­
ciency of the actinomycin D treatment, I have analyzed the c-myc mRNA, which was reported 
to have a short half life, and the more stable GAPDH mRNA (Figure 31C) (Dani et al., 1984).
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2.2.2.1 Initial characterization of possible trans-acting factors recognizing 
the enhancer element
After manual inspection of the 166 bases-long enhancer element (the full sequence is 
shown in Figure 32A), I observed that the region upstream of the stop codon is particu­
larly rich in purines. It is known that purine-rich regions in pre-mRNAs are potential lan­
ding pads for the RNA binding proteins of the SR family, such as SRSF1 (former name 
SF2/ASF). This family of proteins and SR-related proteins participate in constitutive and 
alternative splicing of pre-mRNA, generally as enhancers of the splicing reaction (Blen- 
cowe, 2000), but in some cases they can also enhance 3’end processing (Lou et al., 
1998; Lou et al., 1995; Maciolek and McNally, 2007; McCracken et al., 2003). Interestin­
gly, the purine-rich sequence present in the enhancer element was very similar to that 
one recognized by the SR protein SRSF1 (Caputi et al., 1994; Lavigueur et al., 1993). 
As mentioned above, the insertion of the 166 bases-long enhancer element was able 
to rescue the signal on the Northern blot, but not to the full activity of the complete A1 
region (Figure 30B and D, Lane 4 compared with Lane 1). Therefore, I wondered whe­
ther SR proteins could play a role in 3’end processing at the PAS4. Overexpression 
of SR proteins may increase their binding to the purine-rich region of the enhancer 
element affecting the 3’end processing efficiency at the PAS4, which can either cause 
an increase or decrease in the amount of the mRNA. To this end, HeLa cells were tran­
sfected with the A1[215-380]-A4 construct together with a plasmid expressing the 
SRSF1 splicing factor. The northern blot analysis showed a decrease in the amount of 
mRNA when SRSF1 was overexpressed (Figure 32B, C and D). Therefore, SRSF1 may 
have a negative role in 3’end processing at the PAS4 or, alternatively, the enhanced 
binding of the SRSF1 protein to the purine rich-region may compete with the binding 
of some other factor necessary to confer full activity to the enhancer element. Further 
experiments have to be performed to determine the precise role of SRSF1 in beta 
adducin polyadenylation.
In order to identify and characterize the trans-acting factor/s recognizing the enhancer
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Effect of SRSF1 overexpression on minigene expression.
A: Sequence composition of the 166 nt long enhancer element; the STOP codon (TGA) is indicated in capital letters 
; UP and DOWN are upstream and downstream elements marked by orange letters; numbers correspond to the 
nucleotide position respective to the first base of the last mouse beta adducin exon. B: Northern blot analysis of 
total RNA prepared from HeLa cells previously transfected with the A1 [2 1 5 -3 8 0 ]-A4 constructs together with pCG 
plasmid (CTRL) or pCG-SF2/ASF plasmid containing SRSF1 cDNA (SRSF1); the alpha globin probe was used to detect 
the mRNAs of interest; the p-EGFP-C2 plasmid was used for the normalization of the transfection efficiency; the 
positions of the 28S and 18S rRNAs are indicated on the right; the expected mRNA size is indicated on the left; 
(i.e., the asterisk indicates without the pA tail); C: The relative mRNA levels calculated as the ratio between analyzed 
mRNAs and GFP control mRNAs shown in Panel B; quantification of the Northern blot signals has been performed 
using OptiQuant software; the mean + / -  S.D. of three independent experiments is shown; D: Western blot analysis 
for SRSF1 of the protein extracts prepared from HeLa cells previously transfected as described in Panel B; tubulin 
was used as a loading control.
elements, I have performed some preliminary analysis of the proteins interacting with the 
69 bases-long enhancer element (Figure 29A). These studies were done in parallel with 
the analysis of the functionality of this element. In a first step to identify the trans-acting 
factors recognizing the 69 bases-long enhancer element, I performed Electrophoretic 
Mobility Shift Assays (EMSA) and RNA-Pull-down experiments. The RNAs used for the 
analysis were generated by in vitro transcription of DNA templates. I used three different 
DNA templates to generate the radioactively labeled RNAs: a) a 69 bases-long region
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that contained the complete enhancer sequence, with the upstream and downstream 
enhancer elements (WT)\ b) a 45 bases-long region that lacked the upstream element 
{Aup); c) a 46 bases-long region that lacked the downstream element (Adown) (Figure 
33A). These in vitro transcribed RNAs formed secondary structures which were efficien­
tly digested with RNase V1, an enzyme that specifically degrades double stranded RNA 
(Figure 33B, first three lanes).
I have determined the ability of these RNA sequences to bind a protein or protein com­
plexes by the EMSA assay. The radioactively labeled RNAs were incubated with HeLa 
nuclear extract. RNA-protein interactions were then detected as a band shift on a native 
polyacrylamide gel electrophoresis. All three tested RNAs (Aup ,WT and Adown) were 
able to bind proteins producing lower mobility bands (Figure 33B). Two RNA-protein 
complexes were observed for the Aup probe, while only one complex was observed 
with the WT and Adown probes. To determine the specificity of the complexes and to 
test whether these RNAs were bound by the same protein complexes, I have perfor­
med EMSA competition assays (Figure 34). The labeled RNA probe was incubated with 
HeLa nuclear extract in the presence of a non-radioactive competitor (cold RNA). As it 
can be seen in Figure 34, all cold competitors were able to compete out the complexes 
formed by their corresponding hot RNA probes, confirming the specificity of the com­
plexes. The cold WT  competitor was also able to compete out the complexes formed 
with the hot Adown RNA, as expected, but not those formed with the hot Aup probe 
(Figure 34C and 34B, respectively). In addition, the cold Aup competitor was not able to 
compete for the proteins bound to the hot WT  probe. The cold Adowncompetitor was 
able to compete for the proteins bound to the hot WT  probe (Figure 34A). To conclude, 
it is likely that both the WT  and Adown probes were able to form similar RNA-protein 
complexes, which differ from the ones formed by the Aup probe. These differences 
could be directly related to the folding structure of each RNA and/or to the impossibility 
of crucial proteins to take part in the formation of the complex due to the deletion of 
upstream enhancer element.
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Figure 33
RNA EMSA analysis.
A: DNA sequences used for the in vitro transcription reactions to produce corresponding RNAs (Aup, wt and 
Mown). B: RNA-protein interaction analysis, EMSA assay; the first three lanes represent digestion of the secondary 
structured hot RNAs (A up, wt and A down) by double-stranded RNA specific ribonuclease, RNAse V1; the second 
three lanes represent the hot RNAs; last three lanes represent interaction between the hot RNAs and the proteins 
from the HeLa nuclear extract.
In parallel, to identify the proteins bound to the enhancer element, I have performed pre­
liminary RNA-Pull-down experiments. The RNA probe was bound to agarose beads, fol­
lowed by the binding reaction using HeLa nuclear protein extracts. Protein complexes 
bound to a given RNA sequence were separated from the unbound proteins present in 
the binding reaction, eluted, separated on SDS-polyacrylamide gels and finally stained 
with colloidal coomassie blue. Then, differences in the protein pattern could be rela-
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Figure 35
Pull-dow n analysis of protein bound to the enhancer elem ent.
Left panel - RNA-Pull-down assay for the A t/p , wt and A down, DNA sequences used for the in vitro transcription 
reactions to produce corresponding RNAs (Aup, wt and Mown) are as described in Figure 33; in vitro synthetized 
RNAs were covalently linked to adipic-acid beads and subsequently incubated with HeLa nuclear extract; the unbound 
proteins were washed and the ones that remained bound to the RNAs were eluted, separated on 10% SDS-PAGE and 
visualized by colloidal coomassie blue staining; bands representing single protein differences are indicated with red 
arrowheads and by letters (A, B, C, D, E and F); MWM -  molecular weight marker. Right panel - each of the bands 
represented in the left panel (A-F) was cutted and the corresponding protein identified by mass spectometry (A-F).
«  Figure 34
RNA EMSA com petition analysis.
A: competition of the cold A u p , wt and Mown  RNAs with the hot wt. B: competition of the cold A u p , wt and 
Mown  RNAs with the hot Aup.C: competition of the cold A u p , wt and Mown  RNAs with the hot Mown. 
0.5,1 and 2 pmol of cold competitor were used.
ted to differences in the RNA-protein complex formation for each RNA probe used. 
In line with the EMSA analysis, protein profiles of the WT  and Adown were similar. 
Single protein differences were observed between the pull down profiles obtained 
with the Aup and WT RNAs (Figure 35, the red arrows point to the differences), which 
were then analyzed by mass spectrometry (Figure 35, right panel). Most of the iden­
tified proteins belonged to the hnRNP family of proteins. These proteins are trans­
acting factors that bind pre-mRNA, modulate pre-mRNA splicing and in some cases 
also polyadenylation, such as hnRNP H (Arhin et al., 2002; Wilusz and Beemon, 2006).
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2.3 Study of the functions of the spleen- and 
brain-specific 3’UTRs of the beta-adducin mRNA
To analyze the potential effects of the spleen- and brain-specific 3’UTRs on the beta-addu­
cin mRNA levels I have introduced the different 3’UTRs of the mouse beta-adducin gene 
(ending at the PAS1, PAS23 and PAS4 cleavage sites) into the pGL3-control reporter vector, 
downstream of the firefly luciferase gene (Figure 36A). Downstream of the inserted 3’UTRs 
the SV40 late polyadenylation signal of the reporter vector was present, which assured ef­
ficient cleavage and polyadenylation of the reporter gene. Epithelial (HeLa - human cervical 
carcinoma), neuronal (SK-N-BE - human neuroblastoma) and hematopoietic (MEL-murine 
erythroleukemia) cells were transfected with these constructs together with the pHRG-TK 
vector that contains the renilla luciferase (RL) gene. The RL construct was used to normalize 
for differences in transfection efficiency. Luciferase activity was tested by performing the 
Dual-Luciferase Reporter assay and the relative luciferase activity was used as a measure of 
expression efficiency (Figure 36B). For all the different cells types tested, the same pattern 
of luciferase expression was observed: a decrease in the relative luciferase activity correla­
ted with increasing length of the 3’UTR.
In order to investigate whether the observed differences in luciferase activity (Figure 36B) 
were due to changes in translational efficiency or stability of the mRNAs, I performed RT- 
qPCR. The results showed a decrease in the mRNA levels in the constructs having longer 
3’ UTRs, suggesting that the main mechanism acting on the regulation of luciferase expres­
sion was through mRNA stability (Figure 36C). However, the decrease in mRNA levels did 
not account for all the differences in luciferase observed between the different constructs
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Reporter gene analysis showed that expression of the long beta adducin 3’UTR is repressed.
A: Schematic representation of the pGL3 constructs: pGL3-A1 (1), pGL3-A1-A23 (2) and pGL3-A1-A23-A4 (3); full 
length of different 3 ’UTRs of mouse beta adducin are placed downstream of the firefly luciferase gene of pGL3-control 
vector; different 3 ’UTR fragments containing the tissue-specific polyadenylation sites of mouse beta adducin (PAS1, 
PAS23 and PAS4) are indicated as orange, yellow and blue boxes, respectively (see matherials and methods for 
details; the enhancer sequence element containing the stop codon from beta-adducin that is defined in the above 
mentioned studies is not included in the construct); the green boxes indicate luciferase gene; the grey boxes indicate 
SV40 late polyadenylation signal (SV40pA); B: Graphic representation of the relative luciferase activity in the protein 
extracts of HeLa, MEL and SK-N-BE cells previously transfected with the pGL3 empty control (C) and constructs 
shown in panel A, together with pHRG-TK vector that contains the renilla luciferase gene; the mean + / -  S.D. of 
nine, four and five independent experiments for HeLa, MEL and SK-N-BE, respectively, is shown; experiments were 
performed in triplicates. C: RT-qPCR analysis of the relative mRNA levels calculated as the ratio between the amounts 
of the firefly and renilla luciferase mRNAs from total RNA prepared from HeLa cells previously transfected with the 
pGL3 empty control (C) and constructs shown in panel A, together with pHRG-TK vector; the mean + / -  S.D. of three 
independent experiments is shown; expreriments were performed in duplicates.
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(Figure 36B), suggesting that other mechanisms regulating mRNA translation may be also 
involved. In addition, we should also consider that the efficiency of Pol II in transcribing the 
longer templates may be lower, which may result in lower levels of mRNAs of the constructs 
having the longer 3’ UTRs.
As already mentioned in the Introduction section, the region containing the PAS4 of 
the beta-adducin is highly conserved between mammals (Figure 14 and 15). The re­
gion of conservation contains, in addition to the core polydenylation elements, other 
potential regulatory elements, such as CPE and ARE. There are two potential CPEs 
aproximately 200 bases upstream of the hexanucleotide motif of the PAS4. Recently 
has been demonstrated that the CPE-containing mRNAs can be targeted by CPEB also 
in the nucleus (Lin et al., 2010). The nuclear function of CPEB is still not elucidated, 
although there are some suggestions for its implication in alternative splicing (Lin et 
al., 2010) and polyadenylation (Raul Mendez, personal communication). The CPE role 
in alternative polyadenylation has been proposed for the BUB3 gene where two CPEs 
close to the proximal PASs were involved in the switching to a more distal PAS (Raul 
Mendez, personal communication). In the context of beta-adducin, although no CPE 
consensus sequences were present in the 3’ UTR proximal region, I tested whether the 
mutation of the two distal CPEs could trigger the usage of the proximal PASs. To this 
end, the CPE mutations were introduced into the A1-A23-A4 construct to generate the 
A1-A23-A4[mutCPE] construct (Figure 37A). The expression profile of this construct 
was analyzed by Northern blot of total RNA prepared from transfected HeLa cells. In the 
case the CPEs were regulating alternative polyadenylation of beta-adducin, a new band 
corresponding to polyadenylation in the proximal PAS should appear in the Northern 
blot. However, as shown in Figure 37B, only one signal was obtained which correspon­
ded to the usage of the PAS4. Therefore, we can conclude that CPEs were not regula­
ting beta-adducin alternative polyadenylation. On the other hand, there was a twofold 
increase in the levels of mRNA generated by the construct containing the mutated CPEs 
(Figure 37C). This result suggests a role of CPEs in mRNA stability of beta-adducin.
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M utation of CPEs results in th e  increase o f relative mRNA levels.
A: Schematic representation of the chimeric minigene constructs: A 1 -A 23-A 4  (1), A1-A23-A4[m utCPE] (2); the 
sequence containing CPEs is shown below; the black boxes indicate CPEs; the mutations introduced inside the CPEs 
are indicated in red lowercase letters; the hexanucleotide motif sequence and the cleavage site (PAS4) are indicated in 
blue and red lowercase letters, respectively. B: Northern blot analysis of total RNA prepared from HeLa cells previously 
transfected with the constructs shown in Panel A; the alpha globin probe was used to detect the mRNAs of interest; 
P-EGFP-C2 plasmid was used for the normalization of the transfection efficiency; the positions of the 28S and 18S  
rRNAs are indicated on the right; the expected mRNA size is indicated on the left; (i.e., the asterisk indicates 
without the pA tail); C: The relative mRNA levels calculated as the ratio between analyzed mRNAs and GFP control 
mRNAs shown in Panel B; quantification of the Northern blot signals has been performed using the OptiQuant sof­
tware; the mean + /-  S.D. of two independent experiments is shown.
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Deletion of ARE results in the increase of relative mRNA levels.
A: Schematic representation of the chimeric minigene constructs: A 1 -A 23-A 4 (1), A1-A23-A4[AARE] (2); the sequence 
containing ARE is shown below; the black box indicates the ARE, which has been deleted in the A1-A23-A4[AARE] 
construct; the hexanucleotide motif sequence and the cleavage site (PAS4) are indicated in blue and red lowercase 
letters, respectively; the white box in the construct indicates deleted ARE. B: Northern blot analysis of total RNA pre­
pared from HeLa cells previously transfected with the constructs shown in Panel A; phRG-TK (Renilla) plasmid was 
used for the normalization of the transfection efficiency; the positions of the 28S and 18S rRNAs are indicated on the 
right; the expected mRNA size is indicated on the left; (i.e., the asterisk indicates without the pA tail); C: RT-qPCR 
analysis of the relative mRNA levels calculated as the ratio between analyzed mRNAs and Renilla control mRNA; the 
mean + /-  S.D. of three independent experiments is shown; experiments were performed in duplicates.
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We observed that the region upstream of the PAS4 is an AU-rich region, where a poten­
tial ARE was observed (Figure 38A). To test the functionality of this potential ARE, this 
element was deleted from the A1-A23-A4 construct to generate the A1-A23-A4[AARE] 
construct (Figure 38A). The expression of the deleted construct was tested by transfec­
tion into HeLa cells. The RL plasmid was cotransfected and its expression levels deter­
mined by RT-qPCR to normalize for differences in the transfection efficiency.
The Northern blot analysis showed normal processing at the PAS4 (Figure 38B, Lane 
2). Deletion of the potential ARE resulted in -60%  increase in the relative amounts of 
mRNA levels (Figure 38C), suggesting a role of the deleted ARE in destabilization of the 
beta-adducin mRNA.
To conclude, these results suggest that the RNA levels of the long beta adducin tran­
scripts are regulated, at least partially, by modulating the stability of the mRNA through 
CPE and ARE, elements present only in the mRNA isoform which is polyadenylated in 
the distal PAS. In fact, mutation of CPE and deletion of ARE resulted in a significant 
increase in mRNA levels of the chimeric minigene constructs. Other mechanisms, such 
as regulation by miRNAs, could also account for the regulation of beta-adducin gene 
expression.
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Discussion and conclusions
The presented results underscore the complexity of the mechanisms that regulate 
polyadenylation of the mouse beta adducin pre-mRNA. In order to study the mecha­
nisms acting on the beta adducin distal PAS4, we first identified the core cis-acting 
elements (Hm, DSE and USE) which were necessary to confirm usage of the PAS4. 
Surprisingly, I found that additional long-distance enhancer and silencer cis-acting 
elements are involved in the regulation of 3’end processing at the PAS4. To the best 
of our knowledge, this is the first demonstration of the presence of long-distance 
upstream polyadenylation enhancer and silencer elements in eukaryotic, non-viral, 
pre-mRNAs.
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3.1 Cis-acting elements regulating the mouse beta 
adducin PAS4 usage
3.1.1 Mouse beta adducin PAS4 is preferentially used in HeLa cells
In an array of tandem PASs, the distal PAS tends to be the strongest and most efficien­
tly used PAS (Beaudoing et al., 2000; Legendre and Gautheret, 2003). This tendency 
was also observed in our minigene model containing all three beta adducin polya­
denylation sites. When transfected into HeLa cells, the distal PAS4 was exclusively, 
similar to that observed in brain. The preferentially usage of the distal PASs in respect 
to proximal ones in HeLa cells is detected for several endogenous genes (Kubo et al., 
2006), suggesting that the usage of distal PASs is generally preferred in this cell line. 
The observed inefficient 3 ’end processing at the beta adducin proximal PAS1 and 
PAS2-3 could be explained by the presence of low-conserved and poorly defined 
cis-acting elements regulating their usage. On the contrary, in silico analysis of the 
PAS4 region showed the presence of highly conserved and well-defined polyadeny­
lation cis-acting elements, whose role was confirmed in the presented study. Ad­
ditionally, the recognition and usage of the PAS1 and PAS2-3 might depend on the 
presence of tissue-specific trans-acting factors which may be absent in HeLa cells. 
Thus, the usage of these tissue-specific sites could be expected to occur in a more 
physiological system. Unfortunately, technical problems prevented us from doing 
so, as described above in the section Results.
3.1.2 Canonical cis-acting elements regulate mouse beta adducin 
PAS4 usage
Deletion analyses demonstrated that the in silico predicted sites were indeed the cor­
rect functional polyadenylation core elements defining PAS4 (Figure 17). In accordance,
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absence of either the Hm or the DSE abolished 3’end processing at the PAS4 of the 
beta adducin pre-mRNA. However, inactivation of the PAS4 by either deleting the Hm or 
the DSE, has not led to the activation of the proximal PAS1 and/or PAS2-3. Instead, two 
cryptic PASs located about 200 bases upstream of the PAS4 have been used. In addi­
tion, the proximal PASs were inactive even in the absence of the entire A4 region (data 
not shown). Therefore, the absence of polyadenylation activity at the PAS1 and PAS2-3 
was not due to the presence of the stronger PAS4 in the same transcript. Most likely 
additional trans-acting factors, which may be absent in HeLa cells, are necessary for the 
efficient 3’end processing at the proximal PAS1 and PAS2-3 of beta adducin pre-mRNA. 
The identified Hm, located 18 nucleotides upstream of the PAS4, is represented by the 
non-canonical and less frequent AGUAAA sequence. Immediately downstream of the 
PAS4, a 29 bases long GU-rich region represents the identified DSE. Recognition of the 
Hm and DSE by CPSF and CstF, respectively, represents the main characteristic in 
the initiation of 3 ’end processing factors assembly on the polyadenylation signal. 
Purified CPSF is known to bind the Hm weakly and this binding is enhanced by its in­
teraction with the CstF bound to the DSE (Gilmartin and Nevins, 1991; MacDonald et 
al., 1994; Weiss et al., 1991). Here, we observed the dependence of the Hm on the pre­
sence of the DSE and vice versa, in the recognition of the PAS4. As mentioned above, 
absence of one of these polyadenylation elements disrupted the efficient recognition of 
the PAS4 and led to the usage of two upstream cryptic PASs. These two cryptic PASs 
are located in a highly conserved region at the base positions 5742 and 5793, in respect 
to the first base of the mouse beta adducin terminal exon. Upstream of both cryptic 
PASs, we identified the noncanonical AAUAUA hexamer, which together with various 
U and GU-rich stretches located downstream, may play a role in the recognition of 
both cryptic PASs. The AAUAUA hexamer is detected in -2 %  of human and mouse 
PASs, and is ~ 1.5 folds less active than the AGUAAA hexamer and 10 fold less active 
than the canonical AAUAAA hexamer in in vitro polyadenylation assays (Sheets et al., 
1990; Tian et al., 2005)(Figure 3). Efficiently processed PASs are usually associated with
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a high number of polyadenylated ESTs ending at the PAS position, and those PASs are 
usually the ones bearing canonical hexamer variants, AAUAAA and AUUAAA (Beaudoing 
et al., 2000). Interestingly, approximately the same mean number of ESTs was found to 
be associated with PASs containing the canonical AUUAAA and noncanonical AGUAAA 
hexamer (Beaudoing et al., 2000), suggesting that the AGUAAA hexamer can be as active 
as the canonical AUUAAA. In the case of beta adducin, a higher number of ESTs was 
observed to align with the PAS4 (containing the AGUAAA hexamer) than with the PAS1 
(containing the AUUAAA hexamer), suggesting that the processing at the PAS4 is more 
efficient (Costessi et al., 2006). However, a higher number of ESTs does not necessarily 
corelate with PAS efficiency. A number of ESTs associated with a PAS also depends on 
the number of analysis performed for each tissue that are available in the databases, if 
the sites that one want to compare are tissue-specific. Additionally, mRNAs processed at 
the cryptic PASs were expressed at lower levels than the ones processed at the canonical 
PAS4, suggesting a less efficient processing at these cryptic PASs.
Interestingly, regulatory elements such as ARE and CPE were not lost in the 3’UTR ge­
nerated from the usage of the cryptic PASs. Therefore, the close proximity of the cryptic 
PASs favours the hypothesis of a mechanism for the generation of a long 3’UTR even 
in case of the failure of the 3’end processing at the strong PAS4. Similar 3’end proces­
sing fail-safe mechanisms for the eukaryotic pre-mRNAs have not been described pre­
viously. It would be of interest to extend the studies to other genes whose polyadenyla­
tion signal sequences composition show similarities to that of beta adducin.
In addition to the importance of the Hm and DSE, we demonstrated that the presence 
of the USE was also important for the efficient processing at the PAS4. The general 
role of the USEs is in the enhancement of 3’end processing. Here, we showed that a 
32 bases long U/GU-rich region located upstream of the Hm represents a USE acting 
on the PAS4, as the deletion of this element led to the less efficient processing at PAS4 
manifested by a decrease in mRNA levels (Figure 17B).
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3.1.3 Novel non-canonical long-distance upstream enhancer and 
silencer elements regulate mouse beta adducin PAS4 usage
Although if the core cis-acting elements we described above were critical for processing 
at the PAS4, they were not sufficient to trigger processing at PAS4. In fact, the presence 
of the upstream 1.4 kb long A1 region appeared to be indispensable for 3 ’end proces­
sing at the PAS4, as in its absence no processing at the PAS4 was observed (Figure 
21). Mapping experiments showed that the minimal enhancer sequence able to activate 
the usage of the PAS4 with the same efficiency as the full lenght 1.4 Kb A1 region was 
contained within a 355 nt sequence (Figure 28, construct A1 [17-371 ]-A4). These 355 nt 
comprise of the last part of the coding region, the stop codon and the first 66 nt of the 
3’UTR, spanning from base 17 to base 371 of the mouse beta adducin terminal exon. 
Shorter fragments of 166 nt and 69 nt have been tested, but they were less efficient in 
activating the PAS4. The deletion experiments showed that this non-canonical enhan­
cer element is a complex element, composed of various different sub-elements, each 
of which contribute to the overall function of the enhancer resulting in the activation of 
the PAS4. Several characteristics distinguish this polyadenylation upstream enhancer 
element from the more “classical” USEs that were previously described.
Firstly, the beta adducin enhancer element is located more than 2 Kb upstream of the 
PAS4 in the minigene context (construct A1-A23-A4). In the natural mouse beta adducin 
context the enhancer is positioned more than 5 Kb upstream of the PAS4. Although we 
have not yet proven the functionality of the enhancer element in its natural context, we 
expect it will be active because the enhancer activity was not affected by the distance 
between the enhancer and the PAS4, as verified by several tested constructs (Figures 27 
and 28). The presence of the long-distance upstream polyadenylation enhancer element 
is quite peculiar for eukaryotic polyadenylation signals. In general, the USEs are positioned 
immediately upstream of the Hm. Interestingly, a long-distance upstream polyadenylation 
enhancer element has been observed for the Rous sarcoma virus (RSV) polyadenylation 
signal (Fogel et al., 2002; Wilusz and Beemon, 2006). This element is called negative re­
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gulator of splicing (NRS) and is located in the gag gene, about 8 Kb upstream of the RSV 
polyadenylation signal. Binding of the SR proteins SRSF1, SRSF3 and SRSF7 to the NRS 
stimulates polyadenylation at the RSV PAS (Maciolek and McNally, 2007). The SR proteins 
are in competition for the binding to the NRS with hnRNP H, which inhibits polyadenylation 
at the RSV PAS (Wilusz and Beemon, 2006). Whether the presence of the long-distance 
USE represents an exception or a general property of eukaryotic PASs is yet to be studied. 
Secondly, the non-canonical enhancer element is also upstream of the alternative polya­
denylation sites but only influences the usage of PAS4. The activity of the PAS1 and 
PAS2-3 are not affected by the enhancer even in the absence of the A4 region. Thus, it 
is unlikely that this element acts as a general enhancer of polyadenylation and may be 
specific for the beta adducin gene.
Thirdly, the non-canonical enhancer element has a complex structure spanning imme­
diately upstream and downstream of the stop codon of the mouse beta adducin termi­
nal exon. Thus, this element partially spans throughout the coding region, a USE cha­
racteristic that has not previously been reported. Being positioned in the coding region, 
the sequence composition is subject to evolutionary constrains dictated by the protein 
it encodes which makes it unlikely to be a general enhancer element. Usually, the USEs 
are represented by U-rich sequences, while the coding region of the non-canonical en­
hancer element is purine-rich and contains a high number of potential binding sites for 
SR-proteins. Overexpression of SRSF1, an SR-protein known to be involved in stimu­
lating 3’end processing, resulted in no enhancement of beta adducin PAS4 pre-mRNA 
processing. On the contrary, a twofold decrease in the mRNA levels of the construct 
containing the 166 nt long enhancer element has been detected ^suggesting a decrea­
se in the efficiency of processing at the PAS4 (Figure 32). A possible explanation of this 
observation could be that the overrepresented SRSF1 in the transfected cells competed 
out the binding of other factor(s) to the enhancer element, necessary for the activation 
of the PAS4 processing. Flowever, further experiments are needed to confirm this possi­
bility. One of the potential protein candidates could be the splicing factor SRSF10 (also
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known as Tra2 beta), as its consensus binding sequence is similar to that of the SRSF1 
(Grellscheid et al., 2011; Sanford et al., 2009). Manual inspection of the 355 nt enhancer 
element sequence revealed the presence of 13 out of the 20 most frequent hexamers 
found in CLIP-tags of SRSF10 (Figure 39)(Grellscheid et al., 2011). There is no evidence 
for a potential role of SRSF10 in polyadenylation, apart from its Drosophila homolog, 
which is able to enhance female specific splicing and polyadenylation in the dsx pre- 
mRNA (Hedley and Maniatis, 1991). Nevertheless, the interaction between SRSF10 and 
the 3’end processing factor CFI-68 has been detected in HeLa and HEK293 cell lines 
(Dettwiler et al., 2004). Therefore, SRSF10 represents a good candidate for binding to 
the non-canonical enhancer element. It would be of interest to test its role in 3’end pro­
cessing of the mouse beta adducin PAS4. However, it should be taken into acount that 
none of the pulled-down proteins analyzed was an SR protein (Figure 35). Improving 
the experimental conditions could reveal more protein candidates for the binding to the 
enhancer element. On the contrary, hnRNP proteins were detected in the bands isola­
ted from the pull down experiments, among which I found hnRNP H, already known to 
be involved in 3 ’end processing. Binding of hnRNP H protein to G-rich auxiliary DSEs 
stimulates cleavage and polyadenylation (Arhin et al., 2002; Bagga et al., 1998; Dalziel 
et al., 2007). A recent study has shown that hnRNP H bound to G-rich elements located 
upstream of the PAS stimulates polyadenylation through the interaction with poly(A) 
polymerase (Millevoi et al., 2009). Whether hnRNP H has a role in 3’end processing at 
the beta adducin PAS4 will be addressed in future studies.
I have shown that the PAS4 requires the presence of an upstream non-canonical en­
hancer element. The effect of the enhancer element was lost when located downstre­
am of the “proximal” PAS4, as observed in the A4-A1-A23-A4 construct (Figure 18). 
A position-dependent effect of the polyadenylation enhancer element has also been 
observed for beta globin (Antoniou et al 1998). The last 60 nt of the second beta globin 
intron represent the enhancer element and it was not functional when placed down­
stream of the beta globin PAS. However, the beta globin enhancer element is part of the
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Frequency
Frequency Frequency Genome of6-m erin Transcriptome
of 6-mer in of 6-mer in corrected Ranking mouse testis corrected Ranking
6-mer CLIP tags (S) genome frequency (G) (G) transcriptome frequency (T) (T)
-
H m
AAGAAA 3.55635 1.16015 2.3962 6 1.05244 2.50391 6
GAAGAG 2.64727 0.491786 2.15548 7 0.719154 1.92812 8
GGAAGA 2.62936 0.50618 2.12318 8 0.721032 1.90833 9
CTGAAG 2.24496 0.439994 1.80497 9 0.732098 1.51286 11
GAGAAG 2.24854 0.480449 1.76809 10 0.732883 1.51566 10
AAAGAA 2.8729 1.15234 1.72056 11 0.888027 1.98487 7
AAGATG 2.05633 0.4243 1.63203 12 0.693867 1.36246 14
CAGAAG 2.18049 0.562355 1.61813 13 0.954301 1.22619 16
GAAGAC 1.89636 0.307239 1.58912 14 0.77801 1.11835 20
ATGAAG 1.92024 0.4163 1.50394 15 0.556977 1.36326 13
AGAAAA 2.43835 1.04237 1.39598 16 0.943035 1.49531 12
AGGAAG 2.01515 0.686074 1.32908 17 0.745566 1.26958 15
AAGAGA 1.95844 0.634115 1.32432 18 0.771916 1.18652 18
AGAGAA 2.07364 0.77395 1.29969 19 0.858814 1.21483 17
CAAGAA 1.7167 0.471291 1.24541 20 0.567135 1.14956 19
B
17
I
AGTCAGCGAAGCCAACACAGAGCCTGAGCCAGTGAAACCAGAAGGGCTGGTGGTGAATG
GGAAGGAGGAGGAGCCGAGCGTAGAAGAGGCCCTCAGCAAAGGACTGGGCCAGATGAC
CACCAACGCT G ACACT GATGGCG ACAGCTACAAGGACAAAACCGAGT CAGTTACCAGT GG 
CCCCTTGTCCCCAGAGGGCTCGCCCTCTAAGTCACCCTCCAAAAAGAAAAAGAAATTCCG
I_________________________ z ______
215
AACCCC G AAG G AG AAG GT G G AAT CCT G Attaqtqq ctctq
I "     I
260 306
tgggtcctgctgcatccctgccctccttccttacccttctcccaactctgcccc
328 371
Figure 39
SRSF10 (Tra2beta) putative target sites in the 355n t long enhancer elem ent.
A: List of the 20 most frequent hexamers found in CLIP-tags of SRSF10, as described in Grellscheid et al., 2011; 
B: Sequence composition of the 355 nt long enhancer element; 13 out of the 20 hexamers shown in panel A aligned 
to the 355 nt long enhancer element; green lines indicate hexamer positions, the color code shown in panel A was 
respected; numbers indicate the nucleotide positions in respect to the first nucleotide of the mouse beta adducin last 
exon; stop codon is indicated in red; 24 nt long upstream enhancer element is indicated in orange.
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3’splice site and its replacement could lead to the inactivation of splicing which causes 
a decrease in cleavage and polyadenylation. Similarly, the beta adducin non-canonical 
enhancer element is positioned in the vicinity of the 3’splice site of the terminal exon. It 
is well known that terminal-exon definition relies on the crosstalk between splicing and 
3’end processing events (Martinson, 2011) (seethe Introduction Section). Thus, the non- 
canonical enhancer element could function in the activation of PAS4 by direct stimula­
tion of terminal exon definition and splicing of the last intron. Preliminary data showed 
that removal of all introns from the A1-A23-A4 construct abolished its expression, as no 
signal was detected by Northern blot analysis (A. laconcig and L. Costessi, unpublised 
data). In the present study we showed the absence of expression of the A4-A1-A23- 
A4 construct in HeLa cells, which remained peculiar (Figure 18). As mentioned above, 
the “proximal” PAS4 is probably inactive due to the absence of the upstream enhancer, 
which is present downstream to the first PAS4. However, the reason why the distal PAS4 
is not active in this context remains unclear. One possible explanation could be that 
the non-canonical enhancer element is not functional when located far away from the 
3’splice site of the terminal exon. Insertion of the non-canonical enhancer element in the 
proximity of the 3’splice site, upstream of the first PAS4 of the A4-A1-A23-A4 construct 
resulted in the activation of the “proximal” PAS4 (data not shown). The possibility that 
transcription was blocked downstream of the first PAS4 was ruled out since a construct 
lacking the region downstream to the cleavage site also failed to generate detectable tran­
scripts (Figure 20, construct A4[5405-6015]-A1-A23-A4).Therefore, it is plausible that the 
mechanism of the non-canonical enhancer element to activate polyadenylation of the PAS4 
is connected to splicing of the terminal exon. This would support the hypothesis that the key 
factor could be a splicing factor such as SRSF10 (Tra2beta).
Blocking of the translation by cycloheximide showed that transcripts derived from the con­
structs lacking the non-canonical enhancer element were not subjected to NMD or other 
cytoplasmic surveillance pathways (Figure 22, A4 and INA1-A4 constructs). Instead, 
these transcripts were inefficiently processed which probably led to their degradation
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by the nuclear mRNA quality control pathways (Figure 23). Recently, it has been propo­
sed that the longer is the distance between the natural stop codon and the 3'end of an 
mRNA, there is increased probability that the mRNA is prone to NMD (Brogna and Wen,
2009). As the enhancer element comprises stop codon, it would be interesting to check 
for its possible role in mRNA stability regulated by NMD.
In addition to the non-canonical upstream polyadenylation enhancer element, the present 
study also showed the presence of a non-canonical upstream polyadenylation silencer ele­
ment which inhibited processing at the mouse beta adducin PAS4. The non-canonical si­
lencer element was 200 nt long and spanned from base 1581 of the beta adducin 3’UTR, 
respective to the first base of the terminal exon. Removal of this 200 nt silencer element 
from the A1-A23-A4 construct led to the three-fold increase in the mRNA levels (Figure 25). 
The possibility that this element is affecting the half life of the mRNA was ruled out by the 
mRNA stability assays. In fact, the mRNA stability assays demonstrated that the stability 
of the mRNA derived from the A1-A23-A4 construct, thus containing the silencer element, 
was similar to that of the A1-A4 construct, which lacks this element (Figure 31).
As observed for the enhancer element, the non-canonical silencer element also had 
some characteristics that distinguished this USE from other reported ones. First, the 
non-canonical silencer element represents a long-distance polyadenylation regulatory 
element. In the minigene context, the distance from the silencer element to the PAS4 is 
about 800 bases, and in the natural context of the mouse beta adducin gene it is about 
4 Kb. Another interesting observation is that USEs are usually enhancers of polyadeny­
lation (Schek et al., 1992; Moreira et al., 1995; Brackenridge and Proudfoot, 2000) and 
here I described the presence of a silencer of polyadenylation. The presence of an 
upstream polyadenylation silencer element has also been described for the U1A pre- 
mRNA and is involved in U1A protein autoregulation (Boelens et al., 1993). This silencer 
element is -50 nt long and is located 19 nt upstream of the Hm of the U1A pre-mRNA. 
The U1A protein binds to the silencer element and directly interacts with PAP inhibiting 
the polyadenylation reaction, which leads to the degradation of the U1A pre-mRNA and
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Figure 40
Model of the beta adducin PAS4 activation.
In a tandem array of all three mouse beta adducin PASs, the PAS4 is predominantly used in HeLa cells. The core 
cis-acting elements are necessary for the correct definition and processing at the PAS4. However, those elements 
are not enough for the activation of the PAS4. Additional, long-distance non-canonical polyadenylation elements 
are regulating the usage of the PAS4. The non-canonical long-distance enhancer element is indispensable for the 
activation of the PAS4 and is located in a 355 nt long region comprising mouse beta adducin stop codon (highlighted 
with dots). The non-canonical long-distance silencer polyadenylation element is inhibiting the usage of the PAS4 and 
is located in the 200 nt long region downstream of the PAS2-3 (highlighted with dots). These findings underscore the 
complex mechanisms regulating the processing at the mouse beta adducin PAS4.
decrease in the levels of the U1A protein (Gunderson et al., 1994; Gunderson et al., 1997). 
A very recent study revealed a widespread adenosine methylation in mRNAs of mouse 
brain, which was increased near the stop codons and in 3’UTRs (Meyer et al., 2012). In­
terestingly, the non-canonical enhancer and silencer elements described here are located 
around the stop codon and in the 3’UTR of the mouse beta adducin mRNA, respectively. 
By examining the gene regions containing adenosine methylation in the above mentioned 
study, I found that the brain-specific beta adducin transcripts contain adenosine methy­
lation and the regions containg this modification overlap with the non-canonical enhancer 
and silencer elements. It was shown that mRNA adenosine methylation is important for 
embryonic development of Arabidopsis, oogenesis in Drosophila, nutrient signaling in 
mammals and some studies connected it with RNA processing. However, the functions of 
mRNA adenosine methylation are still largely uncharacterized and it would be of interest 
to check for functional connections between the beta adducin mRNA adenosine methy­
lation and the novel non-canonical polyadenylation regulatory elements.
Taken together, in the presented study I identified novel non-canonical polyadenylation- 
regulatory elements that enhance or silence 3’end processing of the mouse beta addu­
cin PAS4 (Figure 40). The non-canonical upstream enhancer element is indispensable 
for the efficient use of the PAS4. On the contrary, the non-canonical upstream silencer 
element inhibits the use of the PAS4. These results underscore the complex mechani­
sms regulating polyadenylation of the beta adducin gene.
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3.2 Function of the long beta adducin 3’UTR
Usage of the PAS4 leads to the formation of the beta adducin mRNA containing an 
unusually long 3’UTR (Costessi et al., 2006). The preliminary analyses presented in 
the last section of the chapter Results were directed to study the role of the long 
3 ’UTR in the mRNA stability and translation efficiency.
Using firefly-luciferease based reporter constructs containg the different 3’UTRs of 
beta adducin, I showed that the presence of the long mouse beta adducin 3’UTR 
variant led to a decrease in luciferase activity in all the three cell lines tested, HeLa, 
MEL and SK-N-BE (Figure 36B). A similar trend was observed in previous studies 
(Mayr and Bartel, 2009; Sandberg et al., 2008). Performing luciferase assays, they 
showed that the shorter 3 ’UTRs led to the production of the higher levels of pro­
tein than the longer ones, which is explained by the presence of a higher number 
of regulatory elements in the long 3’UTRs that could provoke destabilization of the 
mRNA and translational repression.
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Quantification of the mRNA levels from HeLa cells transfected with the luciferase -re­
porter constructs led to the conclusion that the detected decrease in luciferase activity 
of the construct bearing the beta adducin long 3’UTR was mostly due to mRNA destabi­
lization and, to a minor extent, translational repression (Figure 36C). However, it should 
be taken into account that the length of the 3’UTR itself could have influence in the final 
protein production in HeLa cells, as was noticed by Mayr et al. (Mayr and Bartel, 2009). 
They analyzed luciferase activity in 15 cell lines using reporter constructs containing 
short, long and antisense oriented long 3’UTRs. In four of the 15 tested cell lines, the 
antisense orientation of the long 3’UTRs lost their repressional capacity, influencing the 
expression of the reporter constructs at the same level as the short ones. Whereas, in 
the other tested cell lines, including HeLa, intermediate levels of luciferase activity were 
observed in the presence of the antisense oriented long 3’UTRs.
Preliminary results suggested that the decrease in the luciferase mRNA levels, obser­
ved in the presence of the mouse beta adducin long 3'UTR, was probably linked to the 
presence of the ARE and CPE destabilizing elements. ARE elements are well known 
in influencing the mRNA stability (von Roretz et al., 2011). Here, it was observed that the 
deletion of only one ARE from the beta adducin 3’UTR led to an increase in mRNA levels, 
suggesting that this element has an important role in the regulation of beta adducin mRNA 
stability. However, further studies are necessary to prove this observation and to identify the 
potential ARE binding proteins involved in the destabilization of the beta adducin mRNA. 
Mutation of the two highly-conserved CPEs located upstream of the beta adducin PAS4 
led to an increase in mRNA levels, suggesting a role of these elements in the stability 
control of the beta adducin mRNA. This observation is peculiar, as CPEs are known to 
influence translational repression when bound by CPEB in the cytoplasm. A possible 
explanation for this observation could be that the CPE consensus sequence, UUUUAU 
hexamer, being an AU-rich sequence, could also be recognized by members of the 
ARE-binding protein family. Influence of CPEs in mRNA stability has also been found in 
p53 3’UTR (Rosenstierne et al., 2008). Mutation of two CPEs present in the p53 3’UTR
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led to an increase in mRNA stability and twofold increase in mRNA levels of the reporter 
gene (Rosenstierne et al., 2008). The role of the CPEs in the stability of the beta adducin 
mRNA will be addressed in future studies. Additionally, it would be interesting to study 
the function of CPEs and the CPEB protein in the translational repression of beta ad­
ducin mRNA. Upstream of the two CPEs present in the long 3’UTR of the beta adducin 
mRNA, I also identified one conserved Pumilio-binding element (PBE). The PBE is also 
involved in translational repression and is usually found close to CPEs. Actually, the po­
sition and number of the CPEs in respect to the PBE and Hm influences the efficiency 
of the translational repression (Pique et al., 2008). Interestingly, CPEB shows dendritic 
localization in hippocampal neurons, where it has a role in the regulation of local transla­
tion of mRNAs containing CPEs (Richter, 2001). Moreover, CPEB has a role in dendritic 
targeting of several mRNAs, one of which is CAMKIIa mRNA. The major mRNA isoform of 
beta adducin in brain contains the long 3’UTRs variant and it is expressed at high levels in 
the hippocampus, cerebellum and neocortex showing dendritic localization (Porro et al.,
2010). Therefore, CPEB represents a good candidate for the regulation of the long beta 
adducin mRNA isoform targeting to dendrites and its local translation.
In addition, translational repression of the long beta adducin mRNA can be caused by 
miRNA targeting to its 3’UTR. I screened the mouse beta adducin long 3’UTR for the 
presence of potential miRNA binding sites and observed two interesting candidates, 
mir-125 and mir-219, which were found to be part of the top 50 most conserved octa- 
mer motifs present in the 3’UTR (Xie et al., 2005). The putative target site for mir-125 
was located immediately after the mouse beta adducin PAS1. The putative target site 
for mir-219 represented the longest stretch of conservation found in proximity to the 
mouse beta adducin PAS23, and overlaped with the potential Hm region. The position 
of both miRNA binding sites raises the possibility that they could interfere in a tissue- 
specific manner with polyadenylation at the proximal sites. The presence of the mir-125 
and mir-219 putative target sites in the long beta adducin 3’UTR led to the possibility 
that mir-125 and mir-219 are regulators of the beta adducin mRNA stability in brain. In
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addition, they could account for the observed decrese in the luciferase activity of the 
reporter gene bearing the long beta adducin 3’UTR (Figure 36B). Interestingly, both of 
these miRNAs are expressed at high levels in mouse brain (Bak et al., 2008). Mir-125 
was shown to be involved in the regulation of synaptic function and structure in mouse 
brain (Edbauer et al., 2010), whereas mir-219, in the regulation of oligodendrocyte dif­
ferentiation and myelination (Dugas et al., 2010). I checked for the expression of these 
miRNAs in several mouse tissues and cell lines, performing Northern blot analysis (data 
not shown). As detected previously (Bak et al., 2008), high levels of mir-219 and mir-125 
were observed in mouse brain. The expression of the mir-219 was not observed in any 
of the other tested tissues (spleen, heart, kidney and lung) and cell lines (HeLa, K562, 
SK-N-BE and HEK293), whereas mir-125 was expressed at various levels in these tissues 
and cells but to a lesser extent then in the brain. Therefore, it would be of interest to study 
the role of these miRNAs in the regulation of beta adducin expression and alternative- 
polyadenylation site selection in brain.
To summarize, the long beta adducin 3’UTR contains multiple potentially important 
regulatory elements. Preliminary results suggested the involvement of ARE and CPE 
elements in the regulation of beta adducin mRNA stability. Further studies will be con­
ducted in order to get deeper insight into the functions of the long beta adducin 3’UTR 
and the mechanisms regulating its fate.
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Materials and Methods
4.1 Reagents and solutions
Commonly used chemicals were purchased from Sigma-Aldrich, Boehringer-Mannheim, 
Amersham Biosciences (now GE Healthcare), Merck, Gibco and Invitrogen (now Life 
technologies).
4.1.1 Standard solutions
Commonly used solutions are listed below:
5XTBE:
450 mM Tris-borate, 10 mM EDTA, stored at RT 
TE:
10mM Tris-HCI (pH 7.4), 1mM EDTA (pH 7.4), stored at RT 
PBS:
137 mM NaCI, 10 mM Na2HP04, 2.7 mM KCI, 2 mM KH2P04, pH 7.4, stored at 4°C 
10X MOPS:
200 mM MOPS (pH 7.0), 50 mM CH3COONa (pH 8.0), 10 mM EDTA (pH 8.0), 
stored at 4°C
20X SSC:
3 M NaCI, 0.3 M sodium citrate (dihydrate), pH 7.0, stored at RT
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5X loading dye for agarose gels:
40% (w/v) sucrose, 0.25% (w/v) bromophenol blue, stored at RT 
5X formamide-loading buffer:
1 mg/ml xylene cyanol, 1 mg/ml bromophenol blue, 80% (w/v) deionized formamide, 10 
mM EDTA (pH 8.0), stored at -20°C
1X RNA sample buffer for denaturing agarose gels:
50% (v/v) deionized formamide, 1X MOPS, 6% (v/v) formaldehyde, 5 ml ethidium bro­
mide (1 mg/ml) per 1 ml sample buffer, stored at -20°C
R-loop buffer:
80% (v/v) deionized formamide, 40 mM PIPES (pH 6.4), 1 mM EDTA (pH 8.0), 400 mM 
NaCI, prepared prior to use or stored at -80°C
10X OPA buffer:
100 mM Tris-HCI (pH 7.5), 100 mM Mg acetate, 500 mM K acetate, stored at -20°C 
TSS:
10% (w/v) PEG (MW=4000), 5% (v/v) DMSO, 35 mM MgCI2, LB broth (pH 6.5), prepared 
prior to use or stored at 4°C for a short period
Lysis buffer:
50 mM glucose, 20 mM Tris (pH 8.0), 10 mM EDTA, stored at RT 
SDS buffer:
1 %  SDS, 0.2 M NaOH, stored at RT
4.1.2 Enzymes
The following enzymes were used: restriction endonucleases (New England Biolabs), 
Taq DNA polymerase (New England Biolabs, Roche), T4 DNA ligase (Roche), T4 DNA 
polymerase (Roche), Klenow fragment of DNA polymerase (New England Biolabs), T4 
polynucleotide kinase (New England Biolabs), calf intestinal alkaline phosphatase (CIP) 
(Roche), Pfu DNA polymerase (Stratagene), M-MLV reverse transcriptase (Invitrogen), 
RNase free-DNase (Promega), T7 RNA polymerase (Stratagene), RNase A (Sigma 
Chemicals), RNase T1 (Sigma-Aldrich), proteinase K (Sigma-Aldrich).
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All enzymes were used following the manufacturer’s instructions, except for the restric­
tion endonucleases and CIP, which were all used with OPA buffer, instead of the manu­
facturer’s recommended buffer.
4.1.3 Radioactive isotopes
Radioactive nucleotides [a-32P]dCTP and [a-32P]UTP were purchased from Amersham 
Bioscience.
4.1.4 Synthetic oligonucleotides
Synthetic oligonucleotides were purchased from Sigma-Aldrich or MWG biotech.
4.1.5 Biological reagents
The E.coli DH5a and Dam- strains were used for the amplification of the plasmids. For 
the transfection experiments HeLa (human cervical cancer cells), SK-N-BE (human neu­
roblastoma cells) and MEL (murine erythroleukemia cells) cell lines were used.
4.2 PCR
For preparative PCRs Taq Polymerase supplied by Roche was used, whereas New 
England Biolabs Taq Polymerase was used for analytical PCRs. The final concentration 
of the components in the PCR reaction mix were: 1X corresponding PCR buffer (10X 
stock), 100 nM dNTPs (stock 5 mM), 3.3 ng/pl forward and reverse primers (100 ng/gl 
stock) and 0.025 U/pl of Taq polymerase (5 U/pl stock). The following termocycler steps 
were used for the amplification of a -0.5-1 Kb long product: first step was denaturation 
at 94°C for 3 min, then 30 cycles of denaturation at 94°C for 30 sec, annealing at 56°C 
for 30 sec and elongation at 72°C or 68°C (Taq Roche and Biolabs, respectively) for 30
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sec, and the last step was elongation at 72°C or 68°C (Taq Roche and Biolabs, respec­
tively) for 5 min. In the case the fragments were longer than 1 Kb, for each additional 
500 bp the elongation step was prolonged for 30 sec.
4.3 Enzymatic modifications of DNA
4.3.1 Blunt end formation
In order to form blunt ends, PCR products were treated with Klenow or T4 DNA poly­
merase. Briefly, after the PCR reaction, the Taq polymerase was heat inactivated at 
98°C for 10 min. Subsequently, 2.5 pi of MgCI2 and 1 pi of Klenow were added in a 46 
pi of the PCR and the reaction was incubated at room temperature (RT) for 15 min. The 
Klenow enzyme was then inactivated at 80°C for 10 min, followed by phosphorylation of 
the newly formed blunt ends by T4 polynucleotide kinase: 14 pi of ATP [1 OmM], 1.4 pi of 
T4 kinase buffer, 2.5 pi of EDTA [3mM] and 1 pi of T4 polynucleotide kinase were added 
to the reaction, following incubation at 37°C for 1 hour. Blunt ended and phosphorylated 
PCR fragment were then gel purified and used for the ligation.
4.3.2 Restriction
For analytical purpose, usually 100-300 ng of plasmid DNA were digested with restric­
tion endonucleases, in a 15 pi of final reaction volume. For preparative samples, 2 pg 
of plasmid DNA or 10-20 pi of PCR product were digested in 50 pi of final reaction vol­
ume. 10X OPA buffer was used for all the reactions, in final concentrations optimal for 
the used enzymes. Reactions were carried for at least one hour at 37°C for most of the 
enzymes. Depending on the purpose, the enzymes were heat inactivated, removed by 
gel purification or by phenol-chloroform purification.
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4.3.3 Phosphatase
After digestion and heat inactivation of restriction enzymes, linearized plasmid DNA 
was treated with CIP in order to remove phosphates and to abolish self-ligation. 0.5 pi 
of CIP (1 U/|j| stock) was added for 1 pg of plasmid. Incubation was carried at 37°C for 1 
hour. After the reaction, CIP was inactivated at 65°C for 20 min or removed through gel 
purification of the plasmid.
4.3.4 Ligation
Ligation was carried out with 20-30 ng of digested plasmid and 3-6 folds excess of 
insert, in a 15-20 pi of final volume containing T4 ligase buffer (10X stock) and 1U of T4 
ligase. Two controls were always performed to determine the quality of the vector and 
ligation reaction: CUT (without ligase and insert, to check for the efficiency of digestion) 
and SELF (without insert, to check for the plasmid self-ligation). Ligation reactions were 
incubated at RT for 2-5 hours. Half of the reaction was used for transformation and the 
other half was incubated ON at RT and used for transformation the day after.
4.4 Transformation
4.4.1 Preparation of competent bacteria (E.coli DH5a)
A single bacterial colony was grown ON in 5 ml of LB at 37°C with agitation. 5 ml of ON 
inoculum was transferred into a 200 ml LB and incubated at 37°C with agitation until the 
absorbance at 600nm reached 0.3-0.4 units (optimal 0.35). Next, bacteria were centri­
fuged at 3000 rpm for 5 min at 4°C. The supernatant was discarded and the pellet was 
gently resuspended in TSS solution. Aliquots of 400 pi were transferred into 1.5 ml ep- 
pendorf tubes, immediately frozen in liquid nitrogen, and stored at -80°C. Competence
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was tested transforming bacteria with 0.1 ng of the pUC19 vector. Generally, compe­
tence was ~107 colonies per pg of plasmid DNA.
4.4.2 Transformation of competent bacteria (E.coli DH5a)
Half of the ligation reaction or 30 ng of plasmid (in the case of retransformation) was 
incubated for 30 min in ice with 70 pi of competent bacteria. Next, bacteria were heat- 
shocked at 42°C for 2 min and placed on ice for 1 min, 70 pi of pre-warmed LB was 
added to the bacteria and incubated for 30 min at 37°C. Afterwards, bacteria were 
plated in pre-warmed LB Petri plates containing the corresponding antibiotics. When 
necessary, 70 pi of IPTG (100 mM) and 35 pi of X-gal (4%) were added to the plate. 
Plates were incubated ON at 37°C to allow for bacteria growing and subsequently re­
moved and stored at 4°C.
4.5 DNA purification
4.5.1 Band purification
For cloning, linearized vectors and inserts or blunt-ended PCR products were separated 
on agarose gel of appropriate concentration. Bands corresponding to the desired DNA 
size were cut and DNA extracted from the gel slices using the Qiaquick gel extraction kit 
(cat. No. 28706) from Qiagen, according to the manufacturer’s instructions.
4.5.2 PCR clean-up
PCR products used as templates for the in vitro transcription reactions were purified 
using NucleoSpin Gel and PCR clean-up kit from Macherey-Nagel, according to the 
manufacturer’s instructions for the PCR clean-up protocol.
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4.5.3 Phenol-chloroform purification
After treatments with different DNA modification enzymes, DNA was purified with phenol- 
chloroform. One volume of phenol-chloroform was added to the DNA sample, which was 
vortexed and centrifuged for 2 min at 13200 rpm. The supernatant was transferred into a 
clean 1.5 tube containing 2 volumes of 100% ethanol with 1/10 (v/v) of sodium acetate (3 
M, pH 5.0). The sample was vortexed and left in ice for 10 min. Subsequently, the sample 
was centrifuged at 13200 rpm for 15 min. The supernatant was removed, the pellet was 
washed with 500 \i\ of 70% ethanol and resuspended in dH20.
4.6 Agarose gel electrophoreses of DNA
$
Different concentrations of agarose, from 0.6% to 2% (w/v) were used for the prepara­
tion of gels, according to the expected size of DNA fragments. Agarose was melted in 
1X TBE, which was also used as a running buffer. Gels contained ethidium bromide in 
order to visualize DNA with UV transiluminator. To determine the size of the bands, the 1 
Kb molecular weight marker was used, purchased from Invitrogen (cat.No. 15615-024).
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4.7 DNA preparation
4.7.1 Mini-prep
Small-scale preparations of plasmid DNA from bacterial cultures (mini-prep) were per­
formed in order to screen for the positive clones. Each of the selected colonies was 
picked with a toothpick and introducesd into a tube containing 2.5 ml LB and the cor­
responding antibiotic (1/1000 v/v, stock 10 mg/ml). The inoculum was incubated at 
37°C ON with agitation. Afterwards, the inoculum was transferred into a 1.5 ml-tube 
and centrifuged for 5 min at 13200 rpm. The supernatant was removed and the pellet 
was resuspended in 90 \\\ lysis buffer. The cells were lysed by adding 200 \i\ of SDS- 
buffer and mixed by inversion 4-5 times. Then, 150 \i\ of NaAc (3 M, pH 3.2) were added,
mixed 4-5 times by inversion and left for 2 min on ice. Subsequently, the sample was
«•
centrifuged for 15 min at 13200 rpm. The supernatant was purified with one volume of 
phenol-chloroform, DNA was precipitated in two volumes of 100% ethanol for 5 min 
on ice and washed with 70% ethanol. The DNA was resuspended with 30 \i\ dH20 and 
2 \i\ RNase A (10 mg/ml stock) and incubated for about 10 min at 37°C. An aliquot of 
the DNA samples was then subjected to restriction enzyme digestions. Digested DNAs 
were separated on agarose gel and the size of the bands was visualized on the UV 
transiluminator.
4.7.2 Commercial mini-prep
For the purposes of sequencing, cloning and transfection, plasmid DNA was prepared 
using “Wizard plus SV minipreps DNA purification system” from Promega (cat. No. 
A1460). DNA preparation was performed according to the manufacturer’s instructions.
4.7.3 Midi-prep
Large scale preparation of plasmid DNA from bacterial cultures (midi-prep) was per­
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formed using “Plasmid purification midi kit” from JetStart (cat. No. 210025), according 
to the manufacturer’s instructions.
4.8 Measurment of nucleic acids concentration and purity
DNA and RNA concentration were measured using a nano-drop spectrophotometer. As 
an indication of sample purity, the ratio of the absorbencies at 260 nm and 230 nm was 
used, considering sufficiently pure samples with the ratio 1.7 and above. The concen­
trations were estimated measuring the absorbance at 260 nm.
4.9 Sequencing
PCR amplified products were subcloned into pUC19 and sequenced prior to their trans­
fer into the final vector. Sequencing reactions were performed by “BMR Genomics” 
based in Padova, Italy.
4.10 Mutagenesis
4.10.1 Quick-change PCR mutagenesis protocol
The quick-change PCR mutagenesis protocol was used to introduce point mutations 
into the desired fragments (QuickChange Site-Directed Mutagenesis Kit protocol, 
Stratagene). The amplification was performed with a pair of complementary primers
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containing the mutation flanked by about 15 unmodified nucleotides at each side. 150 
ng of the plasmid to be mutated was used as template in a 30 \i\ PCR reaction. The high 
fidelity Pfu DNA polymerase (Stratagene) was used. The PCR steps were as follows: 
denaturation at 95°C for 30 sec, 18 cycles of denaturation at 95°C for 30 sec, annealing 
at 55°C for 1 min and elongation at 68°C for 4 min, and one last step of elongation at 
68°C for 7 min. The original plasmid used as a template was digested with Dpn I (it does 
not recognizes the Dpnl sites of Taq-polymerase derived DNA), leaving only the mutated 
plasmid in the PCR reaction. 25 \i\ of the PCR reaction were digested at 37°C for one 
to 4 hours with 20 U of the Dpn I enzyme. 14 pi of the reaction were used to transform 
bacteria as described above.
Generally, the template DNA was pUC19 plasmid containing the region with the desired 
sequence to mutate. The mutated pUC19 plasmid was then sequenced to check for the 
presence of the desired mutation and the region of interest was cloned in a final vector.
4.10.2 Two-steps PCR technique
In order to create deletions, a two-steps PCR technique was used. In the first step two 
PCR reactions were performed: the first one was performed with a forward (FWD) exter­
nal and a reverse (REV) internal primer and the second PCR with a FWD internal and a 
REV external primer. The PCR fragments from these two reactions were gel purified and 
used as templates for the second step of the PCR. The external FWD and REV primers 
were used for this PCR. The internal primers were designed to overlap in the ~15 nt long 
region upstream and downstream of the desired deletion, thus allowing the annealing 
and joining of the two fragments in the second step of the PCR reaction. The external 
primers contained two pairs of restriction enzyme sites at their ends (external and inter­
nal). The PCR fragment obtained in the second step was digested in the positions of the 
external restriction enzyme sites and subcloned into pUC19. Sequencing of the insert 
inside the PUC19 was performed in order to check for the presence of the desired dele­
tion. Next, the mutated fragment was cut and cloned in the final vector.
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4.11 Generation of minigene constructs
4.11.1 Generation of chimeric mouse beta adducin minigene 
constructs
The A1-A23-A4 and A4-A1-A23-A4 constructs were previously generated in the labo­
ratory using the pBS SV40 alpha globin minigene. The pBS SV40 alpha globin minigene 
construct derived from pBS II KS plasmid (Stratagene) which contains 352 bp of the 
SV40 promoter and the genomic sequence human alpha globin gene including all three 
exons with their corresponding introns (1071 bp). The last 344 bp of the alpha globin 
third exon containing the PAS were removed by digesting the construct with BstE II 
(located in the coding part of the third exon) and Sal I (located in the pBS II KS poly­
linker) and replaced with a linker (Iinker2) containing several unique restriction sites. This 
construct was called pBS SV40 alpha globin Iinker2. The mouse beta adducin genomic 
regions containing PASs were called A1, A23 and A4, and are described in Figure 16A. 
These regions were inserted into the correct sites of the Iinker2 to create the A1-A23-A4 
construct (Figure 16B). The additional A4 region was cloned in the sites present up­
stream of the A1 region in the A1-A23-A4 construct to create A4-A1-A23-A4 construct 
(Figure 18A). The A1-A23-A4 constructs containing deletions of the polyadenylation 
signal elements (Figure 17) were created using Quick-change PCR mutagenesis meth­
od. All of these constructs were created prior to my arrival at the lab.
Two additional mouse beta adducin exons and introns were inserted into the BstE II 
position of the A1-A23-A4 and A4-A1-A23-A4 constructs to generate EX-A1-A23-A4 
and EX-A4-A1-A23-A4 constructs (Figure 19A). The region starting at base 68 of exon 
14 to base 1910 (in respect to the first base of the exon 14) in the intron 16 was ampli­
fied from mouse genomic DNA using the two-steps PCR technique in order to remove 
a BstE II site present in intron 14.
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The following primers were used:
First PCR reaction
FWD external primer:
mB-Add Ex14 68 dir BstEII - 5’ CACGGTGACCAACCCCTTCAGCCAACTCAC 3’
REV internal primer:
mB-Add 803 rev BstEII mut - 5’ TCCAGAGGGTCACGTGGGGCTTGTTCT 3’
Second PCR reaction
FWD internal primer:
mB-Add 778 dir BstEII mut - 5’ AGAACAAGCCCCACGTGACCCTCTGGA 3’
REV external primer:
mB-Add 1910 rev BstBI - 5’ CAGTTCGAAGAAGGACTGTGAGAAGGAAA 3’
Both PCR reactions were gel purified and used as templates for the joint PCR reaction 
with both external primers. The amplified PCR product, containing a BstE II site on its 
5’end and a BstB I site on its 3’end, was blunt-ended and subcloned into a pUC19 vec­
tor for sequencing.
The second region contained the last 846 bp of intron 15 and the first 16 bp of exon 16 
and was amplified by PCR from mouse genomic DNA using the following primers:
FWD:
mB-Add 8050 dir BstBI - 5’ CAGTT CG AAACT CAAATCGT CACCT CT CACAC 3’
REV:
mB-Add Ex14 8888 rev BstEII-5’CACGGTCACCTTCTGTCTTCTTGGTATCTAGGA3’
The BstE II site was at the 5’end of the amplified PCR product, whereas the BstB I 
site was present on its 3’end. This PCR product was blunt-ended and subcloned into 
pUC19 for sequencing.
Finally, the first region was cut from the pUC19 vector with BstB I and Hind III, gel puri­
fied and joined to the second region through the internal BstB I site, leaving the BstE 
II sites from both ends of the newly formed larger region. Thus, the formed new region 
contained the last 87 bp of exon 14, all intron 14 (957 bp) with the mutated BstE II site, 
all exon 15 (126 bp), the first 674 bp of intron 16 joined with BstB I with the last 864 bp
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of intron 16 and the first 16 bp of exon 16. This region was cut from the pUC19 plasmid 
with BstE II, gel purified, CIP treated and ligated into the BstE II site of the A1-A23-A4 
and A4-A1-A23-A4 constructs to generate the EX-A1-A23-A4 and EX-A4-A1-A23-A4 
constructs (Figure 19A).
For the generation of A4[5405-6015]-A1-A23-A4 and EX-A4[5405-6015]-A1-A23-A4 
constructs (Figure 20A), the short A4 region, spanning from the base 5405 to the base 
6015, in respect to the first one of the mouse beta adducin last exon, was cloned inside 
the A1-A23-A4 and EX-A1-A23-A4 constructs, upstream of the A1 region. This short 
A4 region was amplified using the following primer pair:
FWD:
BR A4 dir 1 - 5’ GGGGTACCGCGGCCGCCATATGAGTGTCTCGTAAGTAATGCT 3’
(Kpn I -  Not I -  Nde I tail)
REV:
mAdd2BRshort rev -5’CGGGATCCCCGCGGGAATTCCCTACATTTCCATACATGA3’
(BamH I -  Sac II -  EcoR I tail)
The PCR fragment was digested at the external restriction enzyme sites (Kpn I and 
BamH I), subcloned into pUC19 which contained the mutated EcoR I and Nde I sites, 
and sequenced. The short A4 region was cut from the pUC19 plasmid with Not I and 
Sac II, gel purified and cloned into the Not I and Sac II positions upstream of the A1 
region in the A1-A23-A4 and EX-A1-A23-A4 constructs.
The A4 construct (Figure 21 A) was generated by placing the A4 region into the Nde I 
and EcoR I sites of the Iinker2 in the construct pBS SV40 alpha globin Iinker2.
The A1 region was removed with Spe I and Xba I digestion from the A1-A23-A4 con­
struct. The digested construct was then treated with Klenow and religated without puri­
fication in order to obtain the A23-A4 construct (Figure 21 A).
The A1 region was added to the A4 construct into the Spe I and Xba I linker positions to 
obtain the A1-A4 construct (Figure 21 A).
To generate INA1-A4 construct (Figure 21 A), the A1 region was cut from the A1-A23-A4
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construct with Spe I and Xba I, treated with Klenow, gel purified and inserted into the A4 
construct which was cut with Spe I and EcoR V, treated with Klenow and gel purified. 
The presence of the A1 region in the antisense orientation was validated by restriction 
enzyme digestion which cuts the plasmid once only in the antisense A1 region (Afl II). 
The different subregions of the A1 region were PCR amplified. The primer pairs con­
tained restriction sites necessary for the cloning strategy at their 5’end. The external 
sites were BamH I and Pst I and the internal ones Spe I and Xba I. The PCR products 
were digested with BamH I and Pst I. After heat inactivation of the enzymes, the PCR 
fragments were subcloned into pUC19 in the BamH I and Pst I position. The pUC19 
plasmids containing the different subregions of the A1 region were sequenced. Then, 
the subregions of the A1 region were cut out with Spe I and Xba I, gel purified and 
inserted into the final vector. The final vector was prepared by digestion of the A1-A4 
construct to remove the whole A1 region, with Spe I and kbal. The enzymes were heat 
inactivated and the cut plasmid was CIP treated. The band corresponding to the A1-A4 
construct without the A1 region was then cut from the gel and purified, and used for 
the ligation reactions with the different subregions of the A1 region. The primer pairs 
used for the amplification of each of the A1 subregions, in the order they appear in the 
figures, are listed below:
A1 [17-305]:
SP A1 dir 1 -  5’ CGGGATCCACTAGTAAGTCAGCGAAGCCAACACA 3’
SPA1 -STOP_rev -  5’ AACTGCAGTCTAGATCAGGATTCCACCTTCTCCTT 3’
A1 [284-887]:
SPA1-268UP dir -  5 ’ CGGG AT CC ACTAGT G AAGG AG AAG GT G G AAT CCT G A 3’ 
SPA1-HALF_rev -  5’AACTGCAGTCTAGACTCAGGGTTAGTGTTTGGAA 3’
A1 [868-1416]:
SPA1 -HALF_dir -  5’ CGGGATCCACTAGTTTCCAAACACTAACCCTGAG 3’
SP A1 rev 1 -  5’ AACTGCAGTCTAGAGTGATGGGCTTGGGAATGC 3’
A1 [17-887]:
SP A1 dir 1 -  5’ CGGGATCCACTAGTAAGTCAGCGAAGCCAACACA 3’
SPA1-HALF_rev -  5 ’ AACTGCAGT CTAGACT CAGGGTTAGT GTTTGG AA 3’
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A1 [284-1416]:
SPA1-268UP dir -  5’CGGGATCCACTAGTGAAGGAGAAGGTGGAATCCTGA 3’ 
SP A1 rev 1 -  5’ AACTGCAGTCTAGAGTGATGGGCTTGGGAATGC 3’
A1 [215-1416]:
SPA1-199UPdir -  5’CGGGATCCACTAGTGCCCTCTAAGTCACCCTCCA 3’
SP A1 rev 1 -  5’ AACTGCAGTCTAGAGTGATGGGCTTGGGAATGC 3’
A1 [260-1416]:
SPA1 -244UPdir -  5’ CGGGATCCACTAGTCTCGTTCCTGAAGAAAAGCA 3’
SP A1 rev 1 -  5’ AACTGCAGTCTAGAGTGATGGGCTTGGGAATGC 3’
A1 [17-531]:
SP A1 dir 1 -  5’ CGGGATCCACTAGTAAGTCAGCGAAGCCAACACA 3’ 
SPA1_Msclrev -  5’ AACTGCAGTCTAGATGGCCATGGGAATCAGGAAG 3’
A1 [17-471]:
SP A1 dir 1 -  5’ CGGGATCCACTAGTAAGTCAGCGAAGCCAACACA 3’ 
s1 +2SPA1 -60rev -  5’ AACTGCAGTCTAGATATGGACAAGACCCCTGGTT 3’
A1 [17-420]:
SP A1 dir 1 -  5’ CGGGATCCACTAGTAAGTCAGCGAAGCCAACACA 3’ 
s1 +2SPA1 -111 rev -  5’ AACTGCAGTCTAGATGAGTGTGATCCCAGGACCT 3’
A1 [17-380]:
SP A1 dir 1 -  5’ CGGGATCCACTAGTAAGTCAGCGAAGCCAACACA 3’ 
s1 +2SPA1 -151 rev -  5’ AACTGCAGTCTAGATATGTTCCAGGGGCAGAGTT 3’
A1 [17-371]:
SP A1 dir 1 -  5’ CGGGATCCACTAGTAAGTCAGCGAAGCCAACACA 3’ 
s1 +2SPA1 -160rev -  5’ AACTGCAGTCTAGAGGGGCAGAGTTGGGAGAAGG 3’
A1 [17-351]:
SP A1 dir 1 -  5’ CGGGATCCACTAGTAAGTCAGCGAAGCCAACACA 3’ 
s1 +2SPA1 -180rev -  5’ AACTGCAGTCTAGAGTAAGGAAGGAGGGCAGGGA 3’
A1 [17-328]:
SP A1 dir 1 -  5’ CGGGATCCACTAGTAAGTCAGCGAAGCCAACACA 3’ 
s1 +2SPA1 -203rev -  5’ AACTGCAGTCTAGAAGCAGGACCCACAAGAGCCAC 3’
A1 [260-328]:
SPA1 -244UPdir -  5’ CGGGATCCACTAGTCTCGTTCCTGAAGAAAAGCA 3’ 
s1 +2SPA1 -203rev -  5’ AACTGCAGTCTAGAAGCAGGACCCACAAGAGCCAC 3’
Chapter 4
A1 [215-380]:
SPA1 -199UPdir -  5’ CGGGAT CCACTAGTGCCCT CTAAGT CACCCT CCA 3’ 
s1 +2SPA1 -151 rev -  5’ AACTGCAGTCTAGATATGTTCCAGGGGCAGAGTT 3’
All constructs containing the different deleted versions of the putative upstream and
downstream enhancer elements, in the A1 region (Figure 29A) were performed using the
two-steps PCR technique. The A1 regions containing the deletions were subcloned into
pUC19, sequenced and transferred to the final vector as explained above. Primer pairs 
and templates used for PCR reactions are listed below for each deletion.
A1 [A260-283] (deletion of the upstream enhancer element):
Template: A1 region in pUC19 
FWD external primer:
SP A1 dir 1 -  5’ CGGGATCCACTAGTAAGTCAGCGAAGCCAACACA 3’
REV internal primer:
dUPrev - 5’TTCTCCTTCGGGGTTCGGAATTTCTTTTTCTTTTTGG 3’
FWD internal primer:
dUPdir - 5’ AACCCCGAAGGAGAAGGTGGAATCCTGATTAG 3’
REV external primer:
SP A1 rev 1 -  5’ AACTGCAGTCTAGAGTGATGGGCTTGGGAATGC 3’
A1 [A306-328] (deletion of the downstream enhancer element):
Template: A1 region in pUC19 
FWD external primer:
SP A1 dir 1 -  5’ CGGGATCCACTAGTAAGTCAGCGAAGCCAACACA 3’
REV internal primer:
d DOWN rev - 5’ CAGGGATGCTCAGGATTCCACCTTCTCCTTC3’
FWD internal primer:
dDOWNdir - 5TCCTGAGCATCCCTGCCCTCCTTCCTTACCCT 3’
REV external primer:
SP A1 rev 1 -  5’ AACTGCAGTCTAGAGTGATGGGCTTGGGAATGC 3’
A1 [A260-283&A306-328J-A4 (deletion of upstream and downstream enhancer ele­
ments):
Template: A1[A260-283] in pl)C19
Primer pairs as for the deletion of only downstream enhancer element.
A1 [A260-328]-A4 (deletion of 69 bases-long putative enhancer element):
Template: A1 [A260-283&A306-328]-A4 in pUC19 
FWD external primer:
SP A1 dir 1 -  5’ CGGGATCCACTAGTAAGTCAGCGAAGCCAACACA 3’
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REV internal primer:
d69rev - 5’ CAGGGATGCGGGGTTCGGAATTTCTTTTTCT 3’
FWD internal primer:
d69dir - 5’AACCCCGCATCCCTGCCCTCCTTCCTTACCCT 3’
REV external primer:
SP A1 rev 1 -  5’ AACTGCAGTCTAGAGTGATGGGCTTGGGAATGC 3’
The different subregions of the A23 region (Figure 25A) were PCR amplified using primer 
pairs containing at their 5’end the restriction sites necessary for the cloning strategy. 
The external restriction sites were Kpn I and BamH I, and the internal ones Cla I and 
EcoR V. The cloning strategy was similar to that one described above for the A1 region. 
The amplified A23 subregions were subcloned into pUC19 using the external restriction 
sites, sequenced and transferred into final vector using internal ones. The final vector 
was prepared by removing the A23 region from the A1-A23-A4 construct, after diges­
tion with Cla I and EcoR V. Next, the vector was gel purified and used for the ligation 
reactions with the A23 subregions. The primer pairs used for the amplification of the 
A23 subregions are listed below.
A23[1416-1781]:
SP A2A3 dir 3 - 5 ’ GGGGTACCATCGATTCTTGCATCCTGAAGCTTG 3’
m-SP A2A3 short rev 2 - 5 ’ CGGGATCCGATATCAGGCAGGACTTGGCTCAGAC 3’
A23[1416-1581]:
SP A2A3 dir 3 - 5 ’ GGGGTACCATCGATTCTTGCATCCTGAAGCTTG 3’
SPA23short2rev -  5’ CGGGATCCGATATCGAGAAACGCTCTTTGAAGAC 3 ’
Mutations of the two CPEs present in the A4 region of the A1-A23-A4[mutCPE] con­
struct (Figure 37A) were created using Quick-change PCR mutagenesis method. The 
plasmid used for mutagenesis was a pUC19 vector (with mutated EcoR I and Nde I 
sites) containing the A4 region. The mutated A4 region was sequenced, cut from pUC19 
with EcoR I and Nde I (present at the ends of the A4 region), gel purified and cloned 
into the EcoR I and Nde I positions of the final vector. The final vector was prepared by
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replacing the wt A4 region from the A1-A23-A4 construct with the A4 fragments con­
taining the CPE mutations, by digesting at the EcoR I and Nde I site. The primers used 
for the Quick-change PCR mutagenesis are listed below (mutations are in lower case).
Mut2xCPEdir -  5’ GCTCTTGGATgTcATTTTGCAATcTgATATATATACAT 3’
Mut2xCPErev -  5’ GTATATATATcAgATTGCAAAATgAcATCCAAGAGCCT 3’
Deletion of the ARE (TATTTAT sequence) from the A4 region present in the A1-A23- 
A4[AARE] construct (Figure 38A) was created using two-steps PCR technique. The 
PCR A4 fragment containing deletion was digested at the external restriction enzyme 
sites present at its ends (Kpn I and BamH I), subcloned into a pUC19 vector contain­
ing the EcoR I and Nde I sites mutated, and sequenced. The A4 region containing the 
ARE deletion was then inserted into the A1-A23-A4 construct (lacking the A4 region) as 
described above for the CPE mutations. The primer pairs used for the two-steps PCR 
reactions are listed below.
FWD external primer:
BR A4 dir 1 - 5’ GGGGTACCGCGGCCGCCATATGAGTGTCTCGTAAGTAATGCT 3’
REV internal primer:
dARErev -  5’ CCATATAAAACCAACCCTATATATTATATATGTA 3J 
FWD internal primer:
dAREdir - 5’ TATATAGGGTTGGTTTTATATGGTTTT CT GTT 3’
REV external primer:
BR A4 rev 1 -  5’ CGGGATCCCCGCGGGAATTCACCACTTTTCACCTTATTCT 3’
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4.11.2 Generation of reporter constructs
Spleen- and brain-specific mouse beta adducin 3’UTRs were amplified by PCR. The 
template used for amplifying the spleen-specific 3’UTR was mouse genomic DNA. For 
the amplification of the long brain-specific 3’UTR, the template was a RIKEN FANTOM™ 
clone containing the mouse brain full-length cDNA, purchased from K.K. DNAFORM, 
Japan (clone ID: M5C1070K15). Long range Taq DNA polymerase (Roche) was used 
for amplification of the brain-specific 3’UTR, whereas for the spleen-specific 3 ’UTR 
amplification it was used Taq DNA polymerase (Roche). The primer pairs contained Xba 
I sites at their 5’ends. PCR amplicons were blunt-ended and subcloned into pUC19 for 
sequencing. The inserts were then cut, gel purified and cloned into the Xba l-linearized 
pGL3-control vector (Promega). Thus, each of the 3’UTRs were placed downstream 
of the stop codon of the reporter firefly luciferase gene. The SV40 late polyadenylation 
signal of the reporter vector was present downstream of the inserted 3’UTRs, which as­
sured efficient 3’end processing of the reporter gene. The final constructs were named 
pGL3-A1, pGL3-A1-A23 and pGL3-A1-A23-A4 and are schematically represented in 
Figure 36A. The primer pairs used for the amplification of the mouse beta adducin 
3’UTRs and the sizes of each 3’UTR are listed below.
Short spleen-specific 3’UTR (present in the construct pGL3-A1):
size: 776 nt, spans from the 303 nt to the 1078 nt in respect to the first nt of the mouse
beta adducin last exon
mBeta-adducin STOP dir Xba -  5’ TGCTCTAG AT G ATTAGT GGCTCTGTGGGTC 3’ 
mBeta-adducin A1 rev Xba -  5’ TGCTCTAGATTCTTAAGCTACAGCTGGGT 3’
Short spleen-specific 3’UTR (present in the construct pGL3-A1-A23):
size: 1332 nt, spans from the 303 nt to the 1634 nt in respect to the first nt of the mouse
beta adducin last exon
mBeta-adducin STOP dir Xba -  5’ TGCTCTAGATGATTAGTGGCTCTGTGGGTC 3 ’ 
mBeta-adducin A2-3 rev Xba -  5’ TG CT CTAG ACCG AT GAG CTAAG AAACTT CCA 3’
Long brain-specific 3’UTR (present in the construct pGL3-A1 -A23-A4):
size: 5629 nt, spans from the 303 nt to the 5931 nt in respect to the first nt of the mouse
beta adducin last exon
mBeta-adducin STOP dir Xba -  5’ TGCTCTAGATGATTAGTGGCTCTGTGGGTC 3 ’ 
mADD2-A4_rev_Xba -  5’ TGCTCTAGAGGGAAGCCAAGCACATCTGG 3’
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4.12 Cell culture maintenance
Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) with GlutaMAX, 
D-glucose and Pyruvate, supplemented with 10% of Fetal Calf Serum (FCS) and 100 
mg/ml of Normicin (antibiotic/anti-mycotic). Cells were cultured in an incubator at 37°C, 
5.5% of C 02, in a humidified atmosphere. Tests for the presence of mycoplasma in cell 
cultures were performed frequently. Adherent cells (HeLa, SK-N-BE) were maintained in 
100 mm Petri dish, whereas cells grown in suspension (MEL, K562) were maintained in 
25cm2 flasks. To pass the cells grown in flasks, cells were transferred into 15 ml Falcon 
tubes and centrifuged. The medium was removed, and the pelleted cells were washed 
twice with PBS, centrifuged and resuspended in 10 ml pre-warmed medium. 2-3 ml of 
the suspension were placed in a new flask containing 8 ml of medium. To pass the cells 
grown in Petri dishes, medium was removed, cells were washed twice with PBS and 
1 ml of 0.1% (w/v) trypsin was added. After 5 min of incubation at 37°C, 5 ml of pre- 
warmed medium were added and cells were transferred into a 15 ml Falcon tube and 
centrifuged for 5 min at 1000 rpm. Pelleted cells were resuspended in 10 ml of medium, 
of which 2-3 ml were plated on a new 100 mm dish containing 8 ml of medium. Cell 
stocks (resuspended in FCS with 10% DMSO) were made and kept at -80°C or liquid 
nitrogen.
4.13 Cell culture transient transfections
Transient transfections of cells were performed using Lipofectamine 2000 reagent 
(Invitrogen), according to the manufacturer’s instructions. For the purpose of transcript 
analysis, transfections of HeLa cells were carried out in 35mm Petri dish or 6-well plates. 
5x105 cells in 2 ml of antibiotic free DMEM supplemented with 10% FCS were plated 
and after 24 hours were transfected (at 90% confluency). 10 pi of Lipofectamine 2000
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reagent were diluted in 250 pi of Optimem medium (Gibco) for each DNA sample. After 
5 min of incubation at RT°C, these 260 pi of the diluted transfection reagent were added 
to the DNA sample which was previously diluted in 250 pi Optimem. The DNA mix con­
tained 3 pg of the minigene construct, 500 ng of the plasmid used for checking trans­
fection efficiency (pEGFP-C2 or phRG-TK vector containing renilla luciferase gene with 
the fibronectin intron inserted, created in the lab) and 500 ng of the plasmid expressing 
SV40 T-antigen (to stimulate SV40 promoter activity). The DNA samples were incubated 
with the transfection reagent for 20 min at RT°C to allow the formation of DNA-liposome 
complexes. Cells were washed twice with PBS and 1.5 ml of Optimem was added. 4-6 
hours after the transfection, the cells were washed twice with PBS and antibiotic-free 
DMEM supplemented with 10% FCS was added. The cells were harvested for the RNA 
extraction 16-18 hours after the transfection.
For the Luciferase assays, transfections were carried out in 24-well plates. The proce­
dure was the same as described above. 1.5x105 cells in 0.5 ml of antibiotic free DMEM 
supplemented with 10% FCS were plated. The amount of DNA and Lipofectamine 2000 
were adjusted to the 24-well plates, as recommended by the manufacturer’s instructions. 
2 pi of Lipofectamine 2000 were used for each sample. 300 ng of pGL3 constructs were 
cotransfected with 150 ng of the phRG-TK renilla plasmid.
4.14 RNA extraction from cell cultures and tissues
Total RNA was extracted from cells in culture and tissues using EuroGold TriFast 
solution from EuroClone (cat. No. EMR507100), according to the manufacturer’s 
instructions.
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4.15 I n  v i t r o  transcription
T7 RNA polymerase was used (Stratagene) for the in vitro synthesis of RNAs. Typical in 
vitro transcription reaction mix contained: 1X T7 buffer (Stratagene, 5X stock), 1.5 mM 
NTPs (stock 15 mM), 10 mM DTT (stock 100 mM), 1.25 U/pI T7 RNA polymerase (50U/ 
\i\ stock) and 0.5 pg of DNA template in 20 pi final volume. The reaction was incubated 
for 2 hours at 37°C, then 5 U of DNAse was added and incubated for another 30 min. 
Afterwards the reaction was phenol-chloroform purified (Section 4.17.3) and the synthe­
sized RNA was separated on agarose or denaturing agarose gels (Section 4.16.1 and
4.16.2) to check quality and size.
In order to radioactively label RNAs (hot RNAs), a-32P]UTP was added to the in vitro tran­
scription reaction. The reaction mix contained: 1X T7 buffer (Stratagene, 5X stock), 0.75 
mM ATP, CTP and GTP (stock 15 mM), 0.1 mM UTP (stock 1 mM), 10 mM DTT (stock 100 
mM), 1.25 U/(jl T7 RNA polymerase (50U/pl stock), 0.5 pg of DNA template and 1 pi of 
the [a-32P]UTP (3000Ci/mmol, 10|jCi/ml) in 20 pi final volume. The reaction was incubat­
ed at 37°C for 2 hours, after which 5 U of DNAse was added and incubated for another 
30 min at 37°C. Then, the reaction was purified through nick-columns (Section 4.17.2). 
RNAs were separated on denaturing polyacrylamide gel (Section 4.16.3) to check qual­
ity and size. To generate probe for the RNAse protection assay, cold UTP were removed 
from the reaction and final concentration of 3NTP mix (ATP, CTP and GTP) was 0.4 mM 
(stock 4 mM). The probe was gel purified (Section 4.17.1).
4.16 Electrophoretic separation of RNA
4.16.1 Agarose gel
Agarose gel electrophoresis was used for checking the quality of in vitro transcribed 
RNA and total RNA after extraction from the cells and tissues. Agarose gels were pre­
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pared as described for the DNA separation (Section 4.6), using the reagents and ap­
paratus that were RNase free. 1 % agarose gels were used for separation of total RNA, 
whereas 2% were used for in vitro transcribed RNA. The integrity of the total RNA ex­
tracted from cells and tissues was evaluated by the presence of three rRNA (28S, 18S 
and 5S).
4.16.2 Denaturing agarose gel
Denaturing agarose gels were used for separation of total RNAs prior to Northern trans­
fer. 1.4% (w/v) agarose was melted in ddH20 and put on a magnetic stirrer plate. 1X 
MOPS (from the 10X MOPS stock) was immediately added to the melted agarose. After 
1-2 min 6% (v/v) formaldehyde (37% formaldehyde stock) was added, everything was 
mixed gently and immediately poured into the electrophoretic chamber (10x12cm) and 
left to solidify. The running buffer contained 1X MOPS and 3.7% (v/v) formaldehyde in 
ddH20. RNA samples were resuspended in 1X RNA sample buffer and denatured at 
65°C for 3 min prior to loading. The gels were usually run at 75 V for 4-5 hours. The pres­
ence of the three rRNA (28S, 18S and 5S) was visualized with the UV transiluminator.
4.16.3 Denaturing polyacrylamide gel
In vitro transcribed radioactive RNAs (hot RNAs) were run in denaturing polyacrylamide 
gels in order to check for their size and for the absence of extra bands that could ap­
pear due to incomplete transcription or degradation. Denaturing polyacrylamide gels 
were also used for hot RNA gel purification purposes and for the separation of RNA- 
protected fragments (RNase protection assay). 8M urea was dissolved in 6-10% (v/v) 
19:1 acrylamide:bis-acrylamide (40% stock; AccuGel, National Diagnostics), 1X TBE 
and ddH20 was added to the final volume. To allow the polymerization of the gel, 100 
|j| of a 10% (w/v) ammonium persulphate (APS) and 10 pi of TEMED were added for a 
15 ml final volume and the mix was immediately poured into 0.75 mm tick, 10x12cm 
sized vertical electrophoretic apparatus. The gel was pre-run for about 1 hour at 200 V
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in 1X TBE running buffer. RNA samples were resuspended in formamide-loading buffer 
and denatured at 95°C for 2 min prior to loading. The gel was usually run at 150-300 
V, depending on the acrylamide concentration. 1 Kb DNA ladder (Invitrogen cat.No. 
15615-024) was radioactively labeled and run in parallel in order to determine the size 
of the bands. Radioactive labeling was performed according to the manufacturer’s T4 
DNA Polymerase Labeling Protocol, with the exception that the [a-32P]dCTP was used 
instead of [a-32P]dATP. Additionally, the correct size of RNAs was estimated by the po­
sitions of bromophenol blue and xylene-cyanol that are present in the loading buffer. 
Migration of these two colors in the gel corresponds to the migration of RNA of specific 
size for each percentage of the gel. For example, in a 6% polyacrylamide gels migration 
of the bromophenol blue and xylene-cyanol coincide with the migration of 26 nt and 106 
nt long RNAs, respectively. After the running, the gel was washed/fixed with fixer solu­
tion (10% methanol, 10% acetic acid) in order to eliminate urea allowing the adequate 
drying of the gel. The gel was dried at 80°C for 2 hours and exposed on a film (Kodak) 
or cyclone phospho-screen (Packard Bioscience Co.).
4.17 RNA purification
4.17.1 Gel purification
The radioactive RNA probe used for RNase protection assays was gel purified as fol­
lows. The hot RNA was in vitro synthesized as described in Section 4.15 and the whole 
reaction was run through a 6% denaturing polyacrylamide gel (4.16.3). The wet gel, 
covered with a thin plastic film, was exposed for 2 min and the borders of the gel were 
marked on the film. The film was developed and, with the help of the marks, it was pre­
cisely placed on the gel to cut-out the radioactive signal on the film corresponding to 
the desired RNA. The gel slice was transferred into a 1.5 ml tube containing 400 \i\ of
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elution buffer (0.2% SDS, 1 mM EDTA pH 8.0, 0.5 M ammonium acetate) and left ON 
at RT°C with agitation. Next, the elution containing hot RNA was transferred into a clean 
1.5 ml tube, acid phenol-chloroform purified and ethanol precipitated. Finally, the hot RNA 
was resuspended in R-loop buffer and used as a probe in the RNase protection assays.
4.17.2 Nick column purification
Nick column purification was used in order to purify in vitro transcribed hot RNAs (4.15) 
from the unincorporated radioactive nucleotides, which were subsequently used for 
EMSA experiments. The in vitro transcription reaction was passed through lllustra nick 
columns (GE Healthcare, cat.no. 17-0855-01). First, the original buffer inside the col­
umn was replaced by 3 ml of TE buffer. Then, the column was placed in a clean 1.5 ml 
tube and the in vitro transcription reaction was added. 350 pi TE buffer were added im­
mediately and left to flow through. Next, the column was placed in a new clean 1.5 ml 
tube and 50 pi TE was added and left to flow through. This procedure was repeated for 
7 times. Radioactivity was monitored on a geiger counter (Canberra Packard SRL) for 
each of the tubes and the elutions containing high picks of radioactivity were collected, 
ethanol precipitated and resuspended in ddH20. The integrity of the RNAs was checked 
by running a denaturing polyacrylamide gel and subsequent exprosure on film.
4.17.3 Acid phenol-chloroform purification
Acid phenol-chloroform purification was used to purify cold in vitro transcribed RNAs 
and also was used after treatments with DNase or RNase (RNase protection assay). 
One volume of acid phenol-chloroform was added to the RNA sample, which is then 
vortexed and centrifuged for 5 min at 13200 rpm at 4°C. The supernatant is transferred 
into a clean 1.5 tube containing 2 volumes of 100% ethanol with 1/10 (v/v) of NaAc (3 M, 
pH 5.0). The sample is vortexed and left in dry ice for 20 min. Subsequently, the sample 
was centrifuged at 13200 rpm for 15 min at 4°C. The supernatant was removed; the pel­
let was washed with 500 pi of 70% ethanol and resuspended in ddH20.
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4.18 cDNA preparation
cDNAs were prepared by reverse transcription (RT) from total RNA. Briefly, 0.5-1 pg of 
total RNA was diluted to a final volume of 10 pi with ddH20 and denatured at 70°C for 3 
min. 10 pi of 2X reaction mix were added to the denatured RNA sample and the reaction 
was incubated for 30 min at 37°C. 10 pi of 2X reaction mix contained: 2.5 pi ddH20, 4 
pi 5X first strand buffer (Invitrogen), 1.25 pi DTT (stock 100 mM), 1.25 pi dNTPs (stock 
5 mM), 0.75 pi random primer or oligo dT primer (stock 100 ng/pl) and 0.25 pi M-MLV 
Reverse Transcriptase (stock 200 U/pl, Invitrogen).
4.19 DNase treatment
DNase treatment of total RNA was used in order to eliminate transfected plasmid or 
genomic DNA contamination. 5 U of RNAse free-DNase (stock 1 U/pl, Promega) were 
used for 5 pg of total RNA in a reaction that also contained 1X DNase buffer (stock 5X, 
Promega) and ddH20 to a final volume. The reaction was then acid phenol-cloroform 
purified, ethanol precipitated and resuspended in ddH20 or R-loop buffer, according to 
the experimental needs.
4.20 3’RACE
3’Rapid Amplification of cDNA Ends (3’RACE) was used to identify the 3’ends of the 
transcripts derived from the A1-A23-A4[AHm] and A1-A23-A4[ADSE] constructs (Fig­
ure 17). First, cDNA was synthesized from 1 pg of total RNA derived from the HeLa cells 
transfected with A1-A23-A4[AHm] and A1-A23-A4[ADSE] constructs. Then, two PCR
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reactions were performed using the cDNA as template for the first PCR. The first PCR 
was performed using forward primer which annealed to the region -500 nt upstream of 
the PAS4 and reverse primer was an oligo dT terminated in A, C or G linked to a specific 
5’extension sequence (anchor). The obtained PCR products were used as template for 
the second PCR. The forward primer for the second PCR annealed to the region -300  
nt upstream of the PAS4 and the reverse primer was the sequence used as anchor in 
the first PCR. The products from the second PCR were gel purified, blunt-ended, cloned 
into pUC19 and fully sequenced. The primer pairs used for both PCRs are listed below.
First PCR:
Brain dir -  5’ CCGGATCCTATAAGGTACCAGTGTCTCGTAAGTAATGCT 3’ 
dT Anchor 1 rev -  5’ TAGGAATTCTCGAGCGGCCGC(T)17 3’
Second PCR:
mXhol dir 1 -  5’ CCGCTCGAGTCTGCCTTTCTCTATGCTAA 3’
Anchor 1 rev -  5’ TAGGAATTCTCGAGCGGCCGC 3’
4.21 Quantitative PCR
Quantitative PCR (qPCR) was used to determine relative pre-mRNA (Figure 24B) or 
mRNA (Figure 36C and 38C) levels. A final volume of the PCR reaction was 20 pi and the 
mix for one sample contained: 10 pi 2X Syber green mix (BioRad, cat. No. 172-5006/25), 
0.66 pi of each primer (stock 100 ng/pl) and ddH20 to the final volume. Syber green mix 
contains DNA polymerase, dNTPs, reaction buffer and syber green fluorescent dye. 2 
pi of cDNA were used as a template. The cDNA was prepared using total RNA previ­
ously treated with DNAse. The reactions were performed in duplicates for each sample. 
A Bio-Rad C1000 thermo-cycler coupled with a CFX96 real-time system was used for 
the amplification. The amplification reaction steps were as follows: a single denaturation 
step at 98°C for 30 sec, then 40 cycles of denaturation steps at 95°C for 5 sec, anneal­
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ing/elongation steps at 58°C for 25 sec. In order to generate the amplicon's melting 
curves, the melting curve protocol followed the amplification reaction and comprised 
of one denaturation step at 95°C for 10 sec and and increase in the temperature from 
65°C to 95°C at 0.5°C intervals, measuring the fluorescence at each step for 1 sec. The 
AACt between the amplicon of interest and reference amplicon was calculated using the 
Bio-Rad software. Primer pairs used for the qPCR reactions showed in the Figure 24B, 
36C and 38C are listed below, respectively.
Alpha globin:
a Glo Ex2 real DIR -  5’ TGGACGACATGCCCAAC 3’ 
a Glo Int2 real REV -  5’ AACCCGCGTGATCCTCT 3’
GFP:
GFP 1004 FW -  5’ TCAAGGAGGACGGCAACATC 3’
GFP 1124 RV -  5’ TTGTGGCGGATCTTGAAGTTC 3’
Firefly luciferase:
LucqPCR 1580 dir - 5' TCGTTGACCGCCTGAAGTCT 3' 
LucqPCR 1769 rev - 51 GGCGACGTAATCCACGATCT 3'
Renilla luciferase:
Renq PCR 1437 dir - 5' TGGAGCCATTCAAGGAGAAG 3' 
Renq PCR 1649 rev - 5' TTCACGAACTCGGTGTTAGG 3‘
Alpha globin:
agloEXI real DIR - 5‘ GCCGACAAGACCAACGTCAA 3‘ 
aGloex2 Real REV - 51 AGGTCGAAGTGCGGGAAGTA 3'
Renilla luciferase containing intron: 
qREN1436D - 51 CTGGAGCCATTCAAGGAGAA 31 
qREN1554R - 5‘ GCGTTGTAGTTGCGGACAAT 31
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4.22 Northern blot analysis
In general, 5 \ig of total RNA prepared from transfected cells were run on a denaturing 
agarose gel, as described in Section 4.16.2. The gel was visualized on a UV transillumi­
nator and photographed. Then, the gel was washed three times for 15 min in ddH20 and 
once in 20X SSC for 15 min. At the same time, a nitrocellulose membrane (Hybond-N+, 
Amersham Pharmacia biotech) was incubated with 20X SSC for 15 min. Then, the RNA 
was transferred ON to the membrane by capillarity. The gel and the membrane were 
then visualized on the UV transilluminator and photographed, in order to check for the 
efficiency of the transfer. The positions of the 28S and 18S rRNAs were marked on the 
membrane with a pencil. The membrane was dried for 5 min at 37°C and the RNA was 
UV cross-linked, twice with 100x1200|jJ (Stratalinker 1800). Then, the membrane was 
wet in 2X SSC and pre-hybridized for 1 hour at 42°C or 65°C (depending on the probe) 
in 5 ml of a commercial hybridization solution (Ultrasensitive Hybridisation Solution, 
Ambion) diluted with 2.5 ml of ddH20. Next, the radioactive probe was denatured, added 
to the membrane and left to hybridize ON at 42°C or 65°C. The probe was then removed 
and the membrane washed using solutions containing descending concentrations of 
SSC (2X SSC, 1X SSC, 0.5X SSC and 0.1X SSC) and 0.1 % SDS. Washing steps lasted 
15 min for each solution at the temperature used for the hybridization. Radioactivity 
was checked after each washing with a geiger counter (Canberra Packard SRL) and 
when the background signal was sufficiently low, the membrane was exposed to a cy­
clone phosho-screen (Packard Bioscience Co.). The exposure time varied from 5 min to 
ON, depending on the signal strength. The signals were detected using cyclone reader 
(Packard Bioscience Co.) and the intensity of the obtained signals was quantified us­
ing OptiQuant that is part of cyclone software system. For the reutilization, membranes 
were exposed to boiling 0.5% SDS and incubated for 1 hour at 65°C, in order to remove 
the specific signal.
Radioactive probes were prepared using Rediprimell DNA labeling System (GE
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Healthcare, cat.no.RPN1633). 50 ng of DNA in TE buffer were denatured at 95°C for 5 min. 
Then, denatured DNA was transferred into a Rediprime tube containing the reaction mix 
and 2 \i\ [a-32P]dCTP (6000Ci/mmol, 10pCi/ml) was added. The reaction was incubated for 
20 min at 37°C and subsequently purified from the unincorporated isotopes using lllustra 
nick column (GE Healthcare, cat.no. 17-0855-01). The nick column purification was per­
formed as described in Section 4.17.2., with the exception that the final eluted probe was 
not precipitated, instead it was denatured and directly used for the hybridization.
The alpha globin probe was amplified from cDNA prepared from total RNA of HeLa cells 
transfected with the construct containing human alpha globin gene, and cloned into a 
pUC19 (from Dr. Laura de Conti, Molecular Pathology Group, ICGEB). The fragment is 
272 nt long and contains the alpha globin exons 1 and 2. The alpha globin probe was 
cut from the pUC19 plasmid with BamHI and EcoRI and gel purified. The temperature 
used for the hybridization was 42°C.
The GFP probe (-500 nt long) was generated by a PCR reaction using the pEGFP-C2 
plasmid as template. The PCR product was gel purified. The temperature used for the 
hybridization was 42°C. The primer pair used for the amplification were:
GFP813FW - 5' CGGCGTGCAGTGCTTCAGCCGCTAC 3'
GFPendRV - 5' CTT GTACAG CTCGT CC ATGCCG AG AG 3'
The c-myc probe (-250 nt long) was generated by a PCR reaction using as template 
cDNA prepared from total RNA extracted from HeLa cells. The PCR product was gel 
purified. The temperature used for the hybridization was 65°C. The primer pair used for 
the amplification were:
c-myc ex 2 dir - 5' CCTACCCTCTCAACGACAGC 3' 
c-myc ex 3 rev - 5' CTCTGACCI I I IGCCAGGAG 3'
The GAPDH probe (-1.2 Kb long) was amplified from cDNA prepared from total RNA of 
HeLa cells and cloned into a pUC19. The GAPDH probe was cut from the plasmid with 
Pstl and gel purified. The temperature used for the hybridization was 42°C.
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4.23 RNase protection assay
The RNase protection assay was used to determine the cleavage efficiency of the 
transcripts derived from HeLa cells transfected with the different minigene constructs 
(Figure 23). The RNase protection assays were performed as described in Sambrook et 
al 1989. and Dalziel et al 2007.
Briefly, the radioactively labeled probe was added to the RNA sample in a final volume 
of 30 pi in R-loop buffer. Thus prepared hybridization mix was denatured at 95°C for 10 
min and left to hybridize at 45°C for 15-18 hours in a water bath. Then, 300 pi of RNase 
mix were added to the hybridized sample and the digestion was carried out for 45 min 
at 30°C in a water bath. The RNase mix was freshly prepared and contained 10 mM 
Tris-HCI pH 7.4, 300 mM NaCI, 5 mM EDTA, 0.5U/pl RNase T1 and 0.01 mg/pl RNase A. 
After the RNase digestion, the sample was incubated with 100 pi Proteinase K mix for 15 
min at 30°C in a water bath. 100 pi Proteinase K mix contained 96 pi Proteinase K buffer 
(100 mM Tris-HCI pH7.5, 2% SDS, EDTA 20 mM) and 4 pi Proteinase K (stock 10 mg/ 
ml). Then, the sample was acid-phenol purified, ethanol precipitated and resuspended 
in 10 pi formamide-loading buffer. Half of the resuspension was denatured for 2 min at 
95°C and loaded onto a 6% polyacrylamide 8M urea gel (see Section 4.16.3). In parallel, 
10 cps of probe and radioactively labeled 1 Kb marker were run and the gel was washed 
with fixer solution, dried at 80°C for 2 hours and exposed to a cyclone phospho-screen. 
The signals were visualized on a Cyclone imager (Packard Bioscience Co.) and quanti­
fied using OptiQuant.
RNA samples were prepared from total RNA of transfected HeLa cells. Total RNA was 
treated with DNase, acid phenol-chloroform purified, ethanol precipitated and resuspend­
ed in R-loop buffer. The quality of the RNA was checked by running 1 % agarose gels and 
the concentration was measured by a “nanodrop” spectrophotometer. The quantity of 
each RNA sample used for the RNase protection assay was normalized for the transfec­
tion efficiency. 400 ng of one RNA sample were used for the assay and this sample was
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chosen as reference in the normalization calculations. 10 of mouse brain total RNA
were used as a control for the correct cleavage protected fragment. Total RNA from
mouse brain was prepared using TriFast reagent and resuspended in R-loop buffer.
For the RNA probe preparation, the fragment upstream and downstream of the PAS4
(Figure 23B) was amplified using following primer pair:
mXhol dir 2 - 5' CCGCTCGAGATTTATGGGTTGGTTTA 3'
mADD2 BR short rev - 5' CGGGATCCCCGCGGGAATTCCCTACATTTC 3'
The PCR product was cloned into a pUC19 plasmid, sequenced and then cloned in
the antisense orientation downstream of the T7 promoter in the PBS II KS plasmid
(Stratagene) in the Sacll and Xhol sites. The plasmid was linearized with Xhol, phenol-
chloroform purified, ethanol precipitated and used for the in vitro transcription reaction
(for the conditions see Section 4.15). The in vitro transcribed probe was gel purified
through 6% polyacrylamide 8M urea gel (see Section 4.17.1) and resuspended in R-loop
buffer. Approximately 500 cps of the probe were used for the hybridization reactions.
4.24 EMSA
Electrophoretic Mobility Shift Assay (EMSA) were performed to detect RNA-protein in­
teractions (Figure 33 and 34). The RNA-protein reaction mix contained: -150-200 cps of 
hot RNA, 1X binding buffer (stock 10X), 2-3 pg/pl FleLa nuclear extract (Cilbiotech, stock 
10-12 pg/pl), 10 pg/pl heparin (stock 200 pg/pl) and ddH20 to the final volume. 10X bind­
ing buffer contained 52 mM Flepes pH 7.5, 10 mM MgCI2, 8 mM Mg acetate, 5.2 mM 
DTT, 7.5 mM ATP, 10 mM GTP, 38% glycerol and ddH20 to the final volume. First, nucle­
ar protein extract was mixed with heparin and left for 5-10 min at RT. In the meantime, 
the hot RNA, binding buffer and ddH20 were mixed. Nuclear extract and heparin were 
then added to the mix and everything was incubated for 20 min at RT. After 20 min, the 
mix was loaded onto a 6% native polyacrylamide gel and run at 200 V at 4°C. One well 
was loaded with 5 \i\ of loading buffer (30% glycerol, 0,25% bromophenol blue) and the
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gel was run until the blue reached two thirds of the gel. The gels contained: 6% 37.5:1 
acrylamide:bis-acrylamide (30% stock, Promega, Serva products), 0.5X TBE, ddH20,
140pl of a 10% (w/v) ammonium persulphate (APS) and 17.5 \i\ of TEMED were added 
for a 17.5 ml final volume. 0.5X TBE was used as running buffer. The gel was pre-run 
for 1 hour at 4°C. After the running, the gel was dried at 80°C for 2 hours, exposed on 
cyclone phosphor-screen and visualized on a cyclone imager (Packard Bioscience Co.). 
Hot RNAs were in vitro transcribed (as described in Section 4.15) using as a template 
the PCR products previously purified using the PCR clean-up protocol (see Section
4.5.2). The primer pairs used for the amplification of the different templates for the in 
vitro transcription are listed below. The forward primer contained the T7 promoter se­
quence and is represented in lower case.
INT
T7pull244UPdir -  5’ tacgtaatacgactcactataggCTCGTTCCTGAAGAAA 3’ 
pull203rev -  5’ AGCAGGACCCACAGAGCCACT 3’
AUP
T7pull268UPdir -  5’ tacgtaatacgactcactataggGGGAAGGAGAAGGTGGAA 3’ 
pull203rev -  5’ AGCAGGACCCACAGAGCCACT 3’
ADOWN
T7pull244UPdir -  5’ tacgtaatacgactcactataggCTCGTTCCTGAAGAAA 3’ 
pullSTOPrev -  5’ TCAGGATTCCACCTTCTCCTT 3’
In vitro transcribed RNAs were purified through nick columns and their quality was 
checked by running 10% polyacrylamide 8M urea gels.
For the EMSA competition assays, cold competitor RNAs were in vitro transcribed (see 
Section 4.15) using the same templates as described above, acid phenol-chloroform 
purified, ethanol precipitated and resuspended in ddH20. The quality of the RNAs was 
checked by running 2% denaturing agarose gel.
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4.25 Pull down analysis
Pull down analysis were performed in order to detect single protein differences between 
the proteins bound to the different RNAs (Figure 35). The cold RNAs used for the pull 
down analysis were the same ones used for the EMSA competition analysis. 
Approximately, 500 pmoles of RNA were incubated with 5 mM sodium m-periodate 
(Sigma) solution in 0.1 M NaOAc (pH 5.0), in a final volume of 400 pi at RT for 1 hour 
in the dark with agitation. Then, the RNA was ethanol-precipitated and resuspended 
in 100 pi of 0.1 M NaOAc (pH 5.0). In the meantime, 500 pi of adipic acid dehydrazide 
agarose bead 50% slurry (Sigma) were washed four times with 10 ml 0.1 M NaOAc (pH
5.0). After the final washing, the beads were resuspended in 300 pi of 0.1 M NaOAc (pH
5.0) and added to the previously prepared 100 pi RNA. The mix was incubated ON in 
the dark at 4°C with agitation. Then, the beads with the bound RNA were centrifuged at 
4000 rpm for 5 min, and the supernatant was discarded. The RNA-loaded beads were 
washed twice with 2 M NaCI and three times with washing buffer (52 mM Hepes pH 7.5, 
10 mM MgCI2, 8 mM Mg acetate, 5.2 mM DTT, 38% glycerol and ddH20 to a final vol­
ume). Subsequently, the RNA loaded beads were incubated with 20 pg/pl HeLa nuclear 
extract, 1X binding buffer (the same one used for the EMSA experiments) and ddH20 
to a 500 pi final volume, for 20 min at RT with agitation. Then, the reaction was centri­
fuged at 4000 rpm for 3 min, the supernatant discarded, and washed four times with 
washing buffer. The final pellet was resuspended with 60 pi of SDS loading buffer (20% 
SDS, 1 M DTT, 0.63 M Tris-HCI pH 7.0, 0.2% bromophenol blue, 20% glycerol, 10 mM 
EDTA pH 7.0), denatured at 95°C for 5 min and loaded onto a 10% SDS-PAGE gel. For 
a final volume of 20 ml, the running gel contained: 6.7 ml of 37.5:1 acrylamide:bis-acryl- 
amide (30% stock, Promega, Serva products), 5 ml Tris-HCI (stock 1.5M, pH 8.8), 8.3 ml 
ddH20, 200 pi 10% SDS, 200 pi 10% APS and 20 pi TEMED. The stacking gel contained: 
0.56 ml of 37.5:1 acrylamide:bis-acrylamide (30% stock, Promega, Serva products), 2.5 
ml Tris-HCI (stock 0.5 M, pH 6.8), 1.86 ml ddH20, 50 pi 10% SDS, 50 pi APS and 10 pi
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TEMED. The gel was run at 25-30 mA for 4-5 hours, or ON at 5 mA, in 1X SDS-PAGE 
running buffer (50 mM Tris, 0.38 M glycine, 0.1% SDS). After running, the gels were 
stained with colloidal coomassie. The bands showing single protein differences (Figure 
34) were excised, digested with trypsin and identified by mass spectrometry analysis. 
The peptide sequence analysis was performed using an electrospray ionization mass 
spectrometer (LCQ DECA XP, ThermoFinnigam). The mass spectrometry analysis was 
performed by the Protein Neworks Group at the ICGEB.
4.26 Luciferase reporter assay
The luciferase reporter assays were performed according to the Promega Dual-Luciferase 
Reporter Assay System instructions. All solutions were purchased from Promega.
Cells were transfected with the reporter constructs in triplicates, as described in Section 
4.13. 24 hours after transfection, medium was removed, cells were washed twice with 
PBS and 100 pi of Passive Lysis Solution were added. The cells were incubated for 
15 min at RT with agitation. Then, the lysates were transferred into 1.5 ml tubes and 
centrifuged for 4 min at 13200 rpm at 4°C. 10 pi of the supernatant were transferred into 
a clean 1.5 ml tube and used to determine luciferase activity with a Turner Biosystems 
Luminometer 20/20. First, 50 pi of LARII solution were added, the reaction was mixed by 
pipetting and the luminescent coming from the firefly luciferase activity was measured. 
Next, 50 pi of Stop&Glow solution was added in order to to stop the activity of the firefly 
luciferase and to measure the luminescent coming from renilla luciferase activity. The ratio 
between firefly and renilla luciferase activity was defined as relative luciferase activity.
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